Integrin signaling modes controlling cell migration and metastasis by Truong, H.H.




Integrin Signaling Modes Controlling Cell Migration and Metastasis
Thesis, Leiden University, 2011
ISBN: 978-90-8570-422-5
© 2011, HH Truong
No part of this thesis may be reproduced or transmitted in any form, by any means, 
electronic or mechanical, without prior written permission of the author.
Cover: 4T1 spheroid stained for E-cadherin (green) and Nuclei (blue) by Blox-Tox  
Nov. 2009
Printed by: Wohrmann print service
Integrin Signaling Modes Controlling Cell Migration 
and Metastasis
PROEFSCHRIFT
ter verkrijging van de graad van Doctor 
aan de Universiteit van Leiden
op gezag van Rector Magnificus 
prof.mr. P.F. van der Heijden
volgens het besluit van het College voor Promoties 
te verdedigen op donderdag 27 oktober 2011
klokke 16:15 uur 
door
Hoa Hoang Truong
geboren te Reno, Nevada, USA
in 1977
Promotie commissie
Promotor:  Prof. Dr. B. van de Water Universiteit Leiden,LACDR
Co-promotor:  Dr. E.H.J. Danen  Universiteit Leiden,LACDR
Overige leden:  Prof. Dr. M. Danhof  Universiteit Leiden, LACDR
Prof. Dr. P. Friedl  Rabdboud Universiteit Nijmegen
   Prof. Dr. T. Schmidt  Universiteit Leiden
   Dr. A. Sonnenberg  Nederlands Kanker Instituut
   Prof. Dr. H. Spaink  Universiteit Leiden 
   Prof. Dr. P. ten Dijke  LUMC, Leiden
The studies presented in this thesis were performed in the Division of Toxicology, 
LACDR, Leiden University. This research was financially supported by a grant from 
the Dutch Cancer Society / KWF (UL 2006-3521).
Financial support for printing of this thesis came from:
- The Dutch Cancer Society, KWF
- Leiden/Amsterdam Center for Drug Research
Table of contents
Chapter 1
General introduction and scope of this thesis. 9
Chapter 2
Truong H and Danen EHJ. Integrin switching modulates cell-matrix adhesion 
dynamics. Cell Adhesion and Migration 2009 29
Chapter 3
Van den Bout I, Truong HH, Huveneers S, Kuikman I, Danen EHJ, and 
Sonnenberg A.  Identification of integrin-regulated genes. Regulation of 
MacMARCKS by integrin β3 expression. Experimental Cell Research 2007
35
Chapter 4
Huveneers S, Truong H, Fassler R, Sonnenberg A, and Danen EHJ. Binding 
of soluble fibronectin to integrin alpha5 beta1 - link to focal adhesion 
redistribution and contractile shape. Journal of Cell Science 2008
47
Chapter 5
Huveneers S, Truong H, and Danen EHJ. Integrins: Signaling, Disease, and 
Therapy International Journal of Radiation Biology 2007 59
Chapter 6
Truong HH, de Sonneville J, Ghotra VPS, Price L, Hogendoorn P, Spaink H, 
van de Water B, Danen EHJ. Automated microinjection of cell-polymer 




Truong HH, Ghotra VPS, Nirmala E, Le Dévédec SE, van der Helm D, Lalai R, 
He S, Snaar-Jagalska BE, Amiet A, Marcinkiewicz C, Vreugdenhil E, Meerman 
JHN, van de Water B, Danen EHJ. Integrin control of ZEB/miR-200 balance 
regulates tumor cell migration strategy and metastasis. Submitted for 
publication
87
Summary and discussion 111
Nederlandse samenvatting 121
Curriculum vitae 129
List of publications 131
To my beloved family: 
Anastasia, Maximilian, and Norman
To my beloved family: 
Anastasia, Maximilian, and Norman

Chapter 1




The assembly of tissues and organs is dependent on adhesion. In addition to providing 
structure, it coordinates cues from the surrounding environment to regulate cellular 
processes such as differentiation and growth during embryonic development and 
tissue morphogenesis (Hynes, 1987; Hynes and Lander 1992; Hynes 1992). It also 
regulates pathological processes such as tumor invasion and inflammation, etc. There 
are two principal types of adhesion: cell-cell and cell-matrix adhesion. Cell adhesion 
is highly dynamic: adhesion structures contain a large network of proteins whose 
interactions and conformation is regulated by extracellular cues (Zaidel-Bar et al., 
2007). Cell adhesion molecules (CAMs) are specialized integral membrane proteins 
that mediate cell-cell (homotypic and heterotypic) and cell-matrix adhesion. These 
adhesions assemble cells into tissues and facilitate communication between cells and 
their environment. There are four major CAM families: cadherins, immunoglobin (Ig) 
superfamily members, integrins, and selectins (Cavallaro and Dejana 2011; Hynes 
1999; Juliano, 2002).
Distinct classes of ECM adhesion
Distinct classes of extracellular matrix (ECM) adhesion, each consisting of a distinct 
subset of proteins, exhibit a characteristic subcellular distribution and participate in 
different signaling events (Yamada and Geiger 1997). Types of cell-matrix adhesion 
structures include: i) focal complexes (FC), which are small, transient structures, 
which usually arise immediately behind the leading edge of spreading or migrating 
cells. These adhesions support nascent filopodial growth and lamellipodia. ii) Focal 
adhesions (FA) most commonly studied are larger mature structures, which are arise 
from FCs containing signalling and actin-binding proteins responsible for providing 
mechanical stability and enabling tractional forces. iii) Fibrillar adhesions (FB) (Geiger 
et al 2001), which have been considered to originate from a subset of FA are highly 
stable elongated structures that run parallel to bundles of fibronectin (FN) in vivo and 
are sites of localized matrix deposition and FN fibrillogenesis  (Pankov et al.,2000; 
Zamir et al., 2000). vi) 3D matrix adhesions are fibrillar-ECM adhesion structures that 
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are dependent in a5b1 integrin-FN interaction (Yamada,Pankov, and Cukierman, 
2003). v) Podosomes and invadopodia are adhesion structures associated with sites of 
proteolytic degradation of ECM (Linder and Kopp, 2005). Hemidesmosomes (HD) are 
epithelial specific adhesion structures that link intermediate filaments to ECM (Green 
and Jones, 1996, Litjens et al., 2006) and are found in epithelial tissues, such as the 
skin and intestine. There are two type of HDs: Type II is usually found in intestine and 
comprised of a6b4 integrin and plectin. Type I, which is established in skin, contains 
a6b4 integrin, plectin, tetraspanin CD151, and bullous pemphigoid (BP) antigen 
180. Integrin α6β4 and plectin play an essential role in HD formation (Borradori and 
Sonnenberg 1999; Litjens et al 2006, Spinardi, et al., 1993)
FC, FA, FB, and podosomes may represent a continuum of related adhesions 
whose structure depends on the protein composition, localization, and proteolytic 
capabilities.  Recent analyses have revealed differences in concentration and post-
translational modifications of adhesion proteins among the different adhesion types. 
For example, transient FC do not contain zyxin but are rich in phosphotyrosine, 
talin, and avb3 integrin (Zaidel-Bar et al., 2004). By contrast, highly stable FB do not 
contain avb3 integrin, phosphorylated (active) focal adhesion kinase (FAK), paxillin 
and phosphotyrosine, but do have a5b1 integrin and tensin (Zaidel-Bar et al 2004). FA 
encompasses FC components and additional proteins like a5b1 integrin and zyxin and 
are enriched in phosphotyrosine (Zaidel-Bar et a, 2003; Zamir et al., 2000). Finally, 
podosomes have an actin core surrounded by tyrosine phosphorylated proteins and 
several typical FA proteins, such as vinculin and talin and show concentration of 
proteases (Linder and Kopp, 2005). The functional relevance of these differences in 
molecular composition is not fully known, but it is likely that distinct populations of 
proteins will convey distinct mechanical properties to each adhesion.
Integrins are the major mediators of cell-matrix adhesion and also serve as one of the 
CAM active in cell-cell adhesion. The engagement of integrin to the ECM initiates the 
adhesion process. Upon interaction with the ECM, integrins are activated by means 
of a conformational change that permits the receptor to interact with cytoplasmic 
proteins. Talin is one of the first adaptor protein to bind to the integrin cytoplasmic 
region Wegener et al., 2007). It’s interaction with the b-subunit cytoplasmic tail, 
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which enhances ligand affinity, which is followed by the clustering of other activating 
integrins to facilitate strong adhesion formation (Carman and Springer, 2004)
Integrin family
The term integrin was introduced by Tamkun and Hynes (Tamkun et al., 1986) 
to describe the receptor’s function of integrating the ECM network to the actin 
cytoskeletal network. As members of a membrane glycoprotein superfamily, integrins 
are transmembrane cell surface receptors consisting of an a- and b-subunit. From 
18 a subunits and 8 b subunits, there are 24 heterodimers known to be formed in 
humans. The assortment of integrins allow for adhesion to probably all ECM proteins, 
by which cells can promote distinct intracellular signaling responses to changes in 
ECM composition. 
Different types of integrins can be expressed in a cell-type specific manner; thus 
some integrins such as a5b1, avb3 and avb6 are associated with migration and 
proliferation in various cell types whereas other integrins are expressed in selective 
cell types. Examples of such cell-type specific integrins include aIIb3 in platelets and 
a6b4 in epithelial cells (Pierschbacher and Ruoslahti, 1984).
There exists functional redundancy among the integrins in particular processes, 
such as wound healing. The expression of several integrins (a2b1, a3b1, a9b1) 
following tissue injury might act as a safe-keeping mechanism ensuring adhesion of 
the epidermis to any component of the provisional matrix during re-epithelialization 
(Hunt et al., 1999; Hynes and Zhao 2000; Margadant et al., 2010).
b-subunit
The b-subunit had been extensively studied, whereas the different a-subunits have 
been less investigated. As reported in previous studies, the β-subunit’s cytoplasmic 
tail is highly conserved and essential for many integrin functions. The removal of the 
β−subunit cytoplasmic tail inhibits integrin-mediated cell adhesion, cell spreading, 
cell migration, FAK phosphorylation, β− subunit localization to FA, reduced ligand-
binding activity, and activation of signaling proteins (Shattil, 2009; Nieves et al., 2010; 
Liu, Calderwood, and Ginsberg 2000).
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The role of the b-subunit cytoplasmic domains particularly in b1 and b3 integrin has 
been studied using mutations. There is a number differences between b1 and b3 
integrins, for example, Leavesley et al 1993 showed that b1 and b3 integrin-mediated 
distinct signaling pathway in endothelial cells. They demonstrated that the cellular 
migration of cells attached to vitronectin through avb3 is calcium dependent. In 
contrast, if the cells attach to collagen through a2b1, migration is calcium independent. 
Even more strikingly, binding to a single ECM protein, FN through either a5b1 or avb3 
leads to highly different cytoskeletal organizations and patterns of cell migration (this 
thesis). It has been reported that in order to regulate cell migration, PKCb-RACK1 
complex must bind to the b3 cytoplasmic tail; whereas b1-mediated migration relies 
on the direct binding of PKCa and ε. This further shows that both b1 and b3 integrins 
are connected to similar however distinct signaling pathway (Besson et al., 2002; Ng 
et al.,1999; Webb et al 2002; Buensuceso et al., 2005).
Interestingly, b1 and b3 integrins coordinate each other function. For instance a5b1 
ligation induces calmodulin-dependent kinase II (CAMKII) activation to mediate cell 
migration, which is inhibited by ligation of avb3. Furthermore, it was reported that 
inhibition of avb3-PKD1 interaction upon platelet-derived growth factor stimulation 
(PDGF) hinders Rab4-dependent recycling of avb3 (Blystone et al.,1999; Kim, Harris, 
and Varner, 2000). This results in an increased recycling of a5b1 through a process 
that involves association with the Rab-coupling protein (RCP)-Rab11 complex (Woods 
et al., 2004; White et al.,2007; Caswell et al., 2008).
Integrin structure
The a- and b-subunits have a large extracellular domain, a short transmembrane 
domain and a short cytoplasmic domain. The extracellular region of b-subunits 
typically consists of ~750 amino acid residues, and the a-subunit has up to ~1000 
residues.  Both subunits participate in the ligand-binding head domain. Within this 
region, the a-subunit contains a divalent cation (ca2+ and Mg2+) binding site and a 
seven bladed b-propeller domain. A subset of a-subunits also incorporates an I-domain 
(a.k.a A domain) in their ligand-binding domain, which possesses a conserved metal 
ion–dependent adhesion site (MIDAS) required for ligand binding. Positioning of the 
___________________________________________________________________________________________________________
14
ligand-binding domain in the a-subunit is mediated by a thigh domain, b-knee, and 
two calf domains.
The b-subunit ligand-binding domain contains a b-I domain, which is analogous to 
the a-subunit’s I-domain. Positioning of the b ligand binding domain occurs through 
a hybrid domain, a PSI (plexin/semaphorin/integrin) domain and four epidermal 
growth factor (EGF) domains.
While cytoplasmic tails of integrins are very short, the b4 cytoplasmic domain forms 
an exception: it has a very large (1000 a.a) cytoplasmic domain that connects to 
intermediate filaments rather than the actin cytoskeleton (Litjens et al, 2006 (Suzuki
and Naitoh, 1990; Hogervorst et al., 1990; Rezniczek et al.,1998).
Signaling
Integrins can transmit signals bidirectionally: integrin-mediated adhesion induces 
intracellular signaling cascades (outside-in signaling) and intracellular stimuli regulate 
integrin-mediated adhesion by controlling integrin affinity (inside-out signaling).
Inside-out signaling – controlling integrin affinity
Electron microscopy, structural analysis, and mutation studies have identified integrins 
in two conformation states: low affinity (inactive form) and high affinity (active form) 
(shimaoka et al., 2002; Liddington and Ginsberg 2002; Hughes et al., 1996; Calderwood 
et al., 2004). In the inactive state, the integrin extracellular region is bent and the 
cytoplasmic tails of a- and b-subunits are close together. The interaction between 
the  a- and b-tails stabilizes the inactive conformation. In its active state, the integrin 
straightens out and the cytoplasmic tails are separated. The mechanism of integrin 
activation involves binding of the cytoplasmic protein, talin to the b cytoplasmic tail. 
The PTB domain within talin’s F3 subdomain binds to the b integrin tail, disrupting 
a salt bridge between the a- and b-tail. As a result, the cytoplasmic tails separate, a 
conformation change occurs, and the integrin ectodomain is extended (Tadokoro et 
al., 2003). More recently, it has been shown that in order to achieve maximal integrin 
activation, assistance of another anchoring protein, kindlin is required. The binding 
site for kindlin in the b-tail is distinct from the talin binding region (Moser et al., 2008). 
How the effects at the cytoplasmic site are propagated to the ligand-binding head is 
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debated and a “deadbolt” model as well as a “switchblade” model has been proposed 
Takagi and Springer, 2002; Zhu et al., 2007; Liddington,2002; Luo et al.,,2007; Anaout, 
Mahalingam, and Xiong, 2005).
Bivalent cations critically regulate ligand recognition by the head domain. The 
major role of cations is to promote a conformation in which the ligand-binding site 
is exposed (Dransfield et al., 1992; Mould et al., 1995; Bazzoni et al., 1995;Oxvig 
and Springer 1998,1999). In addition to affinity regulation, integrin clustering is an 
important factor contributing to adhesion strengthening, whereby post-adhesion 
accumulation of receptor–ligand bonds contributes to overall adhesiveness (avidity 
regulation). Clustering of integrins can also occur from integrin association with soluble 
multivalent ligands. In a ligand-independent manner, valency may also contribute to 
cellular polarization in which integrins cluster at the leading edge of a migrating cell 
(Van Kooyk and Figdor, 2000; Stewart and Hogg, 1996, Sampath et al,. 1998). The 
complexes that form as a result of integrin clustering contain a variety of proteins that 
facilitate crosstalk between other signaling pathways. 
Integrin deactivation is mediated via phosphorylation of tyrosines in the b-tails, which 
interferes with acidic and hydrophobic interactions between the b-tail and talin, thus 
causing changes in conformation that reduce ligand-binding affinity. Alternatively, 
association with negative regulators, such as phosphatidylinositol phosphate kinase 
type Iγ-90 that competes with the b-tail for talin (Calderwood et al., 2004; Ling et al., 
2003).
Outside-in and inside-out signaling - associating transmembrane proteins
Integrins do not transmit signals exclusively, but the interaction/cooperation of other 
transmembrane cell receptors facilitates signal transduction. Such partnership with 
other membrane receptors enhances affinity for ligand or intracellular signaling, e.g. 
during cell migration. 
Techniques for detecting, isolating and analyzing complexes of transmembrane 
proteins, for instance, co-immunoprecipitation and fluorescence resonance energy 
transfer (FRET) have been used to reveal a diversity of transmembrane proteins ranging 
from integrin-associated membrane proteases, growth factor receptors, immune 
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receptors, transporters, and channels  interacting with integrins. The regulation of 
ECM degradation is mediated by the integrin interaction with matrix metalloproteases 
(MMP). For example, MMP1 binds to the I domain of a2 in a2b1), and the MMP2 
carboxy-terminal hemopexin-like (PEX) domain interacts with avb3 (Stricker et al., 
2001; Brooks et al., 1998; Boger et al., 2001). Glycan phosphatidylinositol (GPI)-
linked proteins, such as uPAR (urokinase-type plasminogen activator receptor) bind 
to the b-propeller domain of aMb2 or a3b1 integrin to mediate cell migration, tumor 
invasion and host defense (Preissner et al., 2000; Simon et al., 2000). The association 
of uPAR with a3b1 takes place in caveolae, at least in some cells (Wei et al., 2001).
Integrin-associated protein (IAP; CD47) associates with either b1 or b3 integrins 
via its IgSF-like domain to form a functional unit that modulates heterotrimeric 
G-protein activity (Brown and Frazier, 2001; Wang et al.,1999). Transmembrane-4 
superfamily (TM4SF) members, a.k.a. tetraspanins have 4 membrane-spanning 
domain (2 extracellular loops and intercellular N- and C-termini) and form web-like 
networks (Berditchevski, 2001). Tetraspanin-integrin interactions have been shown in 
co-immunoprecipitation studies (CD9, CD53, CD63, CD81, CD82, CD151/PETA-3, and 
NAG-2). Tetraspanin-integrin complexes vary between cell types and one integrin can 
associate with one or more tetraspanins.  Integrins that are in the tetraspanin web 
are a3b1, a4b1, a6b1, a4b7, and aIIb3. Integrin-tetraspanin complexes have been 
implicated in the regulation of cell motility, metastasis and growth, integrin recycling, 
and directing integrin localization on the cell surface (Maecker,Do, and Levy, 1997; 
Hemler, 1998; Hemler, 2005; Berditchevski, 2001; Boucheix and Rubinstein, 2001; 
Hemler, Mannion, and Berditchevski, 1996;Y áñez-Mó, M. et al.,1998;Tachibana, I. et 
al.,1997).
It was suggested that growth factor receptors may associate with integrins because 
of their localization in FA and the regulation of proliferation in response to cell 
adhesion. Indeed, PDGF receptor and insulin receptor b subunit bind to avb3 integrin 
(Miyamoto, S. et al.,1996; Schneller, Vuori, and Ruoslahti, 1997; Bartfield et al., 1993; 
Vuori and Ruoslahti, 1994. It is speculated that integrin interaction functions to 
cluster growth factor receptors, which promotes efficient signaling or prevent “early 
dephosphorylation of growth factor receptors (Hellberg et al., 2009; Karlsson et 
al.,2006; Ivaska and Heino, 2010). Integrins may also bind growth factors themselves: 
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a9b1 integrin was found to bind to vascular endothelial growth factor (VEGF) to 
regulate aniogenesis and lymphangiogenesis (Vlahakis et al. 2007;2005).
Outside-in signaling - associating cytoplasmic proteins
Integrins have no enzymatic activity and depend on binding to intracellular proteins 
to transduce signaling. The intracellular domains are relatively short which restrict the 
number of proteins can bind at any one time. Approximately ~150 adhesion proteins 
have been identified that reside in integrin-mediated adhesion complexes (Zaidel-
bar et al., 2007). Linker proteins connect integrins with other cytoplasmic proteins, 
e.g, talin, a-actinin, and filamin. Signalling proteins, including adapters and kinases, 
such as Src, FAK, and paxillin mediate downstream signaling. Chaperone proteins, for 
instance Calnexin, which binds to a6b1 integrin, regulates integrin retention in the 
endoplasmic reticulum (Lenter and Vestweber, 1994). 
Upon ligand-binding and integrin clustering, integrins transduce a signal cascade 
through hierarchical assembly of these associated proteins. Talin is the first 
cytoskeletal protein to bind the integrin (thereby increasing integrin affinity - see 
above). Following integrin activation, vinculin interacts with talin and recruits paxillin 
(Brakebusch and Fassler, 2003). Through phosphorylation by the FAK-Src complex, 
paxillin becomes activated and recruits other signaling proteins to stimulate further 
downstream signaling. One example is the activation of the Rho family of small 
GTPases: by controlling their activity, integrins regulate RhoA-dependent cytoskeletal 
structures such as stress fibers and FA as well as Rac-dependent structures such as 
lamellipodia. In this way, integrin signaling controls cytoskeletal dynamics underlying 
membrane protrusion and cell migration.
Integrin function
Besides providing structure to organs through cell adhesion, integrin-mediated 
signaling regulates cell behavior such as, proliferation, migration, but also ECM 
assembly. Integrins mediate binding to - but also formation of ECM networks. In the 
case of FN, initiation of matrix assembly begins with binding of FN dimers to integrins. 
Subsequently, in a manner that depends on Rho GTPase-mediated contractility, 
integrin-bound FN molecules are stretched and this conformational change increases 
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FN-FN interactions by exposing cryptic FN-binding sites (Mao and Schwarzbauer, 
2005). Not all ECM networks depend on integrin interaction: tropocollagens (rod-
like collagens) can spontaneously self-assemble to form collagen fibrils during 
fibrillogenesis (Koide and Nagata, 2005).
Cell migration is crucial for development, wound healing, and tumor metastasis. 
Integrin traffic (recycling) contributes to the dynamics of adhesion assembly and 
disassembly, which drive migration. Internalized integrins (disassembly of adhesion 
structure, FA) from the trailing edge are transported to the newly formed lamellipodium 
at the leading edge (assembly of adhesion structure, FC) (Caswell and Norman, 2006; 
Pellinen and  Ivaska, 2006). In polarized migratory cells, adhesion dynamics at the 
front differ from those at the rear indicating local differences in integrin affinity or 
regulation of the adhesion complex (Broussard, Webb, and Kaverina, 2007; Ridley et 
al., 2003; Schwartz and hortwiz, 2006).
Both cell migration and ECM assembly are important for embryogenesis and tissue 
repair (wound healing) but also for cancer progression. Synthesis and organization 
of the ECM has been implicated in formation of a pre- metastatic niche. For example, 
fibroblasts secrete FN to which bone marrow-derived cells can adhere. Subsequently, 
the presence of these cells primes the environment for colonization by metastatic 
tumor cells (Psaila and Lyden, 2009).
Taken together, integrins mediate cell adhesion in a highly controlled fashion. They 
also participate in the regulation of intracellular signaling cascades. Hence, they 
are important receptors in many physiological processes. Moreover, they appear to 
regulate several pathological processes, including cancer progression.
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Scope of the thesis
Studies from the mid 60’s on malignant cells indicate cell adhesion as a key regulatory 
factor in many cellular functions (Macpherson and Montagnier, 1964). Altered 
adhesion-dependency is a key step in malignant transformation. For instance, 
proliferation and survival (anchorage-dependent processes) are hindered when 
non-transformed cells are cultured in suspension whereas cancer cells are typically 
anchorage-independent (Stoker, 1968). Nevertheless, later studies have shown that 
integrins regulate various aspects of cancer progression (chapter 5 and 7 of this thesis) 
and might be exploited by the pharmaceutical industry.
The aim of this thesis is to address how integrin-mediated signaling regulates cellular 
processes that have profound effects on cell morphology, motility, cancer metastasis, 
and FN fibrillogenesis, and how these findings can be utilized for relevant medical 
purposes or advancement of drug discovery. The effects on migration and remodeling 
of FN fibrils are important for cancer progression and embryo development.  In 
Chapter 2 we discuss how the expression of different FN-binding integrins can have 
dramatic effects on cell adhesion dynamics and cell motility. In Chapter 3 we describe 
how a5b1 and avb3 integrins affect contractility / matrix organization. The ability of 
the integrin α5β1 hypervariable region of the ligand-binding I-like domain but not that 
of avb3, with soluble, compact inactive FN molecules appears to affect FA formation, 
Rho-mediated contractility, and FN fibrillogenesis. Moreover, in chapter 4 we show 
that the interaction with certain cytoplasmic proteins differes between these two 
integrins. We report a novel integrin assocating partner MacMarcks (MRP), which 
regulates cell morphology , actin cytoskeletal organization, and FA distribution through 
the interaction of avb3 integrin. Interestinly, the interaction of avb3 integrin initiates 
transcriptional down-regulation of MRP, which leads to cytoskeletal reorganization. 
Aberrations in expression level of - or mutations in the integrin, can cause defects in 
normal cellular function (e.g. anoikis / loss-of-anchorage-induced apoptosis) or affect 
cancer progression (e.g. enhanced tumor growth). It has been shown that blocking 
integrins can be a means to prevent progression of cancer or other diseases. However, 
drug development has reached a bottleneck because of low efficacy and high toxicity. 
To increase effectiveness of old drugs and improve the speed of drug discovery, 
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development of proper drug screening approaches is required.  In chapter 5 we explain 
how integrin-mediated signaling can affect survival, proliferation, differentiation, and 
disease, and how antagonists of α5β1 and αvβ3 integrins, including disintegrins, RGD 
peptides, small molecules, and function blocking antibodies, may be of therapeutical 
value either alone or in combination with existing therapeutical strategies. In chapter 
6, we describe a novel method that is highly useful for drug screening. Cell-polymer 
suspensions are microinjected as droplets into collagen gels. Formation time of 
microinjected derived-cell spheroid (CS) is strongly reduced compared to other 
methods and can be applied to a broad range of cell types. For high-throughput 
screening purposes, we have automated this method to produce CS with defined x-y-z 
spatial coordinates in 96 well plates. We demonstrate the potential of this automated 
method to develop personalized cancer treatment strategies. Chemical inhibitors are 
tested on cell lines as well as freshly isolated tumor material from mouse and human 
biopsies to identify compounds affecting cancer cell invasion/migration. Finally, in 
chapter 7, we show that silencing b1 integrin has a dual effect on cancer growth and 
progression. In an orthotopic mouse model, growth of b1-deficient breast cancers is 
significantly reduced in accordance with other studies; however intravasation and 
lung metastasis are highly increased. We demonstrate that b1 integrin depletion leads 
to drastic cellular reprogramming, which involves down-regulation of E-cadherin by 
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When cells are stimulated to move, for instance during devel-
opment, wound healing or angiogenesis, they undergo changes in 
the turnover of their cell-matrix adhesions. This is often accom-
panied by alterations in the expression profile of integrins—the 
extracellular matrix receptors that mediate anchorage within these 
adhesions. Here, we discuss how a shift in expression between two 
different types of integrins that bind fibronectin can have dramatic 
consequences for cell-matrix adhesion dynamics and cell motility.
Cells attach to the extracellular matrix (ECM) that surrounds 
them in specialized structures termed “cell-matrix adhesions.” These 
come in different flavors including “focal complexes” (small adhe-
sions found in membrane protrusions of spreading and migrating 
cells), “focal adhesions” (larger adhesions connected by F-actin stress 
fibers that are derived from focal complexes in response to tension), 
“fibrillar adhesions” (elongated adhesions associated with fibronectin 
matrix assembly), and proteolytically active adhesions termed “podo-
somes” or “invadopodia” found in osteoclasts, macrophages and 
certain cancer cells. Common to all these structures is the local 
connection between ECM proteins outside- and the actin cytoskel-
eton within the cell through integrin transmembrane receptors. The 
intracellular linkage to filamentous actin is indirect through proteins 
that concentrate in cell-matrix adhesions such as talin, vinculin, 
tensin, parvins and others.1
Cell migration is essential for embryonic development and a 
number of processes in the adult, including immune cell homing, 
wound healing, angiogenesis and cancer metastasis. In moving cells, 
cell-matrix adhesion turnover is spatiotemporally controlled.2 New 
adhesions are made in the front and disassembled in the rear of cells 
that move along a gradient of motogenic factors or ECM proteins. 
This balance between formation and breakdown of cell-matrix adhe-
sions is important for optimal cell migration. Several mechanisms 
regulate the turnover of cell-matrix adhesions. Proteolytic cleavage 
of talin has been identified as an important step in cell-matrix adhe-
sion disassembly3 and FAK and Src family kinases are required for 
cell-matrix adhesion turnover and efficient cell migration.4,5 Besides 
regulating phospho-tyrosine-mediated protein-protein  interactions 
within cell-matrix adhesions, the FAK/Src complex mediates signaling 
downstream of integrins to Rho GTPases, thus controlling cytoskel-
etal organization.6,7 The transition from a stationary to a motile state 
could involve (local) activation of such mechanisms.
Interestingly, conditions of increased cell migration (development, 
wound healing, angiogenesis, cancer metastasis) are accompanied by 
shifts in integrin expression with certain integrins being lost and 
others gained. Most ECM proteins can be recognized by various 
different integrins. For instance, the ECM protein, fibronectin (Fn) 
can be recognized by nine different types of integrins and most of 
these bind to the Arg-Gly-Asp (RGD) motif in the central cell-
binding domain. Thus, cell-matrix adhesions formed on Fn contain 
a mixture of different integrins and shifts in expression from one class 
of Fn-binding integrins to another will alter the receptor composi-
tion of such adhesions. This may provide an alternative means to 
shift from stationary to motile.
Indeed, we have found that the type of integrins used for 
binding to Fn strongly affects cell migration. We made use of cells 
deficient in certain Fn-binding integrins and either restored their 
expression or compensated for their absence by overexpression of 
alternative Fn-binding integrins. This allowed us to compare in a 
single cellular background cell-matrix adhesions containing α5β1 to 
those containing αvβ3. Despite the fact that these integrins support 
similar levels of adhesion to Fn, only α5β1 was found to promote a 
contractile, fibroblastic morphology with centripetal orientation of 
cell-matrix adhesions8 (Fig. 1). Moreover, RhoA activity is high in 
the presence of α5β1 and these cells move in a random fashion with 
a speed of around 25 mm/h. By contrast, in cells using αvβ3 instead, 
adhesions distribute across the ventral surface, RhoA activity is low, 
and these cells move with similar speed but in a highly persistent 
fashion.8,9 Finally, photobleaching experiments using GFP-vinculin 
and GFP-paxillin demonstrated that cell-matrix adhesions containing 
α5β1 are highly dynamic whereas adhesions containing αvβ3 are 
more static.9
It has been observed that α5β1 and αvβ3 use different recycling 
routes. Interfering with Rab4-mediated recycling of αvβ3 causes 
increased Rab11-mediated recycling of α5β1 to the cell surface. In 
agreement with our findings, the shift to α5β1 leads to increased 
Rho-ROCK activity and reduced persistence of migration.10 One 
possible explanation for the different types of migration promoted 
by these two Fn-binding integrins might involve different signaling 
and/or adaptor proteins interacting with specific amino acids in their 
cytoplasmic tails. However, this appears not to be the case: α5β1 in 
which the cytoplasmic tails of α5 or β1 are replaced by those of αv 
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or β3, respectively, behaves identical to wild type α5β1: it promotes a 
fibroblast-like morphology with centripetal orientation of cell-matrix 
adhesions and it drives a non-persistent mode of migration.8,11 
Together, these findings point to differences between α5β1 and 
αvβ3 integrins in the mechanics of their interaction with Fn, which 
apparently modulates intracellular signaling pathways in control of 
cell-matrix adhesion dynamics and cell migration.
How might this work? It turns out that although α5β1 and αvβ3 
similarly support cell adhesion to immobilized (stretched) Fn, only 
α5β1 efficiently binds soluble, folded (“inactive”) Fn.11 We have 
proposed that such interactions with soluble Fn molecules (possibly 
secreted by the cell itself ) may weaken the interaction with the 
immobilized ligand thereby causing enhanced cell-matrix adhesion 
dynamics in the presence of α5β1,11 (Fig. 1). Preferential binding of 
soluble Fn by α5β1 could be explained by differences in accessibility 
of the RGD binding pocket between α5β1 (more exposed) and αvβ3 
(more hidden) as suggested by others.12 If this is the case, immobi-
lization (“stretching”) of Fn apparently leads to reorientation of the 
RGD motif in such a way that it is easily accessed by both integrins.
The issue is considerably complicated by the fact that other 
recognition motifs are present in the Fn central cell-binding domain. 
In addition to the RGD sequence in the tenth Fn type 3 repeat 
(IIIFn10), binding of α5β1, but not αvβ3, also depends on the 
PHSRN “synergy” sequence in IIIFn9.13-15 The relative contribution 
of these motifs is controversial and there is structural data pointing 
either towards a model in which IIIFn9 interacts with α5β1 or 
towards a model in which IIIFn9 exerts long-range electrostatic 
steering resulting in a higher affinity interaction without contacting 
the integrin.16,17 Cell adhesion studies have suggested that an 
interaction of α5β1 with the synergy region stabilizes the binding 
to RGD.14,18 Such a two-step interaction may facilitate binding to 
full length, folded Fn for instance by altering the tilt angle between 
IIIFn9 and IIIFn10 leading to optimal exposure of the RGD loop, 
perhaps explaining why αvβ3 (which may not interact with the 
synergy site) poorly binds soluble Fn.
Others have shown that the RGD motif alone is sufficient for 
mechanical coupling of αvβ3 to Fn whereas the synergy region is 
required to provide mechanical strength to the α5β1-Fn bond.19 It 
appears that the interaction of α5β1 with Fn is particularly dynamic 
with various conformations of α5β1 interacting with different Fn 
binding surfaces, including the RGD and synergy sequences as well 
as other regions in IIIFn9. Thus, besides the above model based 
on differential binding to soluble Fn molecules, differences in the 
complexity and dynamics of interactions with immobilized Fn 
that determine functional binding strength could also underlie the 
different dynamics of cell-matrix adhesions containing either α5β1 
or αvβ3 (Fig. 1).
Precisely how mechanical differences in receptor-ligand interac-
tions result in such remarkably distinct cellular responses is poorly 
understood. In addition to effects on cell-matrix adhesion dynamics 
and cytoskeletal organization it is also associated with different 
activities of Rho GTPases, indicating that mechanical differences 
between these two integrins must translate into differential activation 
of intracellular signaling pathways.8,9,11 Possibly, different adhesion 
dynamics due to distinct mechanisms of receptor-ligand interaction 
result in different patterns of F-actin organization, which, in turn, 
affects the formation of signaling platforms. It is also possible that 
differences in the extent of integrin clustering have an impact on 
the conformation of one or more cytoplasmic components of the 
cell-matrix adhesions containing either α5β1 or αvβ3. This could 
lead to hiding or exposing binding sites for signaling molecules (e.g., 
upstream regulators of Rho GTPases) or substrates. Whatever the 
mechanism involved, altering the integrin composition of cell-matrix 
adhesions through shifts in integrin expression as observed during 
development, angiogenesis, wound healing and cancer progression 
may be a driving force in the enhanced cell migration that character-
izes those processes.
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Integrin-mediated adhesion regulates multiple signaling pathways. Our group previously
showed that ectopic expression of different integrin β-subunits in the neuroepithelial cell
line GE11, has distinct effects on cell morphology, actin cytoskeletal organization, and on
focal contact distribution. In this report we have investigated changes in gene transcription
levels resulting from overexpression of the integrin β3 subunit. We found that β3
overexpression leads to the transcriptional downregulation of MARCKS related protein
(MRP) resulting in a decreased expression of theMRP protein. Furthermore, we show that the
Ras/MAPK pathway controls the basal level of MRP expression but β3 overexpression
bypasses this pathway downstream of ERK to downregulate MRP. Further studies indicate
that a region of the cytoplasmic tail of β3 containing part of the NITYmotif is responsible for
increased cell spreading and MRP downregulation. However, MRP overexpression failed to
inhibit the β3-induced increase in cell spreading while the knock down of MRP expression in
GE11 cells did not increase cell spreading. We suggest that the downregulation of MRP by β3
is not required for increased cell spreading but instead that MRP downregulation is a
secondary effect of increased cell spreading.












Integrin-mediated cell adhesion is essential during develop-
ment and wound healing and influences the characteristics of
malignant tumors [1,2]. Members of the integrin family of
hetero-dimeric transmembrane proteins connect the extra-
cellular matrix (ECM) to the actin cytoskeleton and modulate
adhesion and migration by means of different downstream
signaling pathways [3,4]. In this complex mechanism the
regulation of gene expression by integrin-dependent adhesion
is also thought to play a role. Studies withmonocytes revealed
that adhesion to diverse substrata regulates the expression of
several genes coding for cytokines and transcription-asso-
ciated factors (see for review: [5]). Fibroblasts upregulate
collagenase, stromelysin, gelatinase and c-fos expression
when adhered to a matrix of fibronectin and tenascin but
not on fibronectin alone [6]. Furthermore, antibodies binding
to the integrin subunits α1 and α2 inhibit stromelysin-1
expression [7]. The binding of α5β1 to fibronectin or of αvβ3
to vitronectin increases Bcl-2 levels through the PI3K–Akt
pathway [8]. Also, in Drosophila, the presence of the integrin
PS1 is required for the normal expression of two genes in the
midgut [9]. More recently it was reported that the cell cycle
regulator cdc2 is upregulated after re-expression of αvβ3 in β3
knockout cells resulting in increasedmigration [10]. Moreover,
overexpression of β3 in CHO cells leads to a decrease in uPAR
expression by bypassing the Ras/MAPK pathway that regu-
lates basal expression of uPAR. The NITY motif in the β3
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cytoplasmic tail is important for uPAR downregulation and
binds to the short isoform of the β3 binding protein, β3-
endonexin, that has been shown to downregulate uPAR
transcription [11].
Previously, the profound effects of β1 re-expression in the
β1 knockout neuroepithelial cell line, GE11, were investigated
[12]. Re-expression of β1 in GE11 cells (GEβ1 cells) results in the
loss of cell–cell contacts while the cells acquire a fibroblast-
like appearance. On the other hand, overexpression of β3 in
this cell line (GEβ3 cells) increased cell spreading and focal
contact formation while disrupting cell–cell contacts. Expres-
sion of β1 or overexpression of β3 enhanced migration albeit
through different modes [12–14]. Since β3 overexpression led
to drastic morphological changes we hypothesized that the
expression of some genes is regulated by β3. To identify such
genes a microarray analysis was performed. Surprisingly, β3
overexpression led to the downregulation of only a single gene
that codes for the protein MacMARCKS. MacMARCKS or
MARCKS-related protein (MRP) is a small acidic protein with
an N-terminal myristoylation site that is inserted into lipid
bilayers [15] and a positively charged effector domain (ED) that
can bind to negatively charged phospholipids in the plasma
membrane [16]. MRP is also thought to bind to actin [17],
calmodulin [18] and dynamitin [19], and is phosphorylated at
serine residues by PKC [20]. MRP is implicated in the activation
of integrins and cell spreading by regulating the cortical actin
network [21,22]. The expression of MARCKS, a protein closely
related to MRP, is downregulated by the oncogenes v-Jun [23],
v-Src [24], c-Ras [25] and H-Ras (dataset from [26]). In contrast,
stimulation of BV-2 microglial cells with LPS increases
MARCKS and MRP expression via Src kinases [27].
We report that the Ras/MAPK pathway regulates MRP
expression in GE11 cells because MEK inhibition led to an
increase in MRP expression while RasV12 expression in GE11
cells downregulated MRP expression. Interestingly, β3 over-
expression bypassed this pathway downstream of ERK to
downregulate MRP expression. Furthermore, we excluded
other pathways since we found that overexpression of
activated Src, or of β3-endonexin or the inhibition of PI3K
did not affect MRP expression. We further show that the
presence of the cytoplasmic tail of β3 up to the isoleucine
residue of the NITY motif is essential for MRP downregulation
but also for increased cell spreading. In another cell line, β3
overexpression also increased cell spreading while MRP
expression was downregulated, suggesting that these two
effects are linked. However, overexpression of MRP in GEβ3
cells did not inhibit cell spreading while knocking down MRP
expression in GE11 cells did not increase spreading. Finally, we
present data showing that β3 overexpression regulates the
localization of MRP.
Materials and methods
Antibodies and other materials
The following antibodies were used: polyclonal antibodies
against MRP (10002-2-Ig, Proteintech Group Inc), MARCKS (m-
20, Santa Cruz), monoclonal anti-α-tubulin (clone B-5-1-2,
Sigma), monoclonal anti-pan cadherin (clone CH-19, Sigma),
monoclonal anti-paxillin (BD Transduction Labs clone 1665),
monoclonal ERK2 (BD Transduction Labs clone 33), phospho-
ERK rabbit Ab (Cell Signaling #9101). The monoclonal anti-
human β3 Ab 23C6 was kindly provided by Dr. Michael Horton
(University College London, London, UK). The monoclonal
anti-vinculin (clone VIIF9; [34]) and anti-β3 (clone C17)
antibodies were kindly provided by Dr. Marina Glukhova
(Institut Curie, Paris, France) and Dr. Ellen van der Schoot
(Sanquin, Amsterdam, the Netherlands), respectively. Texas
Red-conjugated phalloidin was obtained from Molecular
Probes. PMA, LY294002 and PD98509 were from Sigma.
Cell lines
GE11 cells have been isolated previously [12] and GE11 cells re-
expressing the human β1 or overexpressing the human β3
integrin subunit or expressing the chimera integrin subunits
β3-1 or β1-3 were established in our laboratory [12,13]. Cells
were cultured in DMEM with 10% fetal calf serum, penicillin
and streptomycin. mSCC2 is a mouse squamous cell carci-
noma cell line isolated from a skin tumor induced by the two-
stage chemical carcinogenesis protocol (Karine Raymond,
unpublished results). The human pancreatic adenocarcinoma
cell line NP18 has been described previously [28].
cDNA, plasmids and generation of mutants
Full-length MRP was a kind gift from Dr. Deborah Stumpo
(National Institute of Environmental Health Science, Research
Triangle Park, NC). MRP was cloned into the pEGFP-N1 vector
(BD Biosciences, Clontech) by digestion with BamHI and the
fragment encoding MRP–GFP was recloned into the retroviral
vector LZRS-IRES-zeo [29]. β3 deletionmutant constructs were
obtained from Dr. Jari Ylänne (University of Oulu, Oulu,
Finland) and cloned into the same retroviral vector. The
retroviral expression plasmid encoding H-RasG12V (Rasv12) was
provided by Dr. John Collard (The Netherlands Cancer
Institute, Amsterdam, The Netherlands). Both long and short
isoforms of β3-endonexin taggedwith GFPwere obtained from
Dr. Meinrad Gawaz (E.H. University of Tubingen, Tubingen,
Germany) and cloned into the retroviral LZRS vector. The
activated c-Src (Y529F) cDNA was obtained from Upstate
Biotechnology. Restriction sites for EcoRI and NotI were
added on the 5′ and 3′ ends of the construct along with a
myc tag and stop codon at the 3′ end by PCR using the following
primers: 5′ GGAATTGAATTCATGGGCAGCAACAAGAGCAA-
GAGCAAGCCCAAGGAC and 3′ GGACCTTGCGGCCGCCTAGTT-
CAGATCCTCTTCTGAGATGAGTTTTTGTTCTAGGTTCTCCCC-
GGGCTGGTACTGTGGGCTC. The fragment was subsequently
cloned into the LZRS–IRES–EGFP vector.
Retroviral transductions
Cell lines expressing activated RasV12, c-Src, MRP–GFP, β3 or
deletion mutants of this subunit were established using
retroviral transduction. Cells were transduced by adding
1 ml virus-containing supernatant to 105 cells in 8 ml medium
and incubated for 16 h in the presence of DOTAP (Boehringer).
Transduced cells were maintained in fresh medium and
sorted three times for a positive GFP signal by FACS® or were
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labeled with anti-β3 antibody and FACS sorted after selection
with zeocin. A clonal cell line was established from the Src-
expressing GE11 cells and used for transduction of β3.
Resulting cells were sorted three times for β3 expression.
Microarray analysis
Microarray slides were prepared at the central microarray
facility (CMF) at the Netherlands Cancer Institute. A list of
genes is available at http://microarrays.nki.nl/download/geneid.
html. Cell lineswere grown on plastic in normal growthmedium
and total RNA was isolated, labeled and hybridized as described
at http://www.nki.nl/nkidep/pa/microarray/protocols.htm.
Northern blot analysis
Corresponding clones of the identified genes were obtained
from the central microarray facility. DNA was isolated,
sequenced and used as templates for PCR reactions to obtain
a suitable probe for Northern blot analysis. The following
primers were used for MRP (AAGGAGACCCCCAAGAAGAA and
CTCATTCTGCTCAGCACTGG). Total RNA was isolated using
guanidine–isothiocyanate (GIT). Briefly, cells were lysed in a
buffer containing 4 M GIT, 25 mM sodium citrate, 0.1 M β-
mercaptoethanol, and 0.5% sarkosyl. RNA was isolated after
phenol chloroform extraction and was precipitated with
isopropanol. Northern blots were performed using standard
protocols.
Cell labeling and immunoprecipitation
Cells were surface-labeled with 125I using lactoperoxidase as
described previously [30]. Cells were lysed in 1%Nonidet P40 in
25 mM Tris–HCl, pH 7.5, 4 mM EDTA, 100 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride, 10 μl/ml leupeptin and 10 μl/
ml soybean trypsin inhibitor. Cell lysates were clarified by
centrifugation and immunoprecipitations were performed
with antibodies bound to protein A-Sepharose (Pharmacia
LKB Biotechnology Inc.) or to protein A-Sepharose conjugated
with rabbit anti-rat IgG or anti-mouse IgG. Immunoprecipi-
tates were analyzed by SDS–PAGE under non-reducing condi-
tions and visualized using Kodak Biomax XAR film.
Western blot analysis
Cell culture plates containing attached cells were washedwith
PBS and lysis buffer [50 mM HEPES pH 7.5, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 100 mM
NaF, and inhibitor cocktail (Sigma)] was added. Cells were
scraped and centrifuged for 2 min at 14,000 rpm. 20 μl of lysate
was added to 5 μl 3× SDS sample buffer (Biolabs) and boiled.
Samples were loaded onto SDS–PAGE gels, separated and
transferred to polyvinylidene difluoride membranes (Milli-
pore) and analyzed by Western blotting followed by ECL using
the Super signal system (Pierce Chemical Co.).
Immunofluorescence and flow cytometry
For immunofluorescence cells were fixed in 2% paraformal-
dehyde for 15 min and permeabilized with 0.2% Triton X-100
for 5 min with PBS washing in-between steps. Coverslips were
subsequently blocked with 2% BSA in PBS for 1 h at room
temperature (RT). Coverslips were incubated with primary
antibodies for 1 h at RT, washed three times in PBS and
incubatedwith FITC or Texas Red secondary antibody (Jackson
ImmunoResearch Laboratories) for 1 h at RT. Slides were
mounted in MOWIOL 4–88 solution supplemented with
DABCO (Calbiochem) and examined with a confocal Leica
TCSNTmicroscope. For all immunofluorescence experiments,
4 random fields each of three independent experiments were
examined of which a representative image was used for
publication. For cell sorting cells were trypsinized, washed
twice in PBS supplemented with 2% serum and incubatedwith
primary antibody for 1 h at 4 °C. After three washes, cells were
incubated with FITC- or PE-conjugated secondary antibody for
1 h at 4 °C. Finally cells were washed and resuspended in PBS
with 2% serum and sorted using a FACStar plus® (Becton
Dickinson). Cells expressing GFP constructs were trypsinized
and washed before being sorted.
RNAi against MRP
A SMARTpool® from Dharmacon consisting of 4 siRNAs
(catalog number M-042960-00-0010) against MRP (NM_010807)
was used to transfect GE11 cells along with the standard
siCONTROL® siRNA from Dharmacon as negative control. Cells
were transfected using the standard transfection protocol
provided by Dharmacon using the transfection reagent
DharmaFECT® 1. Protein expression was assessed 48 h after
transfection while at the same time cells were fixed and
stained for confocal analysis.
Results
Overexpression of β3 in GE11 cells regulates MRP expression
GE11 cells have an epithelial morphology adhering to one
another with well-defined cell–cell contacts. They have small,
peripheral focal contacts and a thick cortical actin ring present
along the circumference of the entire epithelial island. Over-
expression of β3 in GE11 cells (GEβ3 cells), causes a re-
organization of the actin cytoskeleton resulting in the loss of
the cortical actin ring and the formation of short, thick stress
fibers connected to a large number of focal contacts and the
loss of cell–cell contacts (Fig. 1A).
Since β3 overexpression induced these dramatic morpho-
logical changes in GE11 cells, we hypothesized that the
regulation of some genes would be changed. To identify
these genes we performed a microarray analysis of the GEβ3
cell line using GE11 cells as reference. Genes, whose transcrip-
tion level differed three-fold ormore from that in the reference
GE11 cells were selected. Surprisingly, despite the dramatic
morphological changes induced by β3 overexpression in GE11
cells, the transcription of only a single gene appeared to be
affected. The transcription of this gene, Mlp, coding for the
protein MRP was downregulated by 72% in GEβ3 cells as
compared with GE11 cells. This was confirmed by Northern
blot analysis because mRNA levels for MRP were strongly
decreased in GEβ3 cells in comparison to GE11 cells (Fig. 1B). To
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determine if the decrease in Mlp transcription also led to a
decrease in MRP expression, lysates of GE11, GEβ3 and GEβ1
cells were analyzed by Western blot. Indeed, MRP expression
was diminished after β3 overexpression but remained
unchanged in GEβ1 cells (Fig. 2A). To exclude the possibility
that the observed downregulation of MRP expression is
attributable to clonal variation, we analyzed several indepen-
dent, bulk-sorted GEβ3 cell populations. MRP expression was
diminished in all of them (data not shown). Western blot
analysis showed that β3 overexpression had no effect on the
expression of MARCKS (Fig. 2A). Therefore, overexpression of
β3 in GE11 cells results in the specific downregulation of MRP
expression.
The cytoplasmic tail of β3 downregulates MRP expression only
when it is associated with the αv subunit
Integrins convert signals from the extracellular environment
into intracellular signals via their cytoplasmic tails [3]. We
hypothesize that the cytoplasmic tail of β3 is involved in the
downregulation of MRP expression. To test this, a chimera of
the β3 extracellular and transmembrane domain, fused to the
β1 cytoplasmic tail (β3-1) and a construct of the β1 extra-
cellular and transmembrane domains fused to the β3
cytoplasmic tail (β1-3) were expressed in GE11 cells and MRP
expression was measured (Fig. 2B). Expression of the chi-
meras did not affect MRP expression indicating that the
presence of the cytoplasmic tail of β3 without the extra-
cellular domain, or vice versa, was insufficient to down-
regulate MRP expression.
Possibly, the effect on MRP expression depends on the α
subunit that is associated with β3. For that reason we
identified the integrin complexes present on the surface of
the cells expressing full-length β3 or either of the chimeras
(Fig. 2C). Both full-length β3 and the β3-1 chimera were
associated with the αv subunit while the β1-3 chimera was
associated with α5 and/or α3. Therefore, the cytoplasmic tail
or the extracellular domain of β3 by themselves cannot affect
MRP expression but instead it is the association of the αv and
the β3 subunits that mediates this effect.
A distinct region of the β3 cytoplasmic tail is responsible for
increased cell spreading and MRP downregulation
To characterize the underlyingmechanism responsible for the
regulation of MRP by β3, we sought to identify the region
within the β3 cytoplasmic tail that mediates the down-
regulation of MRP expression. MRP expression was measured
Fig. 2 – αvβ3 only downregulates MRP expression. (A)
Western blot stained for MRP and MARCKS expression in
GE11, GEβ1 and GEβ3 cell lines. Tubulin was visualized
on the same blot as the loading control. (B) Western blot
for MRP expression on lysates of GEβ3, GEβ3-1 and GEβ1-3
cells with tubulin staining used as loading control.
(C) Surface-expressed integrins were labeled using 125I and
immunoprecipitated using antibodies against the indicated
integrin subunit.
Fig. 1 – Analysis of gene transcription afterβ3 overexpression.
(A) Phase contrast and confocal analysis of GE11 andGEβ3 cells.
Cells were stained with anti-paxillin antibodies in green and
withphalloidin in red. (B) Total RNAwas isolated fromGE11and
GEβ3cellsandanalyzedusingNorthernblot.mRNAbandswere
visualized using radioactively labeled probes.
1263E X P E R I M E N T A L C E L L R E S E A R C H 3 1 3 ( 2 0 0 7 ) 1 2 6 0 – 1 2 6 9
___________________________________________________________________________________________________________
40
in several cell lines expressing different truncated β3 con-
structs (Fig. 3A). Our data shows that expression of a construct
with a deletion of the five C-terminal residues of β3
representing the complete Src-binding motif (RGT) [31] and
the tyrosine and threonine residues of the NITY motif still led
to downregulation of MRP expression. However, the expres-
sion of further truncated constructs of the cytoplasmic tail of
β3 no longer had an effect on MRP expression (Fig. 3B).
Interestingly, β3-induced increased cell spreading appeared to
depend on the same region of the cytoplasmic tail that
influences MRP expression (Fig. 3C). Thus, it is possible that
proteins that bind to β3 in the vicinity of the NITY motif are
involved in the regulation of MRP expression as well as in
increased cell spreading.
The Ras/MAPK pathway regulates the basal level of MRP
expression in GE11 cells but β3 overexpression bypasses this
pathway to downregulate MRP
Stimulation of BV-2 microglial cells with LPS upregulates MRP
expression through a Src dependent signaling pathway [27].
Moreover, MARCKS expression is downregulated by v-Src and
c-Ras expression in 3T3 cells [25]. Thus, the question arose
whether β3 overexpression in GE11 cells downregulates MRP
expression through a Src-dependent pathway or the Ras/
MAPK pathway. GE11 cell lines were established expressing
activated c-Src or expressing activated c-Src together with β3.
Western blot analysis of these cell lines indicated that the
expression of activated c-Src did not affect MRP expression in
the GE11 or β3 overexpressing cell lines (Fig. 4A). Src kinases
and protein tyrosine kinases (PTK) were inhibited in GEβ3 cells
using PP2 and Herbimycin A, respectively (Fig. 4B). Neither Src
nor PTK inhibition restored MRP expression. Therefore, the
regulation of MRP by β3 is independent of Src activity.
To test whether the Ras/MAPK pathway is involved in the
regulation of MRP expression, GE11 and GEβ3 cells were
incubated for increasing periods of time with 25 μM PD98509.
ERK phosphorylation levels decreased after an incubation of
1 h. Interestingly, MRP levels increased sharply after 1 h in
GE11 cells but not in GEβ3 cells (Fig. 5A). Both cell lines were
also incubated for 2 h with increasing concentrations of
PD98509. ERK phosphorylation levels were decreased in both
cell lines after incubationwith 10 μM, but MRP expression only
increased in GE11 cells after incubation with 10 μM PD98509
while there was no change in MRP expression in GEβ3 cells
(Fig. 5B). To confirm that the Ras/MAPK pathway regulates
MRP expression, a RasV12 construct was stably expressed in
GE11 cells. Expression of RasV12 resulted in increased ERK
phosphorylation alongwith a decrease in MRP expression (Fig.
5C). Therefore, the Ras/MAPK pathway regulates MRP expres-
sion in GE11 cells, but β3 overexpression bypasses the effect of
ERK phosphorylation to downregulate MRP expression.
Two other pathways that were previously implicated in
gene regulation downstream of integrinswere investigated for
their possible role in the β3-dependent downregulation ofMRP
expression. Firstly, it was reported that the short isoform of
the β3 integrin-binding protein, β3-endonexin, is important
for the downregulation of uPAR expression after β3 over-
expression in CHO cells [11]. To investigate if β3-dependent
MRP downregulation is mediated by β3-endonexin, constructs
with the long or short isoform fused to GFP were expressed in
GE11 cells followed by Western blot analysis of MRP (Fig. 4C).
MRP expressionwas not influenced by the expression of either
isoform of endonexin. Therefore, β3-induced downregulation
of MRP is not dependent on the presence of β3-endonexin.
Secondly, it was shown that ligand binding by αvβ3 and α5β1
leads to increased Bcl-2 expression through the activity of the
PI3K pathway [8]. We investigated if PI3K plays a role in the
regulation of MRP expression by incubating GE11 and GEβ3
cells overnight with the specific inhibitor LY294002 and
analyzing MRP expression. The data shows that LY294002
did not alter MRP expression at the concentrations tested (Fig.
Fig. 3 – The distal NITYmotif is essential for downregulation
of MRP expression and increased cell spreading. (A) Diagram
depicting the deletionmutants of theβ3 and showing the last
amino acids of each mutant. (B) Cells expressing deletion
mutants were analyzed for MRP expression by Western blot.
(C) Confocal images of these cells stained for paxillin and
F-actin indicate the differences in FC formation, F-actin
organization and cell shape.
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4D). Therefore, the PI3K pathway is not involved in β3-
mediated regulation of MRP expression.
MRP downregulation and cell spreading are regulated by β3 in
the NP18 cell line
To determine if the downregulation of MRP expression by
overexpressed β3 only occurs in GE11 cells, we measured
MRP expression in two other cell lines overexpressing β3. In
the pancreatic carcinoma cell line, NP18, MRP was down-
regulated after β3 overexpression but MRP expression was
not affected in the mouse squamous cell carcinoma cell line
mSCC2 (Fig. 6A). Paxillin and actin staining of the parental
NP18 cells indicated that focal contacts were present in
clusters evenly spaced at the cell periphery in close proximity
to a cortical actin network. In contrast, in the NP18-β3 cell
line the focal contacts present around the periphery of cells
were more often connected to thick actin stress fibers
extending across the entire cell. However, overexpression of
β3 in the mSCC2 cell line did not noticeably affect the
morphology of the cells (Fig. 6B). Thus, the effect of β3
overexpression on MRP expression is not limited to the GE11
cell line. Moreover, the overexpression of β3 induced
morphological changes in the NP18 cells similar to those
seen in GE11 cells.
MRP is not essential for β3-induced effects on morphology but
αvβ3 expression does regulate MRP localization
We showed that the downregulation of MRP expression by β3
overexpression is accompanied by morphological changes. To
determine if the loss of MRP is responsible for these
morphological changes, we silenced MRP expression in GE11
cells using a siRNA SMARTpool® from Dharmacon. The
SMARTpool® along with a negative control were transfected
Fig. 5 – MRP expression is regulated by the Ras/MAPK
pathway. GE11 and GEβ3 cells were incubated with PD98509
for different periods (hours) (A) or at different concentrations
(bottom in μM) (B). MRP and phospho-ERK levels were
analyzed with actin or ERK2 as loading control. (C) GE11,
GEβ3, and GE RasV12 were analyzed for MRP and
phospho-ERK levels with ERK2 as loading control.
Fig. 4 – MRP expression is regulated independently of Src
activity. (A) GE11 and GE11-Src cell lines with or without β3
overexpression were analyzed for MRP expression. (B) GEβ3
cells were incubated with Herbimycin A, PP3 or PP2 and
analyzed for MRP expression together with GE11 cells as
positive control. (C) Long (EN-L) and short (EN-S) forms of
endonexin fused to GFP were stably expressed in the GE11
cell line. Western blot analysis was performed for
endogenous MRP levels and the same blot was stained for
GFP and tubulin. Note that endonexin is present as two
distinct bands indicated with filled arrowheads for EN-L and
empty arrowheads for EN-S. (D) GE11 and GEβ3 cells were
incubated with 0, 15 or 30 μM LY294002 overnight before
being lysed and analyzed for MRP expression by Western
blot.
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into GE11 cells and MRP expression was assessed after 48 h.
Western blot analysis showed that MRP was absent in the
SMARTpool® transfected cells while cells transfected with the
control siRNA still expressed MRP (Fig. 7A). Cells were also
fixed and stained for vinculin, cadherin and F-actin. Cells
transfected with the negative control and with the MRP-
directed siRNA formed islands with a normal morphology and
normal F-actin and vinculin distribution (Fig. 7B). There was
no evidence that cell spreading or cell–cell contact formation
was affected by the knockdown of MRP. Additionally, MRP
was re-expressed in GEβ3 cells using a MRP–GFP cDNA
construct. Confocal analysis revealed that MRP–GFP expres-
sion had no effect on the morphology of GEβ3 cells (Fig. 8A).
The cells remained well spread and the formation of actin
stress fibers and focal contacts was not perturbed. To
determine if the downregulation of MRP expression in GEβ3
cells is important for the initial spreading of these cells, MRP–
GFP was stably expressed in GE11 cells before β3 was
overexpressed through retroviral transduction. 24 h after
infection, the morphology of cells expressing MRP–GFP and β3
was similar to that of GEβ3 cells (Fig. 8B). Therefore, we
conclude that cell spreading is not influenced by the levels at
which MRP is expressed. Interestingly, we noticed that the
localization of MRP–GFP was altered after β3 overexpression.
In line with a previous report showing that MRP is localized at
the basolateral membranes of MDCK cells [32], confocal
analysis of GE11 cells indicated that overexpressed MRP–GFP
was concentrated at the basolateral membrane and partially
co-localized with cadherin but not with paxillin (Fig. 8A). In
contrast, after β3 overexpression MRP–GFP was diffusely
distributed along the entire cell membrane with occasional
staining of internal membranes as well as weak actin
filament decoration. In conclusion, MRP is not involved in
the β3-induced morphological effects, but β3 overexpression
clearly influences MRP–GFP localization.
Discussion
It has been suggested that the regulation of gene expression
forms part of the mechanism by which integrins control cell
migration and invasion [10]. Previously, it was shown that the
re-expression of β3 in knockout cells increases cdc2 protein
levels [10] and that overexpression of β3 in CHO cells leads to a
decrease in uPAR protein levels [11]. In both cell lines
migration and spreading were enhanced. Previous work in
our laboratory has shown that overexpression of β3 or re-
expression of β1 subunit has distinct effects on cell morphol-
ogy, migration, Rho activation and cofilin phosphorylation
[13,14].
We hypothesized that the effect on cell morphology
induced by β3 overexpression coincides with changes in the
transcription of several genes, possibly including genes such
as uPAR and cdc2. To test our hypothesis we performed a
microarray analysis of GEβ3 cells and compared the gene
expression profile of these cells to that of the parental GE11
cells. Surprisingly, β3 overexpression resulted in the down-
regulation of only a single gene, i.e. the gene coding for MRP.
Both uPAR and cdc2 cDNAs were present on the array used for
this study but the transcription of these genes was not
changed by the overexpression of β3.
Various signaling pathways have been implicated in gene
regulation downstream of integrins. One of these pathways
was elucidated in CHO cells in which β3 overexpression
inhibits uPAR transcription. It was found that overexpression
of the short isoform of the β3 integrin binding protein, β3-
endonexin, also resulted in decreased uPAR transcription
[11] suggesting that β3-endonexin is the downstream
effector of β3 in a pathway that leads to uPAR down-
regulation [11]. It was also shown that ligand binding by
αvβ3 and α5β1 leads to an increase in Bcl-2 expression that
was dependent on the PI3K–Akt pathway [8]. We investi-
gated if these signaling pathways were also involved in the
β3-mediated downregulation of MRP expression. We show
that overexpression of β3-endonexin in GE11 cells had no
effect on MRP expression and we conclude that this pathway
does not regulate the expression of MRP. Our data also
indicates that MRP expression was not changed by inhibition
of the PI3K pathway.
Fig. 6 – Effect of β3 overexpression in NP18 andmSCC2 cells.
(A)Western blot analysis forMRP expression of two cell lines,
NP18 and mSCC2, overexpressing β3. (B) mSCC2 cells and
NP18 cells with orwithout overexpressedβ3were stained for
paxillin and F-actin.
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On the other hand, a number of soluble factors and
signaling intermediates have been identified that affect MRP
expression. It was shown that LPS stimulation increases MRP
expression in BV-2 microglial cells through the activity of Src
kinase [27]. Moreover, transformation of 3T3 cells with v-Src or
Ras leads to decreased expression of MARCKS [25]. Our results
indicate that active Src does not decrease MRP expression.
Intriguingly, the inhibition of ERK phosphorylation caused an
increase in MRP expression in GE11 cells but had no effect on
MRP expression in GEβ3 cells while RasV12 expression in GE11
cells resulted in increased phospho-ERK levels and decreased
MRP protein levels. Therefore, the Ras/MAPKpathway controls
the basal level of MRP expression in GE11 cells but β3
overexpression bypasses this pathway downstream of ERK
to downregulate MRP expression.
Our studies with β3 chimeras show that downregulation of
MRP expression by β3 only occurs when it is associated with
the αv subunit. Furthermore, we show that the β3 cytoplasmic
tail is essential for MRP downregulation. Within the cytoplas-
mic tail of β3 several motifs have been identified that are
important for different downstream signaling events. For
example, the membrane proximal NPxY motif is important
for binding to talin and critical for integrin activation, while
the distal NITY motif is important for cell spreading although
it appears that the tyrosine residue of this motif is not
essential [33]. We tested several deletion mutants of β3 and
show that the loss of the complete NITY motif does not lower
the expression of MRP. Inclusion of the asparagine and
isoleucine residues of the NITY motif leads to the down-
regulation of MRP expression while also causing cells to
spread like GEβ3 cells. Therefore, the same region of β3
responsible for MRP downregulation also increases cell
spreading. In NP18 cells, β3 overexpression also caused
changes in the cytoskeleton while MRP expression was
downregulated. On the other hand, overexpression of β3 in
mSCC2 cells did not lead to changes in morphology or to the
downregulation of MRP expression, emphasizing that β3
overexpression is responsible for both these phenomena.
MRP has been implicated in cell spreading and cytoskeletal
organization [20,21], both of which are altered in GEβ3 cells,
Fig. 7 – RNAi-mediated downregulation of endogenous MRP in GE11 cells. (A) Western blot analysis of MRP expression in
GE11 cells transfected with siRNA against MRP and a negative control. (B) GE11 cells transfected with siRNA directed against
MRP or with a negative control were fixed and stained for vinculin and actin or for cadherin together with TOPRO that was used
as nuclear staining.
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suggesting that MRP may be important for the β3-induced
effects on cell morphology. However, our data indicates that
altering MRP expression by knock down in GE11 cells or by
overexpression in GEβ3 cells does not influence cellular
morphology. We, therefore, suggest that either MRP is not
involved in cell spreading or morphology or that it is not the
only protein involved and that the stronger effects of other
proteins mask the effect of MRP.
In conclusion, our studies show that the expression level of
β3 can influence cell morphology and the transcription levels
of MRP and that the Ras/MAPK pathway is important for the
regulation of MRP expression.
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Integrins consist of non-covalently linked α- and β-subunits.
Ligands, including extracellular matrix (ECM) components such
as fibronectin, are bound to the integrin extracellular globular head
domain whereas a multitude of cytoskeletal adaptor proteins interact
via the cytoplasmic tail. Thus, integrins create a link between the
ECM and the actin cytoskeleton. Ligand binding can be modulated
at the level of integrin clustering (avidity) or by activation of
integrins through conformational changes in the extracellular
ligand-binding domains (affinity) (Calderwood, 2004; Takagi and
Springer, 2002). For instance, binding to soluble ligands through
integrin α5β1, αvβ3 or αIIbβ3 can be enhanced more than 20-fold
by divalent cations or stimulatory antibodies, leading to firm
adhesion of cells that show no appreciable adhesion to immobilized
ligands in the absence of such stimuli (Danen et al., 1995; Mould
et al., 1995; Smith et al., 1994). In turn, integrin-mediated adhesion
can modulate various intracellular signaling cascades (Hynes,
2002). Following cell adhesion to the ECM, integrins and associated
proteins assemble in cell-matrix adhesions, which organize the actin
cytoskeleton. In epithelial cells, focal adhesions are randomly
distributed across the ventral surface or along the cell border. In
mesenchymal cells such as fibroblasts, they orient centripetally and
concentrate in a few peripheral sites connecting long F-actin stress
fibers, causing a typical elongated, contractile morphology.
Fibronectin is essential for embryonic development and is
abundantly present in the ECM associated with wound healing and
angiogenesis (Hynes and Zhao, 2000). Mesenchymal cells secrete
compact and inactive soluble fibronectin dimers, which are
assembled into insoluble fibronectin fibrils following their
interaction with cell surface receptors of the integrin and syndecan
families (Wierzbicka-Patynowski and Schwarzbauer, 2003).
Fibronectin fibrils are assembled into a matrix that is important for
anchorage of cells and guides cell migration during embryonic
development and wound healing (Hynes and Zhao, 2000). Integrins
α5β1, α8β1, αvβ1, αvβ3, αIIbβ3, αvβ5, αvβ6 and αvβ8 recognize
the common integrin-binding motif Arg-Gly-Asp (RGD) that is
found in many ECM components, including fibronectin (Danen and
Sonnenberg, 2003). Of these integrins, α5β1 is particularly efficient
in mediating fibronectin matrix assembly, although others can
compensate for its absence to some extent (Wennerberg et al., 1996;
Wu et al., 1996; Yang and Hynes, 1996). Fibronectin fibrillogenesis
requires extensive remodeling of cell-matrix adhesions (Pankov et
al., 2000), and contractility of the actin-myosin cytoskeleton, which
is stimulated by the small GTPase Rho through activation of myosin-
II. Contractility drives fibronectin fibrillogenesis by creating
sufficient tension to stretch the compact fibronectin dimers and
expose intermolecular fibronectin-binding sites (Zhong et al., 1998).
Integrin-mediated cell adhesion triggers a rapid inactivation of the
small GTPase RhoA (Ren et al., 1999), which is important to relieve
contractility and allow cell spreading. As cell spreading ends, Rho-
mediated cytoskeletal contractility gradually increases, which
coincides with maturation of focal adhesions and initiation of
Focal adhesions are randomly distributed across the ventral
surface or along the edge of epithelial cells. In fibroblasts they
orient centripetally and concentrate at a few peripheral sites
connecting long F-actin stress fibers, causing a typical elongated,
contractile morphology. Extensive remodeling of adhesions in
fibroblasts also takes part in fibronectin fibrillogenesis, a
process that depends on Rho-mediated contractility and results
in the formation of a fibronectin matrix. Our current study
shows that all these fibroblast characteristics are controlled by
the ability of integrin α5β1 to bind soluble fibronectin molecules
in their compact inactive conformation. The hypervariable
region of the ligand-binding I-like domain of integrin α5β1
supports binding of soluble fibronectin. This supports the
distribution of centripetally orientated focal adhesions in distinct
peripheral sites, Rho activation and fibronectin fibrillogenesis
through a mechanism that does not depend on Syndecan-4.
Integrin αvβ3, even when locked in high affinity conformations
for the RGD recognition motif shows no appreciable binding
of soluble fibronectin and, consequently, fails to support the
typical fibroblast focal adhesion distribution, Rho activity and
fibronectin fibrillogenesis in the absence of integrin α5β1. The
ability of α5β1 integrin to interact with soluble fibronectin may
thus drive the cell-matrix adhesion and cytoskeletal organization
required for a contractile, fibroblast-like morphology, perhaps
explaining why α5β1 integrin, similarly to fibronectin, is
essential for development.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/121/15/2452/DC1
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2453Fibronectin binding and mesenchymal morphology
fibronectin fibrillogenesis. We previously reported that β1 integrinsare dispensable for cell spreading but required to support this secondphase (Danen et al., 2002; Danen et al., 2005). In the studies reportedhere, we expressed different wild-type, chimeric and mutant integrinsubunits in cells lacking the Itgb1, Itgb3 or Itga5 integrin genes, orsilenced expression of integrin β1 or syndecan-4 (SDC4) to studyhow they organize cell-matrix adhesions, cytoskeletal contractilityand fibronectin matrix assembly. Our findings suggest extensivereciprocal signaling between fibronectin and the actin cytoskeleton,which occurs selectively through integrin α5β1 and couples bindingof soluble fibronectin dimers to a fibroblast-like distribution of focaladhesions, Rho-mediated contractility and fibronectin fibrillogenesis.
ResultsIntegrin α5β1 promotes fibroblast-like organization of cell-matrix adhesions, Rho activity and fibrillogenesisWe have previously shown that β1 integrins promote a fibroblast-like distribution of cell-matrix adhesions and a contractile, elongatedcell shape that is associated with high levels of RhoA activity, focaladhesion turnover and fibronectin matrix assembly whereas αvβ3fails to do so in the absence of β1 integrins (Danen et al., 2002;Danen et al., 2005) (see Fig. 1A). There is also evidence thatoverexpression of αvβ3 can stimulate RhoA activity andcytoskeletal contractility in leukocytes and CHO cells (Butler etal., 2003; Miao et al., 2002). Here, we determined the importance








of αvβ3 in these processes using mouse
embryonic fibroblasts (MEFs) isolated
from Itgb3-knockout mice. The levels of
GTP-RhoA in β3-integrin-null MEFs were
similar to those in MEFs isolated from
wild-type littermates, indicating that RhoA
activation does not require αvβ3 integrin
(Fig. 1B, supplemental material Fig. S1A).
Similarly, fibronectin matrix assembly
mediated by β3-integrin-null MEFs
occurred equally efficiently as that
mediated by wild-type MEFs (Fig. 1C).
Ectopic expression of β3 integrin did not
further stimulate RhoA activity, whereas
increased expression of β1 integrin led to
enhanced activation of RhoA (Fig. 1B).
Increased expression of β1 integrins in β3-
integrin-null MEFs also led to a more
elongated, contractile cytoskeletal
organization, whereas the presence or
absence of β3 integrin did not affect
morphology (Fig. 1D). Moreover,
suppression of endogenous β1 integrins
using Itgb1-specific siRNAs caused a
phenotypic switch in wild-type MEFs
characterized by increased cell spreading,
more random distribution of focal
adhesions and formation of cell-cell
adhesions (Fig. 1E,F). We were unable to
completely silence β1 integrin expression
in MEFs and the level of suppression
reached did not lead to detectable reduction
of RhoA-GTP levels (not shown).
Nevertheless, the conversion to a more epithelial morphology
(strongly resembling that of β1-integrin-deficient GEβ3 cells; Fig.
1A) upon β1 integrin silencing was in complete agreement with
our previous findings using β1-integrin-null cells. Silencing
expression of β1 integrins in Itgb3-knockout MEFs caused cell
rounding but the cells that remained attached resembled GE11 β1-
integrin-knockout cells, growing in islands with extensive cell-cell
contacts (Fig. 1E,F; compare with Fig. 3A, left image).
Of the β1 integrins, α5β1 integrin most efficiently supports
fibronectin matrix assembly but integrins α8β1, α4β1 and αvβ1
can also mediate cell adhesion to immobilized fibronectin. To
determine whether α5β1 integrin is the β1 integrin responsible
for the typical fibroblast-like characteristics described above, we
used differentiated Itga5-knockout ES cells (EA5). RhoA-GTP
levels were very low in EA5 cells and restoring expression of α5
integrin induced efficient RhoA-GTP loading (Fig. 2A,
supplementary material Fig. S1B). Expression of an α5αv integrin
chimera, consisting of the α5 integrin extracellular and
transmembrane domains and the αv integrin cytoplasmic domain
similarly induced RhoA-GTP loading, indicating that α5-integrin-
specific sequences in the cytoplasmic tail are not required for
enhancing RhoA activation (Fig. 2A). The very low RhoA-GTP
levels in EA5 cells were accompanied by a flat circular cell shape
with dispersed focal adhesions. Expression of α5 integrin or α5αv
integrin induced a reorganization of the cytoskeleton with long
F-actin stress fibers connecting peripheral focal adhesions (Fig.
2B). Likewise, fibronectin fibrillogenesis was strongly enhanced
in the presence of α5 integrin or α5αv integrin in EA5 cells (Fig.
Journal of Cell Science 121 (15)
2C), which is consistent with previous findings (Sechler et al.,
1997; Wu et al., 1993).
Together, these results demonstrate that the typical fibroblast-
like elongated, contractile morphology that is associated with high
levels of Rho-GTP and fibronectin matrix assembly do not require
αvβ3 integrin and are primarily stimulated by α5β1 integrin.
The extracellular ligand-binding domain of α5β1 integrin
specifies fibroblast morphology, RhoA activation and
fibronectin fibrillogenesis
In addition to the obvious essential role of the extracellular domain
in ligand binding, the integrin transmembrane and cytoplasmic
domains regulate ligand affinity and avidity by controlling integrin
conformation and clustering (Calderwood, 2004; Li et al., 2003;
Luo et al., 2007). The β1 integrin cytoplasmic domain is
exchangeable with that of β3 integrin with no effect on Rho
activation, fibronectin fibrillogenesis or fibroblast morphology
when expressed in β1-integrin-deficient GE11 cells (Danen et al.,
2002). To test whether specific amino acid residues in the
transmembrane domain of β1 integrin are required for α5β1-
integrin-mediated support of fibroblast morphology, Rho activity,
and fibronectin fibrillogenesis, we generated a chimeric β1e3t+i
subunit, consisting of a β1 integrin extracellular domain and β3
integrin transmembrane and cytoplasmic domains. When
expressed in β1-integrin-deficient GE11 cells (supplementary
material Fig. S1C), this chimera promoted focal adhesion
distribution and enhanced RhoA activity similar to wild-type β1
(Fig. 3A,B). Moreover, similarly to wild-type β1 integrin, β1e3t+i
Fig. 2. Integrin α5 is required for efficient RhoA activation and fibronectin fibrillogenesis. (A) Western
blot analysis of RhoA activity assay on lysates of EA5 cells expressing indicated integrins. Quantification
shows relative RhoA activation ± s.d. compared with EA5 cells from two independent experiments.
(B) EA5 cells expressing indicated constructs stained for paxillin (green) and F-actin (red), with the
nucleus in blue. Scale bar: 10 μm. (C) Western blot analysis of assembled fibronectin-biotin and vimentin
(loading control) in DOC-insoluble lysates of EA5 cells expressing indicated constructs. Locations of
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efficiently supported fibronectin matrix assembly (Fig. 3C),
arguing against a specific role of the transmembrane and
cytoplasmic domains of β1 integrin in these processes. By
contrast, expression of a β1[D130A] integrin subunit, containing
a mutation in the extracellular I-like domain that abrogates ligand
binding (Takada et al., 1992), failed to induce RhoA activation,
a mesenchymal morphology, or fibronectin fibrillogenesis (Fig.
3, supplementary material Fig. S1C).
These findings indicate that the support of a fibroblast-like,
contractile morphology associated with Rho activity and fibronectin
fibillogenesis by α5β1 integrin is strictly dependent on ligand
binding to its extracellular domain. Other regions of this integrin
can be exchanged with corresponding regions of αvβ3 integrin
without consequence and surface expression of α5β1 integrin
without ligand interaction, which could affect (expression of) other
surface receptors, is insufficient to support these processes.
The ability to bind to soluble fibronectin dimers correlates with
RhoA activity and fibronectin fibrillogenesis
Many different integrins (including α5β1 integrin and αvβ3
integrin) can recognize the RGD motif and mediate cell adhesion
to immobilized (stretched) fibronectin. However, we observed
that all integrin β-subunits that supported a fibroblast-like
cytoskeletal organization, Rho activity and fibronectin
fibrillogenesis (β1, β1e+t3i and β1e3t+i), efficiently bound to
soluble (compact and inactive) fibronectin dimers whereas the
other β-subunits tested (β3, β1[D130A]) did not (Fig. 3D). This
suggested that differences in binding to soluble fibronectin
between α5β1 integrin and αvβ3 integrin could explain not only
the particular efficiency with which α5β1 integrin mediates
fibronectin matrix assembly but also the different abilities of these
integrins to support a fibroblast-like, contractile cytoskeletal
organization and Rho activation.
Fig. 3. Ligand binding to the extracellular
domain of β1 integrin is required for RhoA
activation and fibronectin fibrillogenesis.
(A) GE11 cells expressing indicated β1
integrin subunits stained for paxillin
(green), F-actin (red). Nuclei are stained
blue with Topro-3. Scale bar: 10 μm.
(B) Western blot analysis of RhoA activity
assay on lysates of GE11 cells expressing
indicated β1 integrin subunits.
Quantification shows relative RhoA
activation ± s.d. compared with GEβ1 cells
from two experiments. (C) Assembled
fibronectin-biotin on GE11 cells expressing
indicated β1 integrin subunits; fibronectin
is red and nuclei are blue. Scale bar: 50 μm.
(D) Mean fluorescence analyzed by flow
cytometry, demonstrating binding of
indicated integrins to different














We used mutants of β3 integrin, which, in the context
of αIIbβ3, are locked in a low- or high-affinity
conformation for the RGD sequence in fibrinogen (Luo et
al., 2003; Luo et al., 2004), the integrin recognition
sequence that is also present in the central cell-binding
domain of fibronectin. Expression of a low-affinity
β3[T329C; A347C] did not affect the poorly spread GE11
cell morphology (Fig. 4A center image; compare with Fig.
3A left image). Expression of the high-affinity β3[N305T]
and β3[V332C; M335C] mutants stimulated cell spreading
but distribution of focal adhesions in these cells was similar
to those expressing wild-type β3 integrin (Fig. 4A; compare
with Fig. 1A right image). In line with these morphological
similarities, the high-affinity mutants failed to enhance
RhoA-GTP levels or fibronectin fibrillogenesis in the
absence of β1 integrin as also seen with wild-type αvβ3
integrin (Fig. 4B,C). As expected, based on findings in CHO
cells (Luo et al., 2003; Luo et al., 2004) the β3[N305T]
and β3[V332C; M335C] mutations strongly increased
αvβ3-integrin-mediated binding of GE11 cells to soluble
RGD (Fig. 5A). However, even in the presence of the
activating divalent cation, manganese, locking αvβ3
integrin in a high affinity state for RGD failed to induce
binding to soluble fibronectin (Fig. 5B,C). Again, α5β1
integrin efficiently bound soluble fibronectin in these
experiments which could be competed with unlabeled
fibronectin (Fig. 5B,C).
These results demonstrate that although RGD is a
common recognition motif, affinity for RGD does not
necessarily indicate binding to all RGD-containing ligands.
The central cell-binding domain of compact soluble
fibronectin dimers appears to be only available for binding
to α5β1 and not to αvβ3 integrin. Notably, this indicates
that efficient binding to soluble fibronectin dimers might
in fact underlie the efficiency with which α5β1 integrin supports
a fibroblast-like distribution of focal adhesions, contractile cell shape
and Rho-mediated cytoskeletal contractility that drives fibronectin
fibrillogenesis.
Specificity in the I-like domain controls binding of soluble
fibronectin, focal adhesion distribution, Rho-mediated
contractility and fibronectin matrix assembly independently of
syndecan-4
Since ligand binding is required for α5β1 integrin to support a
contractile, fibroblast-like morphology and Rho activity
(β1[D130A]; Fig. 3) and since its ability to efficiently bind soluble
fibronectin dimers appeared to underlie the difference between α5β1
integrin and αvβ3 integrin in this respect (Fig. 5), we analyzed a
more subtle mutation in the I-like domain that participates in ligand
binding. Exchanging the CTSEQNC hypervariable sequence in the
I-like domain of β1 integrin with the corresponding region of β3
integrin has been shown to cause a shift in ligand specificity that
leads to adhesion to vitronectin, von Willebrand factor and
fibrinogen without affecting adhesion to immobilized (stretched)
fibronectin (Takagi et al., 1997). We expressed such a β1-3-1
integrin subunit in β1-integrin-deficient GE11 cells (supplementary
material Fig. S1D). Although adhesion to immobilized fibronectin
was similar, cells expressing this chimera displayed strongly
reduced binding of soluble fibronectin compared with cells
expressing wild-type α5β1 integrin (Fig. 6A). Importantly, in
addition to causing a marked inhibition of fibronectin matrix
Journal of Cell Science 121 (15)
assembly, this was accompanied by a strong reduction in RhoA-
GTP levels and by a random (epithelial-like) distribution of focal
adhesions (Fig. 6B,C,D).
Rho-mediated contractility is required for fibronectin
fibrillogenesis (Zhang et al., 1997; Zhong et al., 1998) and RhoA-
GTP levels and fibronectin matrix assembly correlated for all the
integrin constructs we tested. High RhoA-GTP levels were also
associated with soluble fibronectin binding and fibroblast-like
distribution of focal adhesions. We wondered (1) whether the high
levels of RhoA-GTP were up- or downstream of soluble fibronectin
binding to α5β1 integrin and the typical fibroblast-like distribution
of focal adhesions and (2) whether fibronectin fibrillogenesis
couples back to Rho activation in a positive feedback loop. To
investigate these possibilities, binding of soluble fibronectin,
fibronectin fibrillogenesis and RhoA activity were analyzed in cells
expressing α5β1 under conditions where actomyosin contractility
was blocked using ROCK or myosin-II inhibitors. In the presence
of these inhibitors, fibronectin fibrillogenesis was strongly
suppressed (ROCK) or even completely blocked (myosin-II), but
binding of soluble fibronectin and RhoA-GTP levels were not
affected (if anything they were slightly enhanced) (Fig. 7). These
findings suggest that RhoA activity is downstream of fibronectin
binding and they argue against a positive feedback loop from
actomyosin contractility or fibronectin fibrillogenesis back to the
regulation of Rho activity. Furthermore, the fact that the inhibitors
ultimately led to disruption of focal adhesions (not shown)
combined with the finding that silencing β1 in MEFs leads to a
Fig. 4. High-affinity mutants of β3 integrin fail to stimulate RhoA activity and
fibronectin fibrillogenesis. (A) Images of β1-integrin-deficient GE11 cells expressing
indicated β3 integrin affinity mutants stained for paxillin (green), F-actin (red) and the
nucleus (blue). Scale bar: 10 μm. (B) Western blot analysis of RhoA activity assay on
lysates of GE11 cells expressing indicated constructs. Quantification shows relative
RhoA activation ± s.d. compared with GEβ1 cells from two experiments. (C) Western
blot analysis of assembled fibronectin-biotin and vimentin (loading control) in DOC-
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more epithelial distribution of focal adhesions (Fig. 1F) while in
both cases RhoA levels remain high, argues against the possibility
that the fibroblast-like cytoskeletal organization acts upstream of
RhoA.
It has been reported that the transmembrane proteoglycan
syndecan-4 acts in concert with integrins to mediate fibronectin
matrix assembly (Chung and Erickson, 1997) and can modulate
the formation of cell-matrix adhesions and the activities of Rho-
GTPases, including Rac1 (Bass et al., 2007) and RhoA (Dovas et
al., 2006; Saoncella et al., 1999). We investigated whether
syndecan-4 played a role in the support of fibroblast-like
cytoskeletal organization, Rho activity or fibronectin
fibrillogenesis by α5β1 integrin. For this purpose, we silenced
syndecan-4 expression in GEβ1 cells using syndecan-4 specific
siRNAs. A complete knockdown of surface expression of
syndecan-4 was achieved within 48 hours, whereas syndecan-4
expression was unaffected in control siRNA transfected GEβ1 cells
(Fig. 8A). The formation and distribution of cell-matrix adhesions
and organization of the actin cytoskeleton remained unaltered in
cells without syndecan-4 (Fig. 8B). Similarly, fibronectin matrix
assembly and binding of soluble fibronectin by α5β1 integrin was
still intact in GEβ1 cells lacking syndecan-4 (Fig. 8C,D). Finally,
α5β1-integrin-supported RhoA activation was also unaffected by
syndecan-4 silencing (Fig. 8E) although for this assay, cells had
to be expanded to obtain sufficient lysate resulting in incomplete
syndecan-4 downregulation (not shown). Notably, a knockdown
of syndecan-4 expression levels in GEβ3 cells induced a dramatic
morphological change, and GEβ3 cells lacking syndecan-4 were
unable to form their typical flattened circular shape but instead
formed an irregular cell border containing several cytoskeletal
extensions (Fig. 8F,G). These experiments indicate that syndecan-
4 can act in concert with αvβ3 integrin to regulate cell-matrix
adhesion distribution when α5β1 integrin is absent but syndecan-
4 is not required for cytoskeletal organization, focal adhesion
formation/distribution, Rho activity or fibronectin matrix assembly
in the presence of α5β1 integrin.
Taken together, our data demonstrate that following the initial
drop in RhoA activity during cell adhesion, the ability of α5β1
integrin to bind compact soluble fibronectin dimers drives the typical
fibroblast-like distribution of focal adhesions and the accumulation
of Rho activity, which, in turn, stimulates fibronectin fibrillogenesis
(Fig. 9). Interactions of fibronectin with αvβ3 integrin or syndecan-
4 are dispensable for all these processes.
Discussion
Fibronectin fibrillogenesis requires integrin-mediated binding of
soluble fibronectin dimers and depends on Rho-mediated
cytoskeletal contractility to stretch integrin-bound fibronectin
molecules exposing cryptic fibronectin-binding sites (Geiger et
al., 2001; Mao and Schwarzbauer, 2005; Zhong et al., 1998). The
α5β1 integrin mediates fibronectin matrix assembly with particular
efficiency although other integrins can substitute for α5β1 integrin
to some extent (Wennerberg et al., 1996; Wu et al., 1996; Yang
and Hynes, 1996). Our current study indicates that α5β1 integrin
not only promotes fibronectin matrix assembly, but also stimulates
the contractile, fibroblast-like morphology. The ability of α5β1
integrin to efficiently bind compact soluble fibronectin dimers
appears to drive the appropriate redistribution of focal adhesions
to support this cell shape that is associated with increased RhoA
activity, which, in turn, stimulates fibronectin fibrillogenesis. Such
dynamic behavior of α5β1 integrin was previously implicated
directly in fibronectin fibrillogenesis (Pankov et al., 2000). Our
findings indicate that an analogous process underlies the
distribution of focal adhesions leading to the typical contractile
cell shape observed in fibroblasts. Integrins that cannot bind
soluble fibronectin stimulate cell spreading and focal contact
formation but these adhesions distribute randomly and are
connected by short F-actin fibers, leading to an overall non-
contractile, flat, epithelial-like cell shape. These findings point to
Fig. 5. Integrin binding of soluble GRGDSP and fibronectin. (A) Mean
fluorescence ± s.d. demonstrating GRGDSP-biotin binding (10 μM) to
indicated integrins expressed on GE11 cells analyzed by flow cytometry.
(B) Mean fluorescence analyzed by flow cytometry, demonstrating binding of
indicated integrins to different concentrations of soluble FITC-fibronectin.
Binding to integrin β3 was shown previously in Fig. 3D. (C) Mean
fluorescence demonstrating binding of soluble fibronectin-biotin (10 μg/ml) to
indicated integrins upon competition with increasing concentrations of














a critical role for α5β1 integrin as an efficient mechano-transducer,
which couples binding of soluble fibronectin dimers to a
cytoskeletal organization that supports the assembly of a
fibronectin matrix (Fig. 9).
In agreement with our findings, α5β1 integrin has recently been
demonstrated to support ROCK-mediated contractility in fibroblasts
(Gaggioli et al., 2007; White et al., 2007). However, others have
shown that overexpression of αvβ3 integrin can stimulate RhoA
activity in leukocytes (Butler et al., 2003) and CHO cells (Miao et
al., 2002). Notably, these cells express endogenous β1 integrins
making it difficult to compare these studies with our own. In
addition, multiple different cell surface receptors can regulate the
activity of Rho-GTPases and may contribute to the difference
between these studies. Nevertheless, in our previous studies we were
unable to observe any stimulation of RhoA activity by αvβ3 integrin
in the absence of β1 integrins (Danen et al., 2002; Danen et al.,
2005). Here we use Itgb3-knockout MEFs to demonstrate directly
that αvβ3 integrin is dispensable for RhoA activation. Wild-type
and β3-integrin-null MEFs also display the same fibroblast-like
cytoskeletal organization. Moreover, a strong RNAi-mediated
reduction in the expression of β1 integrins in MEFs produces a
cytoskeletal organization that is very similar to that in β1-deficient
cells expressing high levels of αvβ3 integrin (GEβ3). Thus,
although expression of β1 integrin induces a morphological switch
that resembles an ‘epithelial-to-mesenchymal transition’ in β1-
integrin-null cells (Danen, 2002), silencing β1 integrin in MEFs
induces what appears like a ‘mesenchymal-to-epithelial transition’.
We observe a tight correlation between high RhoA-GTP levels
and focal adhesion dynamics, contractile morphology, and
fibronectin matrix assembly (Danen 2002; Danen, 2005) (this study).
Experiments using inhibitors argue against a positive feedback loop
Journal of Cell Science 121 (15)
from cytoskeletal organization to RhoA GTP loading but we do not
know at present how the ability of α5β1 integrin to bind soluble
fibronectin supports the activity of RhoA. Recently, the guanine
nucleotide exchange factors (GEFs) Lsc and LARG were shown
to link cell adhesion on fibronectin to RhoA GTP loading and focal
adhesion and stress fiber formation (Dubash et al., 2007). However,
the integrins tested in our study that do not bind soluble fibronectin
and do not stimulate RhoA activity do in fact efficiently support
the formation of focal adhesions and short stress fibers. RhoA-
mediated contractility appears to be more important for the
distribution of focal adhesions and orientation of stress fibers. If
regulation of GEFs and GAPs (GTPase-activating proteins) is
involved, our experiments using chimeric integrins indicate that
obligate interactions of such proteins or their regulators with α5β1-
integrin-specific residues in the cytoplasmic domains do not underlie
α5β1-integrin-stimulated RhoA activation. However, it is possible
that binding of soluble fibronectin to α5β1 integrin induces
conformational alterations and/or clustering of the integrin that
affects the localization and/or activity of such regulatory proteins.
Syndecan-4 can act in concert with integrins to regulate
cytoskeletal organization during cell adhesion to fibronectin through
interactions at the HepII domain in fibronectin. Using an RNAi
approach we rule out the idea that crosstalk with syndecan-4 is
involved in the fibroblast-like cytoskeletal organization, Rho activity
and fibronectin matrix assembly that is supported by α5β1 integrin.
Our findings do not seem to support the previously reported role
of syndecan-4 in stimulation of RhoA-mediated processes
(Saoncella et al., 1999). However, others have recently shown that
during adhesion to fibronectin, syndecan-4 is required for regulation
of Rac1, but not RhoA (Bass et al., 2007). This might also explain
why syndecan-4 knockdown strongly affects cytoskeletal
Fig. 6. High-affinity binding to the hypervariable
region of the β1 I-like domain controls signaling to
fibronectin fibrillogenesis. (A) Mean fluorescence
analyzed by flow cytometry, demonstrating binding of
integrin β1 and β1-3-1 to different concentrations of
soluble FITC-fibronectin. (B) Images of assembled
fibronectin-biotin on GE11 cells expressing β1 or β1-
3-1; fibronectin is red and nucleus blue. Scale bar: 50
μm. (C) Western blot analysis of RhoA activity assay
on lysates of GE11 cells expressing indicated integrins.
Quantification shows relative RhoA activation ± s.d.
compared with GEβ1 cells from two independent
experiments. (D) Images of GE11 cells expressing β1
integrin or β1-3-1 stained for paxillin (green) and F-
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et al., 2002). cDNA encoding human α5 (provided by Erkki Ruoslahti, Cancer
Research Center, The Burnham Institute, La Jolla, CA) was cloned into LZRS-neo.
To generate a cDNA encoding a chimeric human α5αv integrin subunit, a fragment
containing the extracellular and transmembrane domain of α5 integrin was digested
from LZRS-α5 as a SwaI/HindIII fragment using the internal HindIII site
immediately downstream of the transmembrane region. This was ligated to a
HindIII/SnaBI cDNA fragment derived from LZRS-αv by PCR amplification of
the αv integrin cytoplasmic domain in which the aggatg sequence immediately
upstream of the cytoplasmic tail of αv integrin was changed to aagctt, creating a
HindIII site. To generate a cDNA encoding a chimeric human β1e3t+i subunit, the
Itgb1 sequence downstream of the internal SnaBI site (70 nucleotides upstream of
the transmembrane region) was replaced with the corresponding sequence derived
from LZRS-αv by PCR amplification in which the ccagta sequence was changed
to tacgta, creating a SnaBI site. These cDNAs, as well as cDNAs encoding
β3[N305T], β3[T329C;A347C] and β3[V332C;M335C] (provided by Bing-Hao
Luo and Timothy A. Springer, CBR Institute for Biomedical Research, Boston,
MA) and cDNA encoding β1[D130A] (provided by Yoshikazu Takada, University
of California Davis Medical Center, Sacramento, CA) were recloned into LZRS-
neo. The β1-3-1 expression plasmid was provided by Yoshikazu Takada. Retroviral
constructs were transfected into ecotrophic packaging cells to generate virus-
containing culture supernatants. β3 knockout MEFs, EA5 and GE11 cells were
transfected with cDNA using effectene (Qiagen) or transduction with retroviral
supernatants and positive cells were bulk sorted at least twice by FACS for the
human integrin expressed.
Antibodies and other materials
Monoclonal antibodies used were anti-human α5 NKI-Sam1 (provided by Carl
Figdor, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands),
anti-human β1 TS/2/16, clone 18 (Transduction Laboratories), anti-human β3 C17
(provided by Ellen van der Schoot, Sanquin, Amsterdam, The Netherlands), anti-
Fig. 8. Syndecan-4 is not required for α5β1-integrin-supported RhoA signaling. (A) Flow cytometry analysis of endogenous syndecan-4 surface expression on
GEβ1 cells transfected with syndecan-4 or control siRNA. (B) Images of GEβ1 cells transfected with syndecan-4 or control siRNA stained for paxillin (green), F-
actin (red) and the nucleus (blue). (C) Flow cytometry analysis of soluble FITC-fibronectin (10 μg/ml) binding to GEβ1 cells with or without syndecan-4
knockdown. (D) Images of assembled fibronectin-biotin on GEβ1 transfected with syndecan-4 or control siRNA; fibronectin is red and nucleus is blue. Scale bar:
50 μm. (E) Western blot analysis of RhoA activity assay on lysates of syndecan-4 knockdown and control GEβ1 cells. (F) Flow cytometry analysis of endogenous
syndecan-4 surface expression on GEβ3 cells transfected with syndecan-4 or control siRNA. (G) Images of GEβ3 cells transfected with syndecan-4 or control
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mouse β3 (clone 2C9.G2, Pharmingen), anti-paxillin (clone 349, BD Transduction
Laboratories), anti-RhoA (clone 26C4, Santa Cruz), anti-Syndecan-4 (clone
KY/8.2, Pharmingen), anti-vimentin (clone K36, provided by F. Ramaekers,
University of Maastricht, Maastricht, The Netherlands). Texas-Red-conjugated
phalloidin and Topro-3 were purchased from Molecular Probes. Texas-Red-
conjugated streptavidin was purchased from Pierce Chemical Co. Human plasma
fibronectin and biotinylated-fibronectin were prepared as described previously
(Danen et al., 2002). GRGDSP peptide was generated at the Netherlands Cancer
Institute and biotinylated using EZ-link Sulfo-NHS-Biotin (Pierce Chemical Co.)
according to the manufacturer’s protocol. Y27632 and blebbistatin were obtained
from Calbiochem.
RhoA activity assays
Cells were plated overnight to subconfluency before lysis in Nonidet P-40 lysis buffer
[0.5% Nonidet P-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 10%
glycerol, supplemented with a protease inhibitor mix (Sigma-Aldrich)], and lysates
were clarified by centrifugation at 20,000 g for 20 minutes at 4°C. A 1% aliquot was
removed for determination of total quantities of RhoA. Clarified lysates were then
incubated for 45 minutes at 4°C with a GST fusion protein of the Rho-binding domain
of the Rho effector protein Rhotekin (Ren et al., 1999). Complexes were bound to
glutathione-conjugated beads, and washed three times in Nonidet P-40 lysis buffer.
The samples were analyzed by SDS-PAGE and western blotting.
Immunofluorescence and flow cytometry
For immunofluorescence, cells were fixed in 2% paraformaldehyde, permeabilized
in 0.4% Triton X-100, blocked with 2% BSA, and incubated with anti-paxillin
antibody, followed by FITC-labeled secondary antibody, phalloidin-Texas-Red and
Topro-3 staining. To visualize fibronectin fibrillogenesis, cells were plated on
fibronectin-coated coverslips for 4 hours and subsequently incubated for an additional
20 hours in medium containing 10% fibronectin-depleted serum supplemented with
10 μg/ml biotinylated fibronectin. Cells were fixed in 2% paraformaldehyde, blocked
with 2% BSA and stained with streptavidin-Texas-Red. Subsequently, coverslips were
permeabilized in 0.4% Triton X-100 and stained with Topro-3. Preparations were
mounted in Mowiol 4-88 solution supplemented with DABCO (Calbiochem) and
analyzed using a confocal Leica TCS-NT microscope. Images were obtained using
a 40 or 63 oil objective and imported into Adobe Photoshop.
For flow cytometry of integrin expression and cell sorting, cells were trypsinized,
collected in culture medium, washed with PBS, and incubated with primary antibodies
in PBS containing 2% serum for 1 hour at 4°C. For flow cytometry of syndecan-4
expression, cells were harvested using enzyme-free Dissociaton buffer (Gibco),
washed with 0.1% BSA/0.1% sodium azide followed by primary antibody incubation.
Cells were then washed in PBS, incubated with FITC-, PE- or APC-conjugated
secondary antibodies for 1 hour at 4°C, washed in PBS, and analyzed on a
FACSCalibur or sorted on a FACStar plus® (Becton Dickinson).
DOC insolubility assays
Cells were labeled with biotinylated fibronectin as described above and lysed in DOC
buffer [1% sodium deoxycholate (DOC), 20 mM Tris-HCl pH 8.5, 2 mM N-
ethylmaleimide, 2 mM iodoacetic acid, 2 mM EDTA and 2 mM PMSF]. Lysates
were passed through a 23 GA needle and DOC-insoluble material was collected by
centrifugation at 20,000 g for 20 minutes at 4°C. The pellet was washed once with
DOC buffer, resolved in reduced sample buffer and analyzed by SDS-PAGE and
western blotting.
RGD and fibronectin binding assays
Cells were harvested, resuspended in DMEM supplemented with 0.5% BSA and 2
mM MnCl2, and incubated with 10 μM biotinylated GRGDSP-peptide or 10 μg/ml
biotinylated human plasma fibronectin for 1 hour at 4°C in the absence or presence
of increasing concentrations of unlabeled fibronectin. The cell pellet was washed in
0.9% NaCl and 2 mM MnCl2 and subsequently labeled with PE-conjugated
streptavidin for 30 minutes at 4°C. To monitor dose-responsive fibronectin binding,
cells were incubated with different concentrations of FITC-conjugated human plasma
fibronectin for 1 hour at 4°C. Binding of the RGD-peptide or fibronectin was
determined by flow cytometry.
siRNA transfection
Cells were plated at 40% confluency and were transfected the following day using
DharmaFECT 1 reagent and a final concentration of 100 nM of integrin β1
SMARTpool siRNA (M-040783-00), Syndecan-4 ON-TARGET plus SMARTpool
siRNA (L-044221-00), or siCONTROL non-targeting siRNA#2 (D-001210-02)
purchased from Dharmacon. After replating, the cells were analyzed 48 hours post-
transfection for integrin β1 or syndecan-4 surface expression, and used for
immunofluorescence, RhoA activity assays and fibronectin binding assays.
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Ramaekers, Erkki Ruoslahti, Timothy Springer, Yoshikazu Takada
and Ellen van der Schoot for providing plasmids and antibodies. This
work was supported by grant UL2006-3521 from the Dutch Cancer
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Abstract
Background: Integrins are a family of transmembrane receptors that mediate cell-cell and cell-matrix adhesion. They are
involved in stable cell adhesion and migration of cells. In addition, integrin-mediated interactions modulate the response to
most, if not all growth factors, cytokines, and other soluble factors.
Purpose: In this review, we briefly explain how integrins can affect the multitude of signal transduction cascades in control
of survival, proliferation, and differentiation. Subsequently, we primarily focus on targeting integrins a5b1 and avb3 in
disease and we discuss how antagonists of these integrins, including disintegrins, RGD peptides, small molecules, and
function blocking antibodies, may be of therapeutical value either alone or, especially in the treatment of cancer, in
combination with existing therapeutical strategies.
Keywords: Adhesion, treatment, cancer
Introduction
Integrins are cell surface receptors that mediate
interactions with the extracellular matrix (ECM) or
with counter-receptors on other cells. They cluster
and recruit a large multi-protein complex to cell-
ECM or cell-cell junctions, which connects them to
the cytoskeleton. In addition, signaling proteins and
their substrates accumulate at these sites, which
regulate the stability of the adhesions and control
cytoskeletal dynamics. Besides their critical role in
stable cell adhesion and cell migration, integrin-
mediated interactions modulate signaling by various
other receptors including receptor tyrosine kinases
(RTK), G-protein-coupled receptors, cytokine re-
ceptors, and others. Consequently, integrins play
important roles in survival, proliferation, and differ-
entiation. They are also implicated in several human
diseases and integrin antagonists have been tested in
preclinical models for various diseases including
inflammation, thrombosis, arthritis, and cancer and
some have even entered clinical trials. For the
treatment of cancer, the expectation is that these
antagonists may increase the efficacy of radio- and
chemotherapy.
Integrins
Integrins are heterodimeric transmembrane receptors
that bind with their globular head domain to
components of the ECM. Some integrins can also
bind counter receptors present on other cells,
bacterial polysaccharides, or viral coat proteins.
Intracellularly, integrins are connected via associated
proteins to the actin cytoskeleton. 18 a and 8 b
subunits are encoded in the human genome from
which 24 different functional integrins are currently
known to be generated (van der Flier & Sonnenberg
2001, Hynes 2002). Ligand binding can be regulated
through integrin clustering and through modulation
of the activity of individual integrins which involves
the propagation of conformational changes from the
cytoplasmic tails across the membrane towards the
ligand-binding region (Liddington & Ginsberg,
2002). Integrins can also activate intracellular signal
transduction cascades, a process referred to as
‘outside-in signaling’. Integrin-mediated cell adhesion
can trigger calcium fluxes, activate tyrosine and
serine/threonine protein kinases and inositol lipid
metabolism, and regulate the activity of the Rho
family of small GTPases (Danen & Yamada 2001).
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Genetic studies in flies, worms, and mice have
established important roles for integrins and
integrin-associated proteins in the development and
maintenance of tissues and in the progression of
diseases (De Arcangelis & Georges-Labouesse 2000,
Bouvard et al. 2001, Bokel & Brown 2002).
Integrin signaling
Integrins generally contain a short cytoplasmic
domain which is devoid of enzymatic activity.
Therefore outside-in signaling by integrins largely
depends on interactions with neighbouring recep-
tors, adaptor and signaling proteins.
Nevertheless integrin signaling is critically impor-
tant for regulation of signal transduction pathways
through distinct mechanisms (Figure 1):
(1) Integrins and growth factor receptors may
activate parallel pathways that synergize at the
level of activation of downstream signaling
proteins. In this way threshold levels in signal-
ing pathways can be lowered considerably
(Chen et al. 1996, Renshaw et al. 1997).
(2) Cell-matrix adhesion initiates clustering of
integrins in the plane of the membrane and
reorganization of the actin cytoskeleton, which
further stimulates the organization of integrins
and associated proteins into large multi-protein
platforms like focal adhesions, hemidesmo-
somes or podosomes. In those platforms
integrins may increase signals generated by
growth factor receptors by bringing kinases and
substrates in close proximity (Burridge &
Chrzanowska-Wodnicka 1996, Geiger et al.
2001).
(3) Cell-matrix adhesions act as anchoring sites for
the actin cytoskeleton and as such they allow
the generation of tension and shape changes.
Via cytoskeletal connections with the nucleus
such changes can affect the nuclear shape and
chromatin structure which might explain the
profound effect of integrin-mediated cell adhe-
sion on the expression of genes (Maniotis et al.
1997, Lelievre et al. 1998).
(4) Integrin-mediated adhesion can cluster and
transactivate several RTK including platelet-
derived growth factor receptor (PDGFR),
epidermal growth factor receptor (EGFR),
Ron, Met, and vascular endothelial growth
factor receptor (VEGFR) (Yamada & Even-
Ram 2002) and members of the Src family
kinases (Shattil 2005).
(5) Integrins regulate RTK signaling further up-
stream through their ability to organize the
ECM. Proteoglycans in the ECM can bind and
structurally modify various growth factors and
integrin-mediated cell adhesion then allows
their subsequent presentation to growth factor
receptors (Faham et al. 1998). Through these
mechanisms integrins play an essential role in
regulating signaling pathways in control of
survival, proliferation, and differentiation both
in health and disease.
Survival
Most adherent cell types depend on integrin-
mediated adhesion for survival (Giancotti & Ruoslahti
1999, Cordes 2006, Gilcrease 2007). Loss of adhesion
causes cells to undergo apoptosis, a process referred
to as anoikis (Frisch & Screaton 2001). Likely, anoikis
is important to maintain the integrity of tissues by
preventing cells from growing at inappropriate sites
after losing adhesion from their original surrounding.
Integrin-mediated cell adhesion in 2-dimensional
culture systems stimulates phosphatidylinositol-
3-kinase (PI3K)-mediated protein kinase B (PKB/
AKT) activity and B-cell leukemia-2 (Bcl-2) ex-
pression which mediates survival signals (Giancotti
& Ruoslahti 1999). In absence of serum factors
Figure 1. Cross-talk between growth factor receptors and
integrins. Integrins affect signal transduction pathways through
distinct mechanisms: (1) Together with growth factor receptors,
integrins activate parallel pathways that synergize at the level of
downstream signaling proteins; (2) Integrins initiate clustering of
proteins in cell-matrix adhesions, thereby bringing kinases and
substrates in close proximity; (3) Those cell-matrix adhesions also
anchor the actin cytoskeleton and thereby generate cytoskeletal
tension that affects the nuclear shape and gene expression;
(4) Integrin-mediated adhesion can cluster and transactivate
receptor tyrosine kinases, and (5) integrins organize the extra-
cellular matrix and thereby regulate upstream signaling of
receptors. See text for additional details.





































integrin-mediated adhesion to fibronectin enhances
survival by activating c-Jun N-terminal kinase (JNK)
in a focal adhesion kinase (FAK) dependent manner
(Almeida et al. 2000). Integrin a6b4 ligation also
supports nuclear factor kB (NFkB)-mediated survival
signals in 3-dimensional cultures of mammary epithe-
lial cells (Weaver et al. 2002). On the other hand,
integrins that are not ligand-bound can trigger
apoptosis of fully adherent cells by recruitment and
activation of caspase-8 suggesting that a given integrin
expression profile renders a cell dependent on a
specific ECM environment for its survival (Varner
et al. 1995, Stupack et al. 2001).
Proliferation
The ability to grow in the absence of cell adhesion is
a key property of oncogenically transformed cells. In
normal untransformed cells, integrin-mediated cell
adhesion regulates the G1 phase of the cell cycle
(Assoian & Schwartz 2001). Integrins cooperate with
RTK to stimulate the cyclin E/cyclin dependent
kinase 2 (cdk2) activity that drives S-phase entry.
Multiple different pathways have been described to
connect integrins to cell cycle progression. Regula-
tion of cyclin D1 expression, both at the level of gene
transcription and protein accumulation, is a key
element of the control of cell cycle progression by
RTK and integrins. Control of extracellular signal-
regulated kinase (ERK) activation can largely explain
the transcriptional regulation of cyclin D1 by
integrin-mediated adhesion.
Mitogen-stimulationofRTKand integrin-mediated
adhesion can each independently stimulate ERK
activation. However, only when adherent cells are
stimulated with mitogens ERK activity is strong and
sustained due to convergence of RTK and integrin
signaling at the level of Raf or MAP/ERK kinase
(MEK) (Chen et al. 1996, Renshaw et al. 1997).
There are several ways through which integrins
can regulate ERK activity (Howe et al. 2002):
(1) Binding of integrins to the ECM stimulates the
formation of an active FAK/Src signaling com-
plex at sites of adhesion. Autophosphorylation
of FAK at Tyr397 following integrin-mediated
adhesion creates a binding site for the Src
homology 2 (SH2) domain of Src (Schlaepfer
& Hunter 1998). Subsequently, Src can phos-
phorylate other Tyr residues of FAK thereby
creating binding sites for downstream effectors.
Direct binding of growth factor receptor binding
protein-2 (Grb2) to the active FAK/Src complex
or indirect binding through Shc stimulates the
Grb2-Sos-Ras-Raf-MEK-ERK pathway. Alter-
natively, Src can phosphorylate the scaffolding
protein p130Cas (Crk associated substrate) that
is also associated with FAK via its SH3 domain,
thereby creating a binding site for the adaptor
protein Crk. Either through association with
son of sevenless (Sos) or through association
with C3G (a guanine-nucleotide exchange
factor for the small GTPase Rap-1), the inter-
action with Crk can result in ERK activation.
Integrin-mediated adhesion also stimulates the
association of the adaptor protein Nck with
p130Cas, creating yet another potential link
from p130Cas to ERK activation. Finally,
PI(3)K can associate with phosphorylated
Tyr397 in FAK and it may become activated
upon integrin-mediated cell adhesion. PI(3)K
may activate ERK through its role as a protein
kinase or through modulation of Sos activity via
its production of phosphatidylinositol-3,4,5-tri-
sphosphate (PtdInsP3).
(2) Secondly, certain integrin a-subunits are
coupled to the Src family kinase Fyn through
association with the oligomeric transmembrane
protein Caveolin-1 (Guo & Giancotti 2004).
Upon integrin ligand binding, Fyn is activated
and it subsequently recruits and phosphorylates
Shc, creating a link to the Grb2-Sos-Ras-Raf-
MEK-ERK pathway.
(3) Finally, integrin-mediated adhesion activates
protein kinase C (PKC) and several PKC
isoforms can directly activate Raf. Enhanced
levels of phospholipids probably can explain the
activation of PKC upon integrin-mediated
adhesion. Also integrin-mediated adhesion
leads to the activation of the p21-activated
protein kinases (PAK) through several mechan-
isms, and PAK can activate both Raf and MEK.
Besides controlling ERK activity, suppression or
relocalization of the cyclin dependent kinase in-
hibitors p21 and p27 by integrin-mediated adhesion
also contributes to G1 cell cycle progression.
Additionally, integrin-mediated adhesion increases
expression of c-Myc through activation of c-Src
(Benaud & Dickson 2001). The organization of the
actin cytoskeleton by integrins is essential for
adhesion-regulated proliferation and integrin-
mediated control of the activity of Rho GTPases
(enzymes critically involved in actin cytoskeletal
organization) is an important aspect of adhesion-
mediated regulation of the levels of cyclin D1 and
cdk-inhibitors.
Differentiation
Integrin-mediated cell adhesion also regulates
the expression of genes related to differentiation.
Adhesion to basement membrane components sti-






































phosphorylation of the prolactin receptor in cultured
mammary epithelial cells (Li et al. 1987, Edwards
et al. 1998). Integrin-mediated adhesion also primes
monocytes for inflammatory responses (Haskill et al.
1988, Shi & Simon 2006). Another example of
regulation of differentiation by integrins is the
inhibition by integrin-blocking antibodies of the
formation of contracting myotubes and expression
of meromyosin by embryonic myoblasts (Menko &
Boettiger 1987). Deletion of b1 integrins in embryo-
nic stem (ES) cells showed that b1 is important for
normal in vitro cardiac and myogenic differentiation,
whereas neuronal differentiation is accelerated in b1-
deficient ES cells (Fassler et al. 1996, Rohwedel
et al. 1998). Finally, terminal differentiation of
cultured keratinocytes under semi-solid conditions
is inhibited by the integrin-ligand fibronectin or by
adhesion-blocking antibodies to b1 integrins (Watt
2002). Moreover, a tumor-associated mutation in b1
was recently found that increases ligand binding and
prevents terminal differentiation of keratinocytes
which might contribute to the formation of epider-
mal neoplasia (Evans et al. 2003).
Integrins in disease
Aberrant cell adhesion and migration have been
implicated in several diseases, including a number of
inflammatory disorders such as rheumatoid arthritis,
inflammatory bowel disease and asthma, as well as
cardiovascular diseases, thrombosis, and cancer.
This often correlates with alterations in the expres-
sion or functionality of integrins. For instance,
deletion of the a6b4 integrin leads to a skin blistering
disease termed Epidermolysis bullosa (Borradori &
Sonnenberg 1999), deletion of a7b1 causes con-
genital muscular dystrophy (Vachon et al. 1997), and
in patients with Glanzmann’s Thrombasthenia plate-
lets fail to aggregate, due to quantitative or qualita-
tive defects of aIIbb3 (Hodivala-Dilke et al. 1999).
On the other hand, in osteoporosis up-regulation of
integrin avb3 causes enhanced bone resorption by
osteoclasts (Lakkakorpi et al. 1993) and high
expression levels of various types of integrins have
been correlated with tumor progression in a numbers
of cancers (Mizejewski 1999).
The use of integrin antagonists
Integrin-blocking strategies have been developed to
treat a large number of diseases (Table I). Integrin
antagonists comprise small molecule compounds,
peptidomimetics, and monoclonal antibodies
(mAb). We will discuss use and action of several
drugs with focus on cancer and antagonists of the
integrins a5b1 and avb3, being the most extensively
studied targets in this disease.
Anti-angiogenesis is an emerging approach for
cancer treatment. Angiogenesis, which is the forma-
tion of new blood vessels, is a vital process for
tumor progression (Folkman 1971). Inhibition of
new blood vessel formation has been shown to
block the growth and spread of solid tumors in
various animal models. There is substantial evi-
dence that several integrins, including avb3, avb5,
and a5b1 have an important role in tumor
angiogenesis (Brooks et al. 1994a, Friedlander
et al. 1995, Kim et al. 2000). The regulation of
cell migration and survival of endothelial cells
during angiogenesis and metastasis via these integ-
rins makes them suitable targets for anti-angiogenic
therapy.
Disintegrins and RGD peptides
The RGD sequence is an important cell attachment
recognition site for integrins in many ECM compo-
nents (Pierschbacher & Ruoslahti 1984, Gardner &
Hynes 1985, Plow et al. 1985) and has been used as a
pharmaceutical application to treat aberrant cell
adhesion related-diseases. Disintegrins are RGD-
containing cysteine-rich peptides discovered in snake
venoms (Gould et al. 1990). Some disintegrins
specifically bind to integrin avb3 and are applied as
therapeutic agents for angiogenesis-dependent
tumor growth and metastasis (Huang 1998). Others,
such as Contortrostatin, which is a disulfide-linked
homodimer of 13.5 kDa containing two RGD sites
isolated from the venom of Agkistrodon contortrix, can
bind avb3, avb5, as well as a5b1 and have been
shown to inhibit tumor growth and angiogenesis in
an orthotopic xenograft model for breast cancer
(Swenson et al. 2005).
The disadvantage of natural occurring peptides
such as disintegrins is their relatively large size and
low metabolic stability, which limits their usefulness
for clinical application (McLane et al. 2004, Cai &
Chen 2006). RGD peptides have been further
optimized by incorporation of D-amino acids and
use of cyclic structures. Cyclic RGD-containing
pentapeptides are the most commonly used RGD-
based avb3 antagonists (Ruoslahti 1996). Cyclo
(RGDfV) is a highly effective avb3 antagonist with
anti-tumor and anti-angiogenic effects (Brooks et al.
1994b, Friedlander et al. 1995). In a xenograft
model for melanoma cyclo (RGDfV)-treatment
hindered tumor growth and histological analysis
indicated that the effect results from angiogenesis
inhibition rather than inhibition of tumor cell avb3
(Dechantsreiter et al. 1999). Systematic modification
of this peptide resulted in a more active and selective
compound named c(RGDf(NMe)V) also known as
Cilengitide (EMD 121974) (Goodman et al. 2002).
Cilengitide induces apoptosis in Glioblastoma and





































medullablastoma cells (Taga et al. 2002). It is
applied in phase I and II to treat non-small lung
cancer, prostate cancer, glioblastoma, pancreatic
cancer, melanoma, and lymphoma (www.cancer.
gov/clinicaltrials).
Small molecule integrin antagonists
There is evidence that small molecule antagonists
could be used to treat human diseases, which depend
on angiogenesis, including rheumatoid arthritis,
osteoporosis, and cancer (Hartman & Duggan
2000, Kerr et al. 2000, Giavazzi & Nicoletti 2002,
Shimaoka & Springer 2003). For this purpose, new
classes of small molecule avb3 antagonists have been
developed, including isoxazolines (Pitts et al. 2000),
disubstituted indazoles (Batt et al. 2000), and non-
peptide chemical RGD peptidomimetics. An exam-
ple of this latter class of antagonists, S247, which
blocks avb3/avb5, was shown to decrease tumor
growth and angiogenesis of colon cancer liver
metastases leading to prolonged survival in an
orthotopic murine model (Reinmuth et al. 2003).
Another non-peptide chemical RGD mimetic that
targets avb3, SC56631 inhibits bone resorption
in vitro and suppresses osteoporosis in oestrogen-
deprived animals (Engleman et al. 1997). The
naturally occurring polyphenol, Stilbene Resveratrol
also binds to integrin avb3 at or near the RGD-
binding site and induces apoptosis in cancer cells
through activation of ERK with consequent phos-
phorylation of p53 (Lin et al. 2006). Compared to
avb3, few small molecule antagonists are known to
inhibit a5b1. Nevertheless, treatment with ATN-
161, a non-RGD peptide specific for a5b1 that is
derived from the synergy site in fibronectin that is
part of the a5b1-binding motif but not of that of
avb3, enhanced the efficacy of chemotherapy in a
mouse model for colon cancer metastasis (Stoeltzing
et al. 2003).
Table I. Integrin antagonists and its targeted diseases.
Integrin target Drug Company Disease Reference
b2 Efalizumab (RabTIVA1) Genetech Psoriasis (Lebwohl et al. 2003)
a4 Natalizumab (Tysabri1) Biogen Idec & Elan MS, Crohn’s disease (Miller et al. 2003,
Ghosh et al. 2003)
a4b1/a4b7 TR14035 N/A Asthma (Cortijo et al. 2006,
Sircar et al. 2002)
a4b7 MLN02 Millennium
pharmaceuticals
Ulcerative colitis (Feagan et al. 2005)
a5b1 Volociximab
(M200/Gemzar1)






(O’Reilly et al. 1997)
ATN-161 N/A (Stoeltzing et al. 2003,
Livant et al. 2000)
avb3 Chimeric 7E3 Fab
(Abciximab/ReoPro1)
Centocor (Trikha et al. 2002)
Contortrostatin N/A (Clark et al. 1994,




(Albert et al. 2006,
Taga et al. 2002)
C (RGDfV) cyclo
(Arg-Gly-Asp-D-Phe-Val)
N/A (Allman et al. 2000,
Friedlander et al. 1995,
Brooks et al. 1994b,
Dechantsreiter et al. 1999)
S247 Pharmacia Corp (Reinmuth et al. 2003,
Abdollahi et al. 2005)






(Badger et al. 2001)
SC55631 N/A Osteoporosis (Engleman et al. 1997)
















































LM609 is an anti-human integrin avb3 mAb that
blocks cell adhesion to RGD-containing ligands
(Cheresh 1987). It prevents bFGF (basic fibroblast
growth factor)- and TNFa (tumor necrosis factor-a)-
dependent angiogenesis but has no effect on pre-
existing vessels (Brooks et al. 1994a). LM609 was
effective in preclinical models for glioblastoma,
melanoma, breast, and prostate cancer. Intravenous
administration of LM609 inhibited outgrowth of
avb3-negative human breast cancer cells in a
combined (SCID) mouse/human chimeric model
(Brooks et al. 1995). Fewer human blood vessels and
less invasive tumors were observed in these LM609-
treated animals with no apparent effect on normal
human tissue, indicating that LM609 acts as an anti-
angiogenic compound. Similar effects have been
obtained with antibodies directed against a5b1 (Kim
et al. 2000).
The serum half-life and integrin-binding affinity
of LM609 have been improved by generating a
humanized version, Vitaxin (Carter 2001, Wu &
Senter 2005). Optimization of the complementarity-
determining regions further improved Vitaxin’s
integrin binding affinity allowing it to inhibit tumor
growth in Kaposi’s sarcoma and partially inhibit the
binding of the human immunodeficiency virus-1
(HIV-1) Tat protein to avb3 (Rader et al. 2002).
Vitaxin II, although binding avb3 with even higher
affinity, showed no positive response in cancer
treatment but may be effective as adjuvant in
combination with chemo- or radiation therapy
(Posey et al. 2001). In 2003, MedImmune licensed
Vitaxin II (MEDI-522) for clinical development in
phase II trials in prostate cancer, melanoma,
psoriasis, and rheumatoid arthritis. However in
2004, the clinical trial of Vitaxin in the treatment
of rheumatoid arthritis and psoriasis was ended
because preliminary results failed to demonstrate
clinical benefits. Nevertheless, the trials for mela-
noma and prostate cancer are still in progress
(MedImmune ends some Vitaxin testing, advanced
tests for arthritis treatment halted; cancer research
continues. Article by Michael S. Rosenwald,
Washington Post staff writer; August 31, 2004;
Page E05).
Strongly improved versions of antibodies against
a5b1 have also been generated. For instance,Volo-
ciximab, a chimeric humanized mAb, is a high
affinity function inhibitor of the a5b1 integrin,
which, like avb3 has been found to be upregulated
in activated endothelial cells. It has been applied in
clinical phase II trials for solid tumors in renal cell
carcinoma, metastatic melanoma and pancreatic
cancer. These are ongoing studies with no data
reported yet (www.clinicaltrials.gov).
Potential of integrin antagonists to improve
efficacy of existing anticancer therapy
Similar to other anti-angiogenic agents, integrin
antagonists can be applied in combination with
cytotoxic anticancer therapy, such as chemo- or
radiotherapy. Such combinational approaches can
maximize efficacy in cancer by destroying cancer
cells as well as endothelial cells, the latter depriving
the tumor of nutrients and oxygen (Teicher 1996).
On the other hand, the anti-angiogenic agent may
also ‘normalize’ the abnormal structure and function
of tumor vessels, thereby improving drug (but also
oxygen) delivery (Jain 2005). Examples of such
combination therapies are discussed in the following
(Figure 2).
The ATN-161 a5b1 antagonist enhanced the
efficacy of chemotherapy in a mouse model for
colon cancer metastasis (Stoeltzing et al. 2003). Co-
application with Cilengitide increased the anti-tumor
effectiveness of a tumor-specific antibody against
interleukin 2 (IL-2) fusion proteins in a murine
tumor model (melanoma, colon carcinoma, and
neuroblastoma) (Lode et al. 1999). In pancreatic
cancer, Cilengitide combined with gemcitabine
(a radiation-sensitizing agent and a wide spectrum
anti-cancer drug) inhibited highly vascularized
tumor growth (Colomer 2004, Raguse et al. 2004).
In ongoing trials for breast cancer, colon cancer,
prostate cancer, melanoma, lung cancer, glioblasto-
ma, and ovarian cancer, Vitaxin II is applied in
combination with chemo-, hormonal-, biological-,
immuno-, or radiotherapy. Patients with Stage IV
Figure 2. Integrins as targets in anti-cancer therapy. Open arrows
indicate processes that are blocked by integrin antagonists. These
include survival and proliferation of tumor cells as well as survival,
proliferation, and/or migration of endothelial cells. The latter may
be of particular importance during radiotherapy where increased
expression of avb3 on endothelial cells can mediate therapy escape
through enhanced angiogenesis.





































melanoma have 9.4-month median survival when
treated with Vitaxin II combined with dacarbazine
(DTIC) whereas patients treated with DTIC alone,
have a median survival of 7.9 months (Cai & Chen
2006). It has been reported that radiotherapy in fact
promotes integrin-mediated survival signaling
through PKB/Akt by upregulating avb3 expression
on endothelial cells. This escape mechanism can be
circumvented by administering angiogenesis inhibi-
tors, such as the small molecule avb3 integrin
antagonist S247, which prevents radiation-induced
PKB/Akt phosphorylation leading to enhanced anti-
angiogenic and anti-tumor effects (Abdollahi et al.
2005).
Most integrin antagonists interfere with binding of
natural ECM components to their receptors and
thereby prevent integrin signaling to survival and
proliferation. As such, integrin antagonists may
effectively suppress tumorigenesis by targeting these
signaling pathways in both tumor and endothelial
cells. Ultimately, a trimodal strategy in which radio-,
chemo-, and anti-angiogenic therapies are combined
may be highly effective in the treatment of cancer.
The use of integrin antagonists as anti-angiogenic
agents that may also target tumor cells, may fit well
in such strategies.
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Cell spheroids (CS) embedded in 3D extracellular matrix (ECM) serve as in vitro mimics for 
multicellular structures in vivo. Such cultures, started either from spontaneous cell aggregates 
or single cells dispersed in a gel are time consuming, applicable to restricted cell types only, 
prone to high variation, and do not allow CS formation with defined spatial distribution 
required for high-throughput imaging. Here, we describe a novel method where cell-polymer 
suspensions are microinjected as droplets into collagen gels and CS formation occurs within 
hours for a broad range of cell types. We have automated this method to produce CS arrays in 
fixed patterns with defined x-y-z spatial coordinates in 96 well plates and applied automated 
imaging and image analysis algorithms. Low intra- and inter-well variation of initial CS size 
and CS expansion indicates excellent reproducibility. Distinct cell migration patterns, including 
cohesive strand-like - and individual cell migration can be visualized and manipulated. A 
proof-of-principle chemical screen is performed identifying compounds that affect cancer cell 
invasion/migration. Finally, we demonstrate applicability to freshly isolated mouse breast 
and human sarcoma biopsy material - indicating potential for development of personalized 
cancer treatment strategies.
INTRODUCTION
Cells grown under classical 2D culture conditions behave differently from the same cell 
types grown in vivo. In addition to soluble factors produced in the in vivo microenvironment, 
differences in cell shape, intercellular contacts, and connections to ECM have striking effects on 
gene expression, cell survival, proliferation, differentiation, cytoarchitecture, and migration. 
Various systems have been developed to culture cells within 3D ECM environments, aimed 
at more closely mimicking the in vivo context[1,2]. Several of these systems produce 3D cell 
aggregates in which, after compaction, depletion of oxygen, nutrients, and growth factors 
occurs in the core, leading to cell heterogeneity depending on the position in the resulting 
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cell spheroids (CS)[3,4]. Multistep methods are used in which aggregates are allowed to 
form spontaneously and, following a compaction phase, can subsequently be transferred 
to a 3D ECM. The best-known example of this approach is the “hanging drop assay” that 
was developed to create embryoid bodies from ES cells and has also been applied to cancer 
cell lines to produce tumor-like structures[5,6]. Alternative methods involve mixing of single 
cell suspensions with a solidifying ECM, resulting in individual cells that eventually form 
CS randomly within a 3D ECM structure[7], or seeding polymeric scaffolds with cell/ECM 
suspensions[2].
Cell behavior in 3D cultures is controlled by chemical (composition) and physical 
(rigidity, cross-linking) properties of the gel. Natural ECM proteins can be used such as 
collagen, fibrinogen, or the laminin-rich matrigel to represent the in vivo ECM composition 
most relevant to a given cell type. More recently, synthetic polymers have been developed for 
3D CS culture environments although it remains to be established how well these support a 
variety of cell behavioral outputs, including cell migration[8]. Collagen type 1 is an abundant 
polymer in ECM in vivo, and it is widely used for 3D cultures. Various physical properties of the 
collagen gel, such as rigidity and pore size modulate stem cell differentiation, cancer growth, 
and cell migration[9-11]. Cells can use various migration strategies in 3D environments, 
including mesenchymal or amoeboid individual cell migration modes or collective invasion 
strategies, depending on properties of the cells and of the matrix[10]. Changes in matrix 
pore size can force cells to adopt alternative migration strategies or - if too extreme - pose a 
barrier to cell migration. Importantly, cells can modify the ECM by physical deformation and 
proteolysis, to overcome such barriers[12].
Chemical compound screens as well as RNAi screens for various types of cellular 
functions, including survival, growth, differentiation, and migration are mostly performed in 2D 
culture conditions. Methods to analyze cells in 3D based on the hanging-drop assay are labor 
and time intensive; are limited to cell types that are cohesive and aggregate spontaneously; 
and are prone to high variability between experiments due to variation in aggregation and 
compaction time and CS size. Alternative methods in which single cell suspensions are mixed 
with soluble ECM substrates that are subsequently allowed to form a gel are relatively easy 
to perform but also have several major disadvantages: formation of CS depends on the ability 
of a cell type to survive and proliferate as single cells in low adhesion conditions for extended 
periods; CS formation is time consuming; CS show a large variation in size; and CS form at 
random locations, which is disadvantageous for imaging purposes.
To allow for CS formation that is relatively fast and easy, highly reproducible, and 
overcomes the disadvantages described above we have developed a novel method where 
cell-polymer suspensions are microinjected into multiwell plates containing a collagen gel. 
This method has been automated to produce CS arrays with highly reproducible properties 
in large quantities in 96 well plates. We use this system to visualize distinct 3D migration 
strategies and regulation of those strategies by ECM properties and actomyosin contractility. 
We demonstrate applicability in high-throughput screening platforms in a chemical screen 
for compounds that affect breast cancer invasion/migration. Finally, we apply the method 
to cell suspensions derived from fresh tumor biopsies, which opens the possibility to test 
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therapeutic strategies on freshly isolated material from individual patients.
MATERIALS AND METHODS
Cell culture
The following cell lines were obtained from ATCC: MDA-MB-231, MTLn3, PC-3, HT1080, 4T1, 
and MAE. GEb1 was described earlier[13]. All cell lines were cultured under standard cell 
culture conditions indicated by ATCC or as described[13] at 37ºC, 5% CO2  in a humidified 
incubator. Primary mouse tumor cell suspensions were derived from surplus mouse breast 
tumor material by mincing using scalpel and tissue chopper followed by 2-hour collagenase 
treatment at 37°C. Human biopsy material was obtained from surplus material from patients 
that were surgically treated for chondrosarcoma or osteosarcoma. Tumor cell suspensions 
were derived from biopsies by 12h collagenase treatment at 37ºC. All human specimens 
were handled in an anonymized coded fashion according to the National ethical guidelines 
for secondary use of patient-derived material.
Preparation of collagen
Collagen type I solution was obtained from Upstate-Milipore or isolated from rat-tail collagen 
by acid extraction as described previously[14]. Collagen was diluted to indicated working 
concentrations of ~2.4 mg/ml in PBS containing 1xDMEM (stock 10x, Gibco), 44 mM NaHCO3 
(stock 440 mM, Merck), 0.1 M Hepes (stock 1M, BioSolve).
Hanging drop method
~5,000 cells in 20 ml droplets were dispensed onto a 10 cm dish that was inverted over a dish 
containing 10 ml DMEM.  After 24h, cell aggregates were harvested using a Pasteur pipette 
and transferred into 10 cm dishes coated with 0.75% agarose submerged in 10ml DMEM. 
After 48h CS had formed and these were embedded into a 2.4 mg/ml collagen solution using 
a Pasteur pipette. Collagen gels were allowed to solidify at 37ºC for 30 min and overlaid 
with DMEM. Cell invasion was recorded for 3 days using an inverted phase contrast light 
microscope (Nikon Eclipse E600).
Cell preparation for injection method
Cell suspensions derived from trypsin-detached adherent cultures or from collagenase-
treated biopsies were filtered to remove clumps, centrifuged at 1000 rpm for 5 minutes, 
and washed twice with PBS. ~7x106 cells were re-suspended in 30 ml PBS containing 2% 
polyvinylpyrrolidone (PVP; Sigma-Aldrich). The PVP/cell suspension was loaded into a beveled 
pulled glass needle (Eppendorf CustomTip Type III, oD [µm] 60, Front surface 40, Flexibility: 
rigid).
Manual injection
Cell suspensions in 2% PVP were microinjected (~1x104 cells/droplet) with a microinjector (20 
psi, PV820 Pneumatic PicoPump, World Precision Instruments, Inc) into solidified collagen 




A glass-bottom 96 well plate (Greiner) containing 60ml solidified 2.4 mg/ml collagen gel 
per well was placed in a motorized stage (MTmot 200x100 MR, Märzhäuser) connected to 
a controller (Tango, Märzhäuser). A motorized micro-manipulator (Injectman II, Eppendorf) 
was positioned above the stage and connected to a pump (Femtojet Express, Eppendorf) 
featuring an external compressor (lubricated compressor, model 3-4, JUN-AIR). A firewire 
camera (DFK41BF02.H, The Imaging Source) equipped with an 8x macro lens (MR8/O, The 
Imaging Source) was placed beneath the stage for calibration and imaging. All components 
were connected to the controlling computer (Ubuntu AMD64). A multi-threaded control 
program was written in Python using PySerial and wxPython. Coriander software (http://
damien.douxchamps.net/ieee1394/coriander) was used for imaging.
After the program was calibrated for the 96 well plate the camera height was 
adjusted to focus on the bottom of the 96 well plate. The plate was then removed for needle 
calibration: the injection needle was fixed in the Injectman and moved, using the Injectman 
controller, into the center of the image. The injection height was set to 200mm above the 
bottom of the (virtual) plate. After the needle was moved up, the plate was placed back in 
position and the upper left well was used for multiple test injections to adjust pump pressure 
and injection time for optimization of the droplet size (~8nl ≈ 300mm diameter) using video 
inspection. Subsequently, using a pre-defined macro defining x-y coordinates and number of 
injections per well, all wells were injected with the same pressure and injection time.
Microscopy and image analysis
Manually injected CS were monitored daily using a Nikon Eclipse E600 microscope. CS 
generated by automated injection were used for montage imaging using a Nikon TE2000 
confocal microscope equipped with a Prior stage controlled by NIS Element Software and a 
temperature and CO2-controlled incubator.
Differential interference contrast (DIC) images were captured using a charged coupled 
device (CCD) camera with NIS software at 10x dry objective. Quantification of CS invasion 
area was analyzed from DIC images using ImageJ. The CS ellipsoidal area after three days was 
estimated using the diameter in x and y axis (pi*radius-x*radius-y) occupied by cells in the 
10x montage image in the mid-plane of each CS and normalizing to the occupied area 1h after 
injection. One-way ANOVA was performed to test the significance of the data. The data are 
presented and plotted as average and standard error of the mean.
 For automated imaging, wells containing gel-embedded CS were treated with a 
fixation and staining cocktail containing 3.7% paraformaldehyde, 0.2% Triton X-100 (Sigma) 
and 0.1 mM rhodamine Phalloidin (Sigma) for 3 hrs. Wells were washed extensively with PBS 
and plates were imaged on a Becton Dickinson Pathway 855 using a 4X lens. A montage of 12 
frames was made for each Z plane, with a total of 24 Z planes at an interval of 50 mm.  Image 
stacks were converted into 2D maximum fluorescence intensity projections using ImagePro 
7.0. CS were then digitally segmented using ImageJ to identify the outline of individual CS and 
multiple parameters were measured, including Feret’s diameter, roundness, and number of 
CS scored in each well.
For immunostaining of E-cadherin, gels were incubated for 30 mins with 5 mg/ml 
collagenase (Clostridium histolyticum, Boehringer Mannheim) at room temperature, fixed 
with 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked with 10% FBS. 
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Gels were incubated with E-cadherin antibody (BD Transduction Laboratories) overnight at 
4°C followed by Alexa 488-conjugated secondary antibody (Molecular Probes/Invitrogen) for 
2 hrs at room temperature and Hoechst 33258 nuclear staining (Molecular Probes/Invitrogen) 
for 30 min at room temperature. Preparations were mounted in Aqua-Poly/Mount solution 
(Polysciences, Inc) and analyzed using a Nikon TE2000 confocal microscope. Z-stacks (~100 
stacks, step of 1 mm) were obtained using a 20x dry objective, imported into ImageJ, and 
collapsed using extended depth of field plugin (Z projection) into a focused composite image.
Drug Treatment
LY-294002 (phosphatidylinositol 3-kinase), JSI-124-cucurbitacin (STAT3/Jak2), NSC23766 
(Rac1), and AG-82 (general protein tyrosine kinases) were purchased from Merck/CalBiochem. 
PP2 (Src) and ML-7 (MLC kinase) were purchased from ENZO. Y-27632 (Rock), SB-431542 
(TGFb) and AG1478 (EGFR) were purchased from BioMol Tocris. Cell migration was analyzed 
in the absence and presence of inhibitors for 4 days.
RESULTS
Development and characterization of the method
To design a protocol that rapidly produces CS with highly reproducible characteristics we 
developed a novel method based on microinjection. For the microinjection method we 
mixed cells with polyvinylpyrrolidone (PVP), which is an inert (hydrophilic) water-soluble 
synthetic polymer, also used as emulsifier, food-additive (E1201) and as solubilizing agent 
for injections[15]. In our application it was used to delay cell sedimentation within the 
capillary needle. Furthermore, in our experience cells rapidly disperse in the absence of PVP while 
cells injected in the presence of PVP remained localized (e.g. trapped by the polymer) at the site of 
injection, allowing time for aggregation and CS formation.
We first compared our method to the established hanging drop assay[5]. 20 ml drops 
containing 5x103 GEβ1 cells were used to create hanging drops in an inverted 10 cm dish (Fig 
1a). The time required to form cell aggregates was 24h. These cell aggregates were transferred 
to agarose-coated dishes where they formed tightly packed CS over a period of 48h. Next, the 
CS were embedded in 2.4 mg/ml collagen solution that was subsequently allowed to solidify. 
For microinjection, GEb1 cells were suspended in 2% PVP, loaded into a pulled glass needle, 
and ~80nl droplets containing ~1x104 cells were injected directly into preformed 2.4 mg/ml 
collagen gels where they formed tightly packed CS within 1h (Fig 1a). Microinjection-derived 
CS at 24h post-injection and hanging-drop-derived CS at 96h post initiation (24h in collagen) 
displayed similar cell migration the following days (Fig 1b). Microinjection-derived CS were 
also established from 4T1 mouse breast carcinoma cells where E-cadherin staining marked 
cell-cell contacts within the first day post-injection that were maintained for at least 96h (Fig 
1c).
CS derived by microinjection of different cancer - or non-cancerous cell types allowed 
analysis of various distinct motile strategies in 3D (Fig 1d). Cell types that do not typically 
form cell-cell contacts in 2D cell culture (and that are typically difficult to study in 3D using the 
hanging-drop-, liquid overlay-, or other assays in absence of additives like matrigel[16,17]) 
such as MTLn3 and MDA-MB-231 breast cancer cells and HT1080 fibrosarcoma cells, displayed 
amoeboid (MTLn3) or mesenchymal (HT1080 and MDA-MB-231) movement of individual 
___________________________________________________________________________________________________________Chapter 6
77
cells. On the other hand, 4T1 breast cancer, PC-3 prostate cancer, and human microvascular 
endothelial cells (HMEC) that grow as islands in 2D culture, invaded as cohesive strands into  
nto collagen matrix.
ECM rigidity influences cell behavior in 3D and the actin cytoskeleton is believed to 
be essential for sensing and responding to such physical ECM properties[12]. We used these 
CS to study the effect of alterations in ECM network composition or intracellular cytoskeletal 
network properties on migration strategies in 3D. Lowering ECM rigidity by decreasing collagen 
concentration from 2.5 to 0.25 mg/ml or lowering cytoskeletal tension by application of a 
ROCK inhibitor, both caused a switch from cohesive strand invasion to individual cell migration 
in 4T1 cells (Fig 1e). This suggests that tension exerted on cell-cell adhesion structures either 
from outside or inside the cell is required for cohesive 3D movement.
Fig. 1. Characteristics of 
microinjection-derived sper-
oids. A, Comparison of hang-
ing-drop and microinjection 
method for GEb1 cells. B, 
Migration of GEb1 cells from 
hanging-drop and microin-
jection-derived spheroids. 
C, E-cadherin staining in 
spheroids at indicated time-
points post-injection for 4T1 
cells. D, Different modes of 
cell migration from sphe-
roids for indicated cell types 
showing individual (top 
row) and cohesive strand 
migration (bottom row). E, 
Modulation of cell migration 
modes by alterations in col-
lagen gel network (left and 
middle) or interfering with 
cytoskeletal network (right 
image, ROCK inhibitor). Ar-
rowheads indicate cohesive 
migration strands; arrows 
indicate individual migrat-
ing cells. Scales, 120 μm.
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Altogether, these results demonstrate that the microinjection method produces CS 
for 3D growth and migration studies rapidly (hours versus days), conveniently (one step), with 
a broad spectrum of cell types including those that are incompatible with previous methods, 
and displaying a variety of migration patterns.
Method automation
Since this novel method has the potential to rapidly create CS with high reproducibility for 
large-scale analysis in 3D ECM of cell growth and migration/invasion we set up a procedure to 
automate the CS formation process. For this purpose, a 96 well plate containing 60 ml collagen 
gel per well was placed on a motorized stage and the glass needle containing the cell/PVP 
suspension described above was placed vertically in a motorized micromanipulator above the 
stage (Fig 2a). After calibration of needle and 96-well plate using camera vision from under 
the stage, a computer script was used to automate the injection process with various macros.
With this set up, cell droplets were injected resulting in CS of ~300 mm diameter 
(Movie S1). To increase reproducibility, using commercial needles reduced needle tip 
diameter variance and gels were prepared from a single large batch of collagen isolated in-
house from rat-tail. Various layouts of injection patterns were tested. A hexagonal pattern of 
19 CS spaced at 1.2 mm started to show interaction between migration strands of CS at day 
4 but a less dense hexagon pattern of 7 CS at 2 mm spacing provided sufficient spacing for 
96h analysis of CS migration (Fig 2b,c). Visual inspection indicated reduced CS migration on 
the most outer rows and columns of each plate, pointing to edge effects. We therefore chose 
to exclude these wells in all further experiments. We determined reproducibility in all other 
wells and detected no significant intra- or inter-well variation in initial CS size (ANOVA, P>0.5) 
or CS expansion over ~92h (ANOVA, P>0.5) (Fig 2d).
These data demonstrate that the microinjection method can be automated to create 
with high reproducibility and predefined x-y-z coordinates CS arrays in 96 well plates. Such 
properties make this protocol ideal for automated imaging strategies.
Application of the method to automated drug screens
A proof of principle drug screen was performed to test the applicability of this procedure to 
automated high-throughput drug screening assays (HTS). 4T1 CS were generated and various 
previously described inhibitors, including AG1478 (EGFR), PP2 (Src), ML-7 (MLCK), Y-27632 
(ROCK), NSC23766 (Rac), SB-431542 (TGFbR activin-like kinases), AG-82 (EGFR), LY-294002 
(PI3K), JSI-124 (STAT3) were added one hour later at different concentrations (4, 10, 20 mM) 
in duplicate. Effects on cell migration could be clearly observed by DIC imaging after 2 and 4 
days for ML-7 and JSI-124 (Fig 3a). For automated imaging and image analysis protocols, we 
labeled the actin cytoskeleton at day 4 of all 10 mM-treatments and controls (Fig 3b). This 
allowed automated capture of Z-stacks that were converted to maximum projection images, 
thresholded, and used for automated multiparameter analysis including Feret’s diameter and 
circularity.
Visual inspection and manual assessment of Feret’s diameter from DIC images at day 
0 and 4 demonstrated that initial CS size, CS expansion, and inhibition of invasion by ML-7 
and JSI-124 were highly reproducible (Fig 3a,c). Automated image analysis fitted well with 
these data showing that ML-7 and JSI-124 caused significantly reduced Feret’s diameters 
(p<0.05) (Fig 3d). For JSI-124 this correlated with increased circularity (p<0.05) in agreemen 
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with inhibition of invasion and a remaining round CS. The extremely low values observed for 
ML-7 (Fig 3d) despite the fact that a CS was observed by DIC (Fig 3a) can be explained by ML-
7-induced loss of filamentous actin fibers causing reduced staining in this particular method. 
Alternative staining procedures should lead to improvement and compatibility with real-time 
analysis. Nevertheless, the reproducibility of the injection procedure (Fig 2 and 3) combined
                                                                                                                                                             
with the similarity between visual inspection and automated imaging (Fig 3c,d), demonstrates 
that this automated injection system can be coupled to fully automated imaging and image 
analysis methodology that is accurate and reproducible.
Compatibility of the method with primary biopsy material
We determined if this methodology is compatible with freshly isolated biopsy material. 
First, a cell suspension was generated from 4T1-GFP orthotopic breast tumors in mice using 
collagenase-treatment. In contrast to alternative methods, the microinjection method 
circumvents any 2D tissue culture steps, which may cause altered cell behavior[18-22]. 
Following injection, these cells rapidly formed CS from which migration was analyzed after 3 
days (Fig 4a). CS were stained for actin and Hoechst and the near complete overlap between 
actin and GFP staining demonstrates that these CS consist mainly of tumor cells.
Next, cell suspensions were derived by collagenase treatment of freshly isolated 
human osteosarcoma and chondrosarcoma tissue. Following injection, CS readily formed 
from these human biopsies and survival and migration could be studied for up to one week 
with the two tumor types showing distinct migratory behavior (Fig 4b). Osteosarcoma 
Fig. 2. Automated production of spheroid arrays. A, Automated injection system (left) and cell/PVP suspension in needle during injection (right). B, Bottom view of multiple wells 
with 4T1 spheroid arays 96 hours post-injection. Scale, 10mm. C, Upper row shows stitched brightfield images showing spheroid arrays at indicated timepoints. Scale, 1 mm. Bot-
tom row shows cell migration from single bright-field images of spheroids marked by dashed rectangle in upper row. Scale, 100 μm. D, Mean and SD for initial spheroid size 4h post-
injection (black bars) and CS migration over ~4 days determined from outline of migration strands (grey bars) obtained from all 7 spheroids /well for indicated wells of a 96-well plate.
___________________________________________________________________________________________________________
80
mainly displayed individual amoeboid movement whereas chondrosarcoma showed 
predominantly individual mesenchymal movement. We treated these CS with the 
range of compounds described above at 10 mM starting 1 day post-injection. Several 
of the chemical inhibitors effectively inhibited migration of both tumor types (Fig 4b,c). 
Notably, the ROCK inhibitor Y-27632 did not affect mesenchymal movement but caused 
switching from amoeboid to mesenchymal movement in the osteosarcoma cells, in 
line with the described requirement for ROCK activity only in amoeboid single cell 
movement[23].
Taken together, these data indicate that the automated CS injection methodology 
has the potential to be used for drug testing on tumor cells freshly isolated from 
individual patients.
DISCUSSION
Here, we describe a method for generation of 3D CS cultures based on microinjection 
of cell suspensions into premade gels, that has a number of features making it highly 
useful for drug screening applications: compared to previous methods it is easy (one 
step procedure) and fast (minutes instead of days); CS are generated with high accuracy 
at predetermined x-y-z positions in multiwell plates; it is applicable to many different 
cell types irrespective of the ability of cells to form spontaneous cell-cell contacts; it 
shows good intra- and inter-well reproducibility with respect to CS size and migration; 
because of the predefined coordinates of each individual CS the method can easily be 
combined with fully automated imaging and image analysis protocols (Fig 4d).
2D culture conditions are a very poor representation of the environment cells 
encounter in vivo. Besides implications for cell biology studies, this has important 
consequences for the interpretation of genetic – and drug screens[24]. So far, these 
Fig. 3. Results from a drug screen performed on 4T1 cells in a 96 well plate. A, DIC images showing tumor cell migration in the presence of indicated inhibitors at indicated timepoints (scale = 100 μm). B, 
Top 2 rows, rhodamine-phalloidin staining and thresholding for indicated wells at 4 dpi (columns correspond to treatments from A; rows represent duplicates); bottom row, zoom in on well D2 (Ctr), 
D4 (PP2), and D10 (JSI-124). Scale, 1 mm. C, effect of indicated inhibitors on CS migration over ~4 days determined from outline of migration strands derived from DIC images in A (mean and SD for 14 
spheroids derived from 2 wells is shown). D, Quantification of data derived from automated analysis of fluorescent images shown in B (mean and SD for 14 spheroids derived from 2 wells is shown).
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have mostly been performed on 2D cultures. For the study of tumor cell invasion the Boyden 
chamber assay (trans-well migration assay) is also commonly used. Here, a monolayer of 
cells migrates through a thin layer of gel to reach the bottom of a filter. This particular assay 
Fig. 4. Application to tumor biopsies. A, Overview DIC image (left) and zoom in on individual spheroid obtained from 4T1-GFP orthotopic mose breast tu-
mor. Scales, 1 mm (left DIC); 500μm (fluorescent images). B, DIC images showing spheroids derived from osteosarcoma (top) and chondrosarco-
ma biopsy (bottom) treated with indicated inhibitors. Scale, 100μm. C, effect of indicated inhibitors on CS migration over ~4 days determined from 
outline of migration strands derived for DIC images in A (mean and SD 12 spheroids derived from 2 wells is shown). D, Schematic overview of high-
throughput spheroid screening indicating procedure at day 1 (steps 1-3) and imaging in absence or presence of compounds at days 2-8 (steps 4-6).
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does not resemble cells disassociating from a solid tumor. For this purpose, CS cultures 
have been developed that provide a pathophysiological context that mimics solid cancer 
microenvironments. However, these have not been used for large-scale drug screens due 
to the complicated procedures, which negatively affect reproducibility of results and lead 
to higher costs. Reproducibility of CS size is critical for a reliable 3D culture platform. Size 
and compactness of CS will inevitably affect drug penetration and previous studies have 
indicated that CS with diameters between 200 and 500μm are required to develop chemical 
gradients (e.g. of oxygen, nutrients,and catabolites) that may represent conditions found in 
tumors[3,4,25-28]. Our automated approach yields CS with a diameter of ~300μm, a size that 
may thus represents solid tumor traits.
 We have used collagen-based gels but the same method could be easily adapted 
to studies using alternative 3D matrices. The type and concentration of matrix proteins will 
have considerable influence on scaffold structure, rigidity, and porosity, which will impact 
on cell morphology, survival, proliferation, and migration efficiency[8,29,30]. We find that 
changing collagen concentrations has a major impact on CS cell migration and that optimal 
conditions differ for distinct cell types, in agreement with findings from others[8,29-32]. 
Hence, it is essential that gel formation is standardized and optimized for each cell type. 
The use of ECM proteins such as collagen has some limitation in terms of controlling batch-
to-batch variation. Therefore, chemical crosslinking stabilization may be applied to better 
control the mechanical properties (porosity and mechanical strength). A number of different 
cross-linking agents that react with specific amino acid residues on the collagen molecule, 
synthetic biopolymer scaffolds, and self-assembling synthetic oligopeptide gels are available 
to address this[29,30,33,34].
 We demonstrate that we can automate each step of the procedure, from injection 
of cell suspensions to imaging and image analysis, while maintaining reproducibility. Our 
method not only accelerates and simplifies CS formation but by generating up to 7 CS per well 
at predefined x-y-z coordinates it is compatible with fully automated imaging procedures, 
enhanced data collection, and robust statistical analysis. We present a small drug screen to 
demonstrate such properties. Finally, we show that the method presented here can be used 
for CS formation directly from freshly isolated tumor biopsy material without the need of 
any intermediate culture steps. This eliminates artificial traits induced by 2D culture. A fully 
analyzed CS cancer migration screen in 96 well plates can be derived from a biopsy within 1 
week. This opens the door to screening on a patient-by-patient basis for drug sensitivity of 
tumor cells under conditions that may closely mimic the in vivo pathophysiological situation. 
Clinical tests to validate inhibitor effects in CS screens by comparing with therapeutic 
efficacy can be performed without further modifications of the presented system. Moreover, 
expansions of this method can be envisioned in which multiple cell types are combined (e.g. 
cancer cells and cancer-associated fibroblasts and/or endothelial cells) to further improve 




Current methodologies do not allow formation of multicellular structures in 3D ECM 
scaffolds with defined spatial distribution at high speed and high-throughput, properties 
that are especially important for use in high content screening (HCS) platforms. In our novel 
method, cell-polymer suspensions are microinjected as droplets into solidified collagen gels. 
CS formation time is strongly reduced compared to other methods (minutes rather than 
days) and it can be applied to a broad range of cell types. Several distinct 3D cell migration 
strategies are observed and can be manipulated. For HCS, the method has been automated 
to produce CS arrays with defined x-y-z spatial coordinates in multiwell plates and coupled to 
automated imaging and image analysis algorithms. Low intra- and inter-well variation allows 
chemical screening for compounds affecting cancer cell invasion. CS can be derived from 
primary mouse and human tumor biopsy material without intermediate culture steps to be 
subjected to image-based 3D compound screening.
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Cellular interactions with the extracellular matrix (ECM) are mediated by transmembrane 
receptors of the integrin family, which coordinate signal transduction cascades impinging on 
cell survival, proliferation, and migration1. Interactions through b1 integrins support initiation 
and growth of breast and skin cancers and b1 antibodies sensitize breast tumors in mice to 
radiotherapy2-4. Here, we show that peptide blocking or gene silencing of b1 integrins can 
also cause a switch from cohesive multicellular strand invasion to individual cell migration in 
3D matrices and in a zebrafish xenograft model where b1 integrin depletion promotes breast 
cancer cell spreading. In an orthotopic mouse transplantation model, tumor growth of b1 
integrin-depleted breast cancer cells is reduced, but intravasation and lung metastasis of cells 
from these small tumors is strongly enhanced. Depletion of b1 integrins alters the balance 
between miR-200 microRNAs (miRNAs) and ZEB transcriptional repressors resulting in a 
transcriptional downregulation of E-cadherin, which is essential for the induction of individual 
cell migration and enhanced metastasis. These findings demonstrate that disturbed integrin-
mediated interactions with the ECM in cancer cells can attenuate tumor growth but also 
alter cell migration strategies leading to increased metastasis through a miRNA-transcription 
factor network that controls cell-cell adhesion.
A panel of breast epithelial cell lines was microinjected into collagen gels where they formed 
tumor cell spheroids within the first day and cell migration was analyzed over the next 4 days. 
MTLn3 and MDA-MB-231 carcinoma cells, which lack E-cadherin-mediated cell-cell contacts in 
2D culture, migrated into the collagen as single cells; a process here referred to as “individual 
cell migration” (not shown). MCF10a immortalized epithelial cells and 4T1 carcinoma cells, 
both forming E-cadherin-mediated intracellular junctions in 2D, invaded the collagen gel as 
multicellular strands; here referred to as “cohesive invasion” (Fig 1A, S1; Mov S1). We asked 
how integrin-mediated ECM attachment regulates cohesive invasion of cells with a relatively 
stable epithelial phenotype (MCF10A) and transformed cells displaying a mix of epithelial 
and mesenchymal characteristics (4T1). Silencing b1 integrins in MCF10a blocked invasive 
capacity whereas 4T1shb1 spheroids lost the ability to invade as cohesive strands but instead 
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Figure 1.  Integrin control of 3D migration patterns. A, spheroids of 4T1 and MCF10a cells expressing 
indicated shRNAs 4 days post-injection in collagen gels. B, E-cadherin staining of 4T1 and 4T1sh1 
spheroids 4 days post-injection in collagen gels. C, spheroids of 4T1 cells in the presence of indicated 
peptides (top) or expressing indicated shRNAs (bottom) 4 days post-injection in collagen gels. Scale bars, 
50 m. 
 
Figure 2.  Integrin control of in vivo migration. A-C, primary tumor growth (A), spontaneous metastasis 
(B), and circulating tumor cells (C) following orthotopic transplantation of 4T1 cells expressing indicated 
shRNA constructs in mammary fat pad (>25 mice per condition from 3 independent experiments). D, 
CM-DiI labeled 4T1sh1 cells injected in zebrafish yolk sac (top) and spread towards tail region 5 days 
post-injection (bottom). E, graphic representation of tumor cell spreading in ~40 zebrafish embryos per 
condition taken from 2 independent experiments (each pattern/color depicts tumor cells in a single 
embryo) in which labeled 4T1 cells expressing indicated shRNAs were injected in yolk sac. F, average of 
cumulative migration distances of tumor cells per embryo, calculated from E. *p<0.05; **p<0.001. 
 
Figure 3. Suppression of E-cadherin is critical for integrin regulation of invasion and metastasis. A-C, E-
cadherin mRNA (q-PCR) (A), surface expression (FACS) (B), and total protein (C) levels in 4T1 or MCF10a 
cells expressing indicated shRNAs. D, E-cadherin staining in 4T1 and 4T1sh1 orthotopic breast tumors 
(arrow indicates skin, which serves as positive control in both). E, spheroids of 4T1sh1 cells without 
(top) or with E-cadherin cDNA (bottom) 4 days post-injection in collagen gels (arrow indicates individual 
cell migration; arrow heads point to cohesive invasion strands). F-G, Lung metastasis (F) and primary 
tumor growth (G) of orthotopically transplanted 4T1 cells expressing indicated shRNAs and cDNAs (>20 
mice per condition from 2 independent experiments). Scale bars, 50 m. *p<0.05; **p<0.001. 
 
Figure 4. Integrin regulation of miR-200/ZEB balance controls E-cadherin expression and cohesive 
migration. A-B, E-cadherin promoter activity (luc assay) (A) and Zeb1 and Zeb2 mRNA levels (qPCR) (B) 
in 4T1 cells expressing indicated shRNAs. C, Relative levels of miRNAs in 4T1 expressing indicated 
shRNAs (qPCR array). D, 4T1 cohesion suppressed by sh1 and restored by synthetic miR-200C Mimic in 
2D culture (top) and in 3D collagen gels (middle and bottom) (arrows point to cohesive invasion 
strands). E, E-cadherin, Zeb2, and Zeb1 mRNA levels in 4T1sh1 cells expressing indicated synthetic 
miRNA Mimics. Scale bars, 50 m. *p<0.05; **p<0.001. 
tumor cells was strongly increased for 4T1shb1 tumors as compared to control tumors (Fig 
2C). We further a alyzed the in viv  mi ra ory cap city using a xenograft model where tumor 
cells were injected in the yolk sac of zebrafish embryos and spreading throughout the embryo 
was quantified. Again, silencing b1 integrins led to an increased ability to migrate away from 
the primary tumor cell mass and travel to distant sites in the body (Fig 2D-F). When cells were 
injected into t e dev loping blood system of these embryo’s th y rapidly bec me trapped 
in the vasculatu e a , i  agree ent with the migration patterns observed in 3D collagen 
matrices, wild type 4T1 cells showed cohesive outgrowth in those regions whereas 4T1shb1 
cells spread in a non-cohesive fashion (Fig S5).
We compared gene expression profiles n b1 knockd wn and c ntr l 1 cells. Using a false 
discovery rate (FDR) <0.001 and 1.5-fold difference as a cut-of, 1230 differentially expressed 
genes were shared between both shb1 lines (Table S1). In this set, Ingenuity Pathway Analysis 
predicted “cellular movement” as the process most significantly affected by b1 integrin 
silencing and also predicted “cell-to-cell signaling”. Both processes contained the Cdh1 
gene that was sig ifican ly d wnregulated in both shb1 lines but not in the sh- ntrol line, 
which was confirmed by qPCR (Fig 3A, S6). Indeed, silencing b1 integrins in 4T1 caused a 
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cadherin mRNA (q-PCR) (A), surface expression (FACS) (B), and total protein (C) levels in 4T1 or MCF10a 
cells expressing indicated shRNAs. D, E-cadherin staining in 4T1 and 4T1sh1 orthotopic breast tumors 
(arrow indicates skin, which serves as positive control in both). E, spheroids of 4T1sh1 cells without 
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Figure 4. Integrin regulation of miR-200/ZEB balance controls E-cadherin expression and cohesive 
migration. A-B, E-cadherin promoter activity (luc assay) (A) and Zeb1 and Zeb2 mRNA levels (qPCR) (B) 
in 4T1 cells expressing indicated shRNAs. C, Relative levels of miRNAs in 4T1 expressing indicated 
shRNAs (qPCR array). D, 4T1 cohesion suppressed by sh1 and restored by synthetic miR-200C Mimic in 
2D culture (top) and in 3D collagen gels (middle and bottom) (arrows point to cohesive invasion 
strands). E, E-cadherin, Zeb2, and Zeb1 mRNA levels in 4T1sh1 cells expressing indicated synthetic 
miRNA Mimics. Scale bars, 50 m. *p<0.05; **p<0.001. 
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~75% reduction in E-cadherin surface expression and a similar trend was observed upon a2 
silencing (Fig 3B). b1 silencing also diminished total E-cadherin protein levels and E-cadherin 
was reduced in primary tumors derived from 4T1shb1 cells as compared to control tumors 
(Fig 3C,D). Notably, in agreement with their inability to switch to an individual cell migration 
mode (Fig 1A), silencing b1 integrins in MCF10a did not affect E-cadherin surface expression 
(Fig 3B).
There is evidence that integrin-mediated ECM adhesion can modulate cell-cell adhesion 
and both positive and negative regulation has been reported but crosstalk at the level of 
E-cadherin expression has not been demonstrated9-11. A very recent report showed that 
low levels of α2β1 integrin in human breast cancer are associated with poor survival12. This 
association was confirmed in the same “NKI 295” set but not in a larger, pooled breast cancer 
cohort from The Netherlands Cancer Institute, Amsterdam, NL13 or in an independent breast 
cancer cohort from Erasmus University Rotterdam, NL14 (not shown). Global expression of α2 
or β1 was not associated with E-cadherin expression and associations detected in sub-groups 
were not corroborated in each cohort (not shown). This indicates that reduced expression 
of b1 integrins is not a general phenomenon in breast cancer, which may not be surprising 
given their dual role in growth and migration. Cell-ECM interactions can also be locally 
altered in tumors by changes in integrin activity or surface levels, or by altered proteolytic 
ECM degradation. Our findings indicate that such events can lead to transient E-cadherin 
downregulation in tumor cells already on the edge of EMT, allowing a subset of tumor cells to 
escape from the primary tumor mass and metastasize to distant organs.
We tested if the reduction in E-cadherin expression levels was critically involved in the 
pro-metastatic switch in cell migration strategy upon b1 integrin silencing. In support of 
this, ectopic expression of E-cadherin in 4T1shb1 at similar surface levels as found in control 
4T1 cells, restored cohesive invasion (Fig 3E, S7). It also blocked lung metastasis of 4T1shb1 
tumors (Fig 3F) whereas E-cadherin expression did not affect tumor growth, which was 
slow in b1 integrin-depleted tumors irrespective of the absence or presence of E-cadherin, 
further demonstrating that integrins control tumor growth and metastasis through separate 
pathways (Fig 3G).
Having established that the ability of b1 integrins to control E-cadherin levels can critically 
affect metastatic behavior, we investigated the mechanism by which b1 integrins control 
E-cadherin expression. Luciferase reporter assays showed that b1 integrin silencing led 
to a ~80% transcriptional downregulation of the Cdh1 gene (Fig 4A). This prompted us to 
investigate regulation of a group of E-cadherin transcriptional repressors, including members 
of the Snail, bHLH, and ZFH families that are implicated in EMT15. Analysis of the micro-array 
data showed that of these repressors, only Zeb2 (also known as Sip1) was significantly and 
specifically upregulated in both 4T1shb1 lines and qPCR confirmed the induction of Zeb2, 
but not Zeb1, upon b1 integrin silencing (Fig 4B, S6). ZEBs act as transcriptional repressors 
of miRNAs of the miR-200 family, which are expressed from two clusters on two distinct 
chromosomes. Vice versa, miR-200 family members post-transcriptionally repress Zeb1 and 
Zeb2 by targeting their 3’ UTRs. This ZEB/miR-200 feedforward loop has been implicated 
in EMT, and alterations in the balance between ZEB and miR-200 may underlie progression 
of a number of different types of cancer, including breast carcinomas16-18. miRNA profiling 
indicated a strong downregulation of all five members of the miR-200 family in b1 integrin-
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Figure 2.  Integrin control of in vivo migration. A-C, primary tumor growth (A), spontaneous metastasis 
(B), and circulating tumor cells (C) following orthotopic transplantation of 4T1 cells expressing indicated 
shRNA constructs in mammary fat pad (>25 mice per condition from 3 independent experiments). D, 
CM-DiI labeled 4T1sh1 cells injected in zebrafish yolk sac (top) and spread towards tail region 5 days 
post-injection (bottom). E, graphic representation of tumor cell spreading in ~40 zebrafish embryos per 
condition taken from 2 independent experiments (each pattern/color depicts tumor cells in a single 
embryo) in which labeled 4T1 cells expressing indicated shRNAs were injected in yolk sac. F, average of 
cumulative migration distances of tumor cells per embryo, calculated from E. *p<0.05; **p<0.001. 
 
Figure 3. Suppression of E-cadherin is critical for integrin regulation of invasion and metastasis. A-C, E-
cadherin mRNA (q-PCR) (A), surface expression (FACS) (B), and total protein (C) levels in 4T1 or MCF10a 
cells expressing indicated shRNAs. D, E-cadherin staining in 4T1 and 4T1sh1 orthotopic breast tumors 
(arrow indicates skin, which serves as positive control in both). E, spheroids of 4T1sh1 cells without 
(top) or with E-cadherin cDNA (bottom) 4 days post-injection in collagen gels (arrow indicates individual 
cell migration; arrow heads point to cohesive invasion strands). F-G, Lung metastasis (F) and primary 
tumor growth (G) of orthotopically transplanted 4T1 cells expressing indicated shRNAs and cDNAs (>20 
mice per condition from 2 independent experiments). Scale bars, 50 m. *p<0.05; **p<0.001. 
 
Figure 4. Integrin regulation of miR-200/ZEB balance controls E-cadherin expression and cohesive 
migration. A-B, E-cadherin promoter activity (luc assay) (A) and Zeb1 and Zeb2 mRNA levels (qPCR) (B) 
in 4T1 cells expressing indicated shRNAs. C, Relative levels of miRNAs in 4T1 expressing indicated 
shRNAs (qPCR array). D, 4T1 cohesion suppressed by sh1 and restored by synthetic miR-200C Mimic in 
2D culture (top) and in 3D collagen gels (middle and bottom) (arrows point to cohesive invasion 
strands). E, E-cadherin, Zeb2, and Zeb1 mRNA levels in 4T1sh1 cells expressing indicated synthetic 
miRNA Mimics. Scale bars, 50 m. *p<0.05; **p<0.001. 
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depleted, but not control shRNA cells (Fig 4C).
We investigated the significance of miR-200 suppression for the observed b1 integrin-
mediated control of the mode of invasion. Synthetic or lentiviral expression of any individual 
miR-200 family member restored cell-cell adhesion in 2D cultures of 4T1shb1 cells and 
induced a reversal to cohesive 3D migration (Fig 4D, S8, S9, and data not shown). On the other 
hand, none of the miRNA hairpin inhibitors targeting miR-200 family members was able to 
interfere with cell-cell adhesion in wild type 4T1 cells (not shown). Together, these data point 
to overlapping functions of the miR-200 family members in this system and demonstrate that 
downregulation of all five members is required for the observed inhibition of cohesion upon 
depletion of b1 integrins. We noted that expression of each miR-200 expression construct 
was invariably lost within 5 days after GFP sorting, suggesting that the expression of mature 
miR-200 species caused a growth disadvantage (not shown). Finally, restored cell-cell 
adhesion upon expression of miR-200 family members in 4T1shb1 cells was accompanied by 
a downregulation of Zeb2, concomitant with an upregulation of E-cadherin (Fig 4E), further 
pointing to a central role for Zeb2/miR-200 in b1 integrin-mediated control of E-cadherin 
based cohesion.
Altogether, our findings establish a novel connection between integrin-mediated cell-ECM 
interactions and E-cadherin-mediated adherens junctions. Interfering with b1 integrin-
mediated ECM adhesion attenuates tumor growth but it can also disturb the ZEB/miR-200 
balance leading to E-cadherin downregulation. This triggers a switch from cohesive to individual 
cell migration, which we find to act pro-metastatic in an orthotopic breast cancer model. The 
findings raise concerns with respect to the use of integrins as drug targets to sensitize tumors 
to radio- or chemotherapy. They also point to a new cross talk mechanism between cell-
ECM and cell-cell adhesions that may regulate transient loss of cohesion in subpopulations 
of cancer cells within tumors where EMT has not been documented. While E-cadherin is 
almost invariably lost in invasive lobular breast carcinomas its expression is retained in many 
other types including the common ductal invasive carcinomas19,20. In those cases, a transient 
downregulation of E-cadherin through disturbed tumor cell-ECM interactions in a minor 
population of invading cells may drive metastasis while going unnoticed.
METHODS SUMMARY
4T1 mouse breast cancer cells and MCF10a human mammary epithelial cells were 
transduced using lentiviral shRNA or cDNA vectors and selected for integrin or E-cadherin 
surface expression by bulk FACS sorting. Synthetic miRNA Mimics and Hairpin Inhibitors were 
transfected at 50 nM, cells were replated next day, and used for FACS, qPCR, or collagen 
invasion 48 hours later. Cells expressing lentiviral miRNA shMIMICS were selected by bulk 
FACS sorting for GFP. E-cadherin firefly luciferase reporter21 was transfected with CMV-renilla 
luciferase reporter and cells were analyzed using dual luciferase assay kit 3 days later. For 3D 
invasion, cell suspensions were microinjected into collagen gels followed by DIC imaging or 
immunostaining for F-actin or E-cadherin. Disintegrins and C-lectin type proteins, including 
Obustatin (α1β1), VLO4 (α5β1; αvβ3), VLO5 (α4β1; α9β1) and VP12 (α2β1), were used at 
4.6 mM5. For orthotopic tumor growth, cells were injected into the fat pad of recipient mice 
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migration. A-B, E-cadherin promoter activity (luc assay) (A) and Zeb1 and Zeb2 mRNA levels (qPCR) (B) 
in 4T1 cells expressing indicated shRNAs. C, Relative levels of miRNAs in 4T1 expressing indicated 
shRNAs (qPCR array). D, 4T1 cohesion suppressed by sh1 and restored by synthetic miR-200C Mimic in 
2D culture (top) and in 3D collagen gels (middle and bottom) (arrows point to cohesive invasion 
strands). E, E-cadherin, Zeb2, and Zeb1 mRNA levels in 4T1sh1 cells expressing indicated synthetic 
miRNA Mimics. Scale bars, 50 m. *p<0.05; **p<0.001. 
and tumor size was monitored. Affter 3-4 weeks, animals were anesthetized, primary tumor 
and lungs were excised for immunostaining and spontaneous metastasis counting, and in 
some cases blood was drawn for circulating tumor cells. For zebrafish xenotransplantation 
experiments, labeled tumor cells were injected into the yolk sac or developing vascular 
system of Fli-GFP transgenic zebrafish embryos. Embryos were maintained at 34°C for 6 days, 
and cumulative distance of spread tumor cells was calculated from confocal images. Real-
time qPCR data were expressed using 2^(-∆∆Ct) method. Taqman microRNA qPCR assay kit 
was used for miRNA profiling. Affimetrix MG430 PM Array plates were used for micro-arrays. 
Differentially expressed genes were identified using random-variance t-test after quality 
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control and median normalization. Western blot and FACS were done as described22. Data 
are presented as mean ± SEM of at least 3 independent biological replicates unless otherwise 
stated. Student’s t test (two-tailed) was used to compare groups.
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SUPPLEMENTARY TABLE, FIGURE, AND MOVIE LEGENDS
Figure S1. Spheroids of 4T1 cells expressing indicated shRNAs at indicated timepoints post-
injection in collagen gels. Scale bars, 50 mm.
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Figure S2. FACS analysis of b1 or a2 integrin surface expression in 4T1 or MCF10a cells 
expressing indicated shRNAs.
Figure S3. Spheroids of 4T1 cells in the presence of indicated peptides 4 days post-injection 
in collagen gels. Scale bars, 50 mm.
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Figure S4. Spheroids of 4T1 cells expressing indicated shRNAs 4 days post-injection in collagen 
gels. Scale bars, 50 mm.
Figure S5. Cohesive outgrowth of wild type 4T1 cells (left image) versus non-cohesive 
spreading of 4T1shb1 cells (right image) 3 days post-injection into the developing blood 
system of zebrafish embryos. DIC (top) and confocal fluorescent image stacks of bloodvessels 
(green) and labeled tumor cells (red) are shown. Graph shows % of injected embryos showing 




Figure S6. Micro-array analysis of E-cadherin and indicated E-cadherin repressors in two 
independent 4T1shb1 lines. Fold change compared to control group (4T1 wild type and 4T1 
sh-control) and p-value is shown. Genes showing significant change (p<0.001) are indicated 
in blue.




Figure S8. 4T1 cohesion in 2D culture suppressed by shb1 and restored by lentiviral (top) or 
synthetic (bottom) expression of indicated miR-200 species. Scale bars, 50 mm.
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Figure S9. 4T1 cohesion in collagen gels suppressed by shb1 and restored by synthetic 
expression of indicated miR-200 species. DIC (A) and actin & nuclear staining (Phalloidin & 
Hoechst; B) is shown. Arrows point to cohesive invasion strands. Scale bars, 50 mm.
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1428380_PM_at 0610007C21Rik 1.58 1.52
1429252_PM_at 0610010K14Rik -1.81 -1.73
1447870_PM_x_at 1110002E22Rik -2.06 -2.13
1435464_PM_at 1110003E01Rik 3.88 4.70
1442363_PM_at 1110012J17Rik 2.03 2.66
1434441_PM_at 1110018J18Rik 1.82 2.15
1431786_PM_s_at 1190003J15Rik -2.64 -4.10
1429219_PM_at 1200009F10Rik 1.90 2.59
1428851_PM_at 1300014I06Rik 1.68 1.64
1442992_PM_at 130004C03 2.17 2.39
1417474_PM_at 1500035H01Rik 1.56 1.59
1439014_PM_at 1600021P15Rik -1.51 -1.60
1429758_PM_at 1700017B05Rik 2.15 2.39
1423289_PM_a_at 1810029B16Rik -1.52 -1.58
1454224_PM_at 2010300F17Rik -3.26 -2.79
1424520_PM_at 2010305A19Rik 1.53 1.57
1453275_PM_at 2310002L13Rik -16.31 -23.14
1428241_PM_at 2310035K24Rik 1.84 1.70
1429215_PM_at 2310058N22Rik 1.76 2.12
1428350_PM_at 2310061F22Rik -2.14 -1.79
1428404_PM_at 2410025L10Rik 1.73 1.93
1434581_PM_at 2410066E13Rik 2.06 2.00
1436216_PM_s_at 2610204M08Rik 1.93 2.15
1426012_PM_a_at 2610301G19Rik 1.81 1.87
1429268_PM_at 2610318N02Rik 1.54 1.82
1424983_PM_a_at 2700078E11Rik -1.73 -1.82
1418389_PM_at 2810453I06Rik -1.98 -1.97
1432757_PM_at 2900011L18Rik 2.00 2.10
1444062_PM_at 2900056L01Rik 3.82 4.18
1436462_PM_at 3100002L24Rik 3.21 2.53
1452779_PM_at 3110006E14Rik 3.42 3.58
1458491_PM_at 4930422I07Rik 1.75 1.97
1441749_PM_at 4930447F24Rik 2.06 2.71
1435052_PM_at 4930455F23Rik 1.75 2.03
1429055_PM_at 4930506M07Rik -1.72 -1.63
1454606_PM_at 4933426M11Rik 1.95 1.63
1432059_PM_x_at 5031425E22Rik 2.35 2.43
1430023_PM_at 5133400G04Rik -1.54 -1.73
1435830_PM_a_at 5430435G22Rik 5.20 1.68
1454460_PM_at 5730433N10Rik 6.12 4.66
1441972_PM_at 6230424C14Rik 10.99 5.17
1439770_PM_at 6430598A04Rik 3.40 1.69
1454686_PM_at 6430706D22Rik 2.36 1.78
1433338_PM_at 6720460K10Rik 1.99 1.79
1429478_PM_at 6720463M24Rik 1.91 2.12
1428284_PM_at 8430427H17Rik 4.76 2.12
1430221_PM_at 9130008F23Rik -3.27 -2.92
1415705_PM_at 9130011J15Rik -1.61 -1.54
1436054_PM_at 9130227C08Rik 2.02 2.14
Table S1: Differentially expressed genes shared between 
two independent 4T1shβ1 lines
1443934_PM_at 9230110C19Rik 1.71 2.03
1441779_PM_at 9530006C21Rik 3.25 2.76
1441241_PM_at 9630013D21Rik 1.71 1.65
1455680_PM_at 9630025H16Rik -1.70 -1.56
1447934_PM_at 9630033F20Rik -1.99 -2.33
1433801_PM_at 9930012K11Rik 3.40 3.27
1444482_PM_at A130078K24Rik 2.22 2.54
1426168_PM_a_at A130082M07Rik -4.84 -3.90
1436825_PM_a_at A630095E13Rik -3.59 -4.37
1424829_PM_at A830007P12Rik 2.41 2.80
1435169_PM_at A930001N09Rik 1.89 1.72
1453062_PM_at A930026I22Rik 1.76 2.00
1440736_PM_at AI131651 2.23 1.72
1456878_PM_at AI646023 1.61 1.71
1455172_PM_at AU020094 -2.04 -1.83
1452150_PM_at AU040320 1.72 1.98
1455144_PM_s_at AU040829 1.98 2.40
1458648_PM_at AU042950 3.30 2.47
1423797_PM_at Aacs -1.72 -1.74
1451083_PM_s_at Aars -1.95 -1.72
1416402_PM_at Abcb10 -1.66 -1.63
1428988_PM_at Abcc3 4.06 3.46
1416014_PM_at Abce1 -1.98 -1.66
1423570_PM_at Abcg1 2.37 3.94
1439259_PM_x_at Abhd4 1.73 1.52
1416946_PM_a_at Acaa1a 2.44 2.93
1424184_PM_at Acadvl 1.76 1.76
1439021_PM_at Acap3 1.66 1.64
1424183_PM_at Acat1 1.57 1.54
1425195_PM_a_at Acat2 -1.58 -1.75
1429421_PM_at Accs 1.66 1.63
1425326_PM_at Acly -2.55 -2.22
1436788_PM_at Acp2 2.16 1.83
1456735_PM_x_at Acpl2 2.83 3.12
1415873_PM_a_at Actr1a -1.57 -1.74
1419140_PM_at Acvr2b 1.51 2.13
1417976_PM_at Ada -1.57 -1.90
1421172_PM_at Adam12 -7.19 -11.30
1421858_PM_at Adam17 1.56 1.70
1416871_PM_at Adam8 -2.73 -2.23
1450716_PM_at Adamts1 -9.42 -5.84
1437785_PM_at Adamts9 6.21 7.75
1440668_PM_at Adamtsl3 1.94 4.25
1423298_PM_at Add3 -1.61 -1.85
1424393_PM_s_at Adhfe1 2.77 1.70
1451992_PM_at Adrbk1 -1.76 -1.79
1436870_PM_s_at Afap1l2 8.48 3.43
1416645_PM_a_at Afp 3.54 3.63
1434287_PM_at Agpat5 -1.76 -1.69
1426670_PM_at Agrn -1.58 -1.54
1422631_PM_at Ahr 2.84 2.26
1422184_PM_a_at Ak1 1.68 1.82
1457032_PM_at Ak5 2.62 3.60
1434764_PM_at Akap11 1.65 1.63
1419706_PM_a_at Akap12 -2.79 -2.31
1455870_PM_at Akap2 1.60 1.63
1433905_PM_at Akap7 -1.87 -1.93
1450455_PM_s_at Akr1c12 10.84 4.73
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1418672_PM_at Akr1c13 14.47 6.23
1423364_PM_a_at Aktip -1.90 -1.99
1415836_PM_at Aldh18a1 -2.63 -2.06
1418752_PM_at Aldh3a1 10.72 5.07
1415776_PM_at Aldh3a2 2.18 1.88
1448104_PM_at Aldh6a1 2.00 2.04
1460167_PM_at Aldh7a1 2.18 2.43
1419115_PM_at Alg14 -1.83 -1.56
1455887_PM_at Alg8 1.70 1.63
1434601_PM_at Amigo2 13.54 10.99
1430697_PM_at Ammecr1 -2.24 -2.29
1434444_PM_s_at Anapc1 1.79 1.55
1439066_PM_at Angpt1 8.76 15.63
1448831_PM_at Angpt2 1.99 1.54
1455090_PM_at Angptl2 2.55 2.52
1453287_PM_at Ankrd33b 2.76 5.11
1451182_PM_s_at Ankrd54 1.68 1.60
1451446_PM_at Antxr1 4.84 4.02
1418468_PM_at Anxa11 1.93 2.16
1460330_PM_at Anxa3 -1.59 -1.50
1416137_PM_at Anxa7 1.52 1.74
1460190_PM_at Ap1m2 -3.42 -3.22
1447903_PM_x_at Ap1s2 3.23 2.99
1427077_PM_a_at Ap2b1 -1.76 -2.01
1422593_PM_at Ap3s1 2.04 1.80
1449070_PM_x_at Apcdd1 7.71 13.26
1456500_PM_at Aph1b 1.78 2.27
1416203_PM_at Aqp1 23.48 9.06
1418818_PM_at Aqp5 7.03 2.53
1452291_PM_at Arap2 -2.92 -8.37
1421134_PM_at Areg 2.45 2.39
1418847_PM_at Arg2 2.58 3.03
1426952_PM_at Arhgap18 6.87 5.56
1435108_PM_at Arhgap22 2.10 2.17
1435694_PM_at Arhgap26 1.87 2.05
1434809_PM_at Arhgap28 3.07 3.10
1454745_PM_at Arhgap29 -2.49 -1.86
1451867_PM_x_at Arhgap6 5.99 4.61
1448660_PM_at Arhgdig -2.25 -1.58
1421164_PM_a_at Arhgef1 -1.51 -1.83
1424250_PM_a_at Arhgef3 -1.95 -3.81
1431429_PM_a_at Arl4a 1.86 1.75
1427167_PM_at Armcx4 -2.59 -3.90
1454617_PM_at Arrdc3 7.73 7.49
1434961_PM_at Asb1 2.34 1.82
1423422_PM_at Asb4 -3.38 -3.65
1451095_PM_at Asns -2.35 -1.87
1448763_PM_at Atad1 -1.78 -1.99
1449363_PM_at Atf3 -3.57 -3.31
1451747_PM_a_at Atg12 2.00 1.73
1434092_PM_at Atg9b -2.76 -3.27
1456388_PM_at Atp11a -1.61 -1.59
1452746_PM_at Atp13a2 1.53 1.62
1436921_PM_at Atp7a 2.15 2.12
1418774_PM_a_at Atp7a 2.15 2.00
1434026_PM_at Atp8b2 2.17 1.98
1415932_PM_x_at Atp9a 1.73 2.00
1453681_PM_at Atpif1 1.69 1.94
1452370_PM_s_at B230208H17Rik -1.62 -1.88
1428568_PM_at B230217C12Rik 2.66 2.10
1436842_PM_at B230380D07Rik 3.14 3.93
1457043_PM_at B3galtl 1.71 2.61
1418014_PM_a_at B4galt1 1.62 1.64
1425934_PM_a_at B4galt4 -1.80 -1.53
1433617_PM_s_at B4galt5 1.95 2.10
1460329_PM_at B4galt6 -11.53 -5.34
1438635_PM_x_at B930041F14Rik 2.30 1.84
1427947_PM_at B9d2 2.20 1.98
1434200_PM_at BC010981 -1.59 -1.75
1424360_PM_at BC019943 -1.93 -1.70
1455437_PM_at BC033915 2.11 2.96
1456929_PM_at BC042782 2.42 4.11
1435794_PM_at BC050254 1.66 1.70
1424117_PM_at BC056474 -1.56 -1.53
1435209_PM_at BC057079 -1.77 -1.53
1424951_PM_at Baiap2l1 -1.75 -1.79
1453076_PM_at Batf3 1.64 1.79
1450622_PM_at Bcar1 -1.89 -2.16
1416647_PM_at Bckdha 2.22 2.27
1419406_PM_a_at Bcl11a -2.40 -2.77
1420888_PM_at Bcl2l1 1.60 1.67
1456006_PM_at Bcl2l11 2.28 2.20
1452614_PM_at Bcl2l15 -1.95 -2.60
1442187_PM_at Bdkrb2 -2.83 -2.74
1422169_PM_a_at Bdnf 2.70 4.76
1426489_PM_s_at Bfar 1.55 1.63
1418025_PM_at Bhlhe40 -4.86 -7.41
1425532_PM_a_at Bin1 1.82 1.82
1417691_PM_at Bin3 2.22 1.99
1426238_PM_at Bmp1 1.58 1.52
1418910_PM_at Bmp7 -3.06 -2.58
1416923_PM_a_at Bnip3l 1.57 1.73
1435480_PM_at Braf -2.09 -2.06
1448521_PM_at Brd7 -1.67 -1.51
1427270_PM_a_at Bsdc1 1.73 1.86
1435249_PM_at Btaf1 -2.03 -1.70
1424054_PM_at Btbd2 2.05 1.63
1417987_PM_at Btd 1.83 1.96
1424074_PM_at Btf3l4 1.67 2.07
1426268_PM_at C130090K23Rik -2.05 -2.64
1422772_PM_at C1galt1 -1.93 -1.86
1435580_PM_at C230081A13Rik 2.74 3.75
1436709_PM_at C230096C10Rik 1.79 1.83
1457046_PM_s_at C77370 -1.89 -1.94
1446288_PM_at C78692 2.15 2.13
1441673_PM_at C80120 1.75 2.20
1440513_PM_at C80258 1.91 2.51
1453232_PM_at Calr3 1.71 1.98
1452050_PM_at Camk1d 3.29 6.73
1439168_PM_at Camk2d 1.82 1.55
1423941_PM_at Camk2g 2.39 1.92
1439843_PM_at Camk4 2.00 2.73
1426901_PM_s_at Camta2 1.92 2.03
1437537_PM_at Casp9 1.75 1.86
1449145_PM_a_at Cav1 -2.48 -2.66
1422666_PM_at Cblc -1.73 -2.16
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Movie S1. 4T1 cell migration in collagen gel (start 48h post injection; duration ~3h).
Movie S2. 4T1shb1 cell migration in collagen gel (start 48h post injection; duration ~3h).
Movie S3. 4T1 cell migration in collagen gel incubated with VP12 (start 48h post injection; 
duration ~3h).
FULL METHODS
Cell lines and animals.  4T1 mouse breast cancer cells and MCF10a human mammary 
epithelial cells were obtained from ATCC and cultured according to the provided protocol. 
Rag2−/−;γc−/− mice were housed in individually ventilated cages under sterile conditions. 
Housing and experiments were performed according to the Dutch guidelines for the care and 
use of laboratory animals. Sterilized food and water were provided ad libitum. Zebrafish were 
maintained according to standard protocols (http://ZFIN.org). Embryos were grown at 28.5-
30˚C in egg water (60 mg/ml Instant Ocean Salts). During injection with tumor cells, embryos 
were kept under anesthesia in 0.02% buffered 3-aminobenzoic acid ethyl ester (Tricaine, 
Sigma).
Antibodies and peptides.  For FACS, primary antibodies included HMb1 anti-mouse b1 (BD 
Pharmingen), AIIB2 anti-human b1, Ha1/29 anti-mouse a2 (BD Pharmingen), or DECMA 
anti-mouse/human E-cadherin (Sigma-Aldrich). For Western blot, primary antibodies 
included HMb1 anti-mouse b1, 36/E-cadh anti-mouse/human E-cadherin (BD Transduction 
Laboratories), and B-5-1-2 anti-a-tubulin (Sigma). For immunohistochemistry on frozen 
tumor sections and in fixed collagen gels, 36/E-cadh anti-mouse/human E-cadherin antibody 
(BD Transduction Laboratories) was used. For tumor cell migration interference studies, snake 
venom-derived disintegrins and C-lectin type proteins, including Obustatin (a1b1), VLO4 
(a5b1; avb3), VLO5 (a4b1; a9b1) and VP12 (a2b1), were used at a concentration of 4.6 mM5.
Stable cDNA and shRNA expression.  4T1 and MCF10a cells were transduced using lentiviral 
shRNA vectors (LentiExpressTM; Sigma-Aldrich) according to the manufacturers’ procedures 
and selected in medium containing 2 mg/ml puromycin. Control vectors included shRNA 
targeting TurboGFP (shc#1) and shRNA targeting eGFP (shc#2). shRNAs silencing mouse 
b1 integrin included those targeting gcacgatgtgatgatttagaa (shb1#1; nucleotides 360-383 
in the mouse Itgb1 coding sequence) and gccattactatgattatcctt (shb1#2; nucleotides 1111-
1131 in the mouse Itgb1 coding sequence). shRNAs silencing mouse a2 integrin included 
those targeting gcgttaattcaatatgccaat (sha2#1; nucleotides 733-753 in the mouse Itga2 
coding sequence) and gcagaagaatatggtggtaaa (sha2#2; nucleotides 2274-2294 in the 
mouse Itga2 coding sequence). shRNAs silencing human b1 integrin included those targeting 
gccctccagatgacatagaaa (shb1#1; nucleotides 360-380 in the human ITGB1 coding sequence) 
and gccttgcattactgctgatat (shb1#2; nucleotides 2367-2387 in the human ITGB1 coding 
sequence). 4T1shb1 cells were transduced with pCSCG/mECAD lentiviral cDNA expression 
vector for mouse E-cadherin (provided by Dr. Patrick Derksen, University Medical Center, 
Utrecht NL). Cells transduced with integrin shRNAs or E-cadherin cDNA were selected for 
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stable knockdown or stable expression phenotypes, respectively by two rounds of bulk FACS 
sorting (see below for technical details).
Lentiviral expression of miRNA shMimics.
4T1shβ1 cells were transduced using miRIDIAN shMIMIC Lentiviral miRNAs (non-targeting 
control, miR-200a, miR-200b, miR-200c, miR-141, and miR-205; ThermoFisher Scientific) 
according to the manufacturers’ procedures followed by two rounds of bulk sorting for GFP 
expression. Subsequently, cells were used for E-cadherin FACS, qPCR analysis, or collagen 
invasion studies.
Transfection of synthetic miRNA Mimics, and miRNA Hairpin Inhibitors.
Cells were seeded at 5x105 cells per well in 12 wells plates and transfected at a final 
concentration of 50 nM of miRIDIAN miRNA Mimics (ThermoFisher Scientific; control non-
targeting, miR-200a, miR-200b, miR-200c, miR-141, and miR-205), or miRIDIAN miRNA 
Hairpin Inhibitors (ThermoFisher Scientific; control non-targeting, miR-200a, miR-200b, 
miR-200c, miR-141, and miR-205) using DharmaFECT2 (ThermoFisher Scientific). Cells were 
replated 24 hours post transfection and used for E-cadherin FACS, qPCR analysis, or collagen 
invasion 48 hours later.
Luciferase reporter assay.  4T1 wild type and 4T1shb1 cells were transiently transfected with 
10 ng of an E-cadherin firefly luciferase reporter plasmid21 (provided by Dr. Geert Berx, VIB, 
Gent BE) and 2 ng of a CMV-renilla luciferase reporter using lipofectamine plus (Invitrogen) 
and analyzed using a dual luciferase kit (Promega) 3 days later, according to the manufacturers’ 
procedure.
3D invasion assays.  Cell suspensions in PBS containing 2% polyvinylpyrrolidone (PVP; Sigma-
Aldrich) were microinjected (~1x104 cells/droplet) using an air driven microinjector (20 psi, 
PV820 Pneumatic PicoPump; World precision Inc) into collagen gels prepared from 2.5 mg/
ml acid-extracted rat tail collagen type 1. Tumor cell spheroids were monitored for 4 days. 
For immunostaining at 4 days post-injection, gels were incubated for 30 min with 5 μg/ml 
collagenase (from Clostridium histolyticum, Boehringer Mannheim) at room temperature, 
fixed with 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked with 1% 
BSA. Gels were incubated with Rhodamin-conjugated Phalloidin or with E-cadherin antibody 
followed by Alexa 488-conjugated secondary antibody and Hoechst nuclear staining. 
Preparations were mounted in Aqua-Poly/Mount solution (Polysciences, Inc) and analyzed 
using a Nikon TE2000 confocal microscope. Z-stacks (50 x 1 μm) were obtained using a 20x dry 
objective and converted into a single Z projection using the “extended depth of field” plugin 
from ImageJ software.
For real time imaging, ~3 hours time-lapse movies of spheroids were obtained starting 
at 48 hours post-injection. Image acquisition was performed using a Nikon TE2000 confocal 
microscope with a temperature and CO2 controlled incubator. Differential interference 
contrast (DIC) time-lapse videos were recorded using a charged coupled device (CCD) camera 
controlled by NIS Element Software. Images were converted into a single avi file in Image-Pro 
Plus (Version5.1; Media Cybernetics).
Mouse orthotopic transplantation experiments. 1×105 tumor cells in 0.1 mL PBS were injected 
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into the fat pad of 8-12-week old female Rag2−/−;γc−/− mice. Size of the primary tumors was 
measured using calipers. Horizontal (h) and vertical (v) diameters were determined and tumor 
volume (V) was calculated: V = 4/3π{1/2[√(h x v)]3}. After 3-4 weeks, animals were anesthetized 
with pentobarbital and primary tumor and lungs were excised. Primary tumor and left lung 
were divided into two pieces that were snap frozen in liquid nitrogen for E-cadherin immuno-
staining or fixed in 4% paraformaldehyde for H&E staining. For counting of lung metastases, 
right lungs were injected with ink solution, destained in water, and fixed in Feketes [4.3% 
(vol/vol) acetic acid, 0.35% (vol/vol) formaldehyde in 70% ethanol]. To analyze circulating 
tumor cells in some mice blood was drawn from the right atrium via heart puncture after 
anesthetizing but before excision of primary tumor and lungs. 0.2 ml of blood was plated into 
60-mm tissue culture dishes filled with growth medium. After 5 days, tumor cell clones were 
stained using MTT (Sigma) and counted using ImageJ.
Zebrafish xenotransplantation experiments. For quantification of tumor cell spreading, 
tumor cells were labeled with CM-DiI (Invitrogen), mixed with 2% PVP, and injected into the 
yolk sac of enzymatically dechorionated, two-day old Fli-GFP transgenic zebrafish embryos 
using an air driven microinjector (20 psi, PV820 Pneumatic PicoPump; World precision Inc). 
Embryos were maintained in egg water at 34°C for 6 days and subsequently fixed with 4% 
paraformaldehyde. Imaging was done in 96 well plates containing a single embryo per well 
using a Nikon Eclipse Ti confocal laser-scanning microscope. Z stacks (15 x 30 mm) were 
obtained using a Plan Apo 4X Nikon dry objective with 0.2 NA and 20 WD. Images were 
converted into a single Z projection in Image-Pro Plus (Version 6.2; Media Cybernetics). 
Automated quantification of cumulative tumor cell spreading per embryo was carried out 
using an in-house built Image-Pro Plus plugin.
For analysis of tumor cell migration strategies, labeled tumor cells were injected in the 
developing blood system and clusters of cells trapped in the vasculature were imaged 3 days 
post injection. Z stacks (75 x 1 mm) were obtained using a Plan Apo 20X Nikon dry objective 
with 0.2 NA and 20 WD.
mRNA and miRNA analysis.  Total RNA for qPCR and miRNA profiling was extracted using Trizol 
(Invitrogen). cDNA was randomly primed from 50 ng total RNA using iScript cDNA synthesis 
kit (BioRad) and real-time qPCR was subsequently performed in triplicate using SYBR green 
PCR (Applied Biosystems) on a 7900HT fast real-time PCR system (Applied Biosystems). The 
following qPCR primer sets were used: b-actin, forward aacctggaaaagatgacccagat reverse 
cacagcctggatggctacgta; E-cadherin, forward atcctcgccctgctgatt reverse accaccgttctcctccgta; 
Zeb1, forward ccttcaagaaccgctttctgtaaa reverse cataatccacaggttcagttttgatt; Zeb2, forward 
cagcagcaagaaatgtattggtttaa, reverse tgtttctcattcggccatttact. Data were collected and 
analysed using SDS2.3 software (Applied Biosystems). Relative mRNA levels after correction 
for b-actin control mRNA, were expressed using 2^(-∆∆Ct) method.
Detection of mature miRNAs was performed using Taqman microRNA qPCR assay kit 
according to the manufacturer's instructions (Applied Biosystems). The U6 small nuclear RNA 
was used as internal control.
For micro-arrays, total RNA was extracted using mirVana RNA isolation kit (Ambion 
Inc). RNA quality and integrity was assessed with Agilent 2100 Bioanalyzer system (Agilent 
technologies). The Affymetrix 3’ IVT-Express Labeling Kit was used to synthesize Biotin-
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labeled cRNA and this was hybridized to an Affimetrix MG430 PM Array plate. Data quality 
control was performed with Affymetrix Expression Console v1.1 and all raw data passed the 
affimetrix quality criteria. Median normalization of raw expression data and identification 
of differentially expressed genes using a random-variance t-test was performed using BRB 
ArrayTools23 version 4.1.0 Beta 2 release (developed by Dr. Richard Simon and BRB-ArrayTools 
Development Team members; http://linus.nci.nih.gov/BRB-ArrayTools.html). Annotation was 
done according to the NetAffx annotation date release 2009-11-23. Corrections for multiple 
testing were performed as described by calculating the FDRs24.
Western blot and flow cytometry. For Western blot, cells were lysed with modified RIPA buffer 
(150 mM NaCl, 1.0% triton-X 100, 0.5% Na deoxycholate, 0.1% 50mM Tris pH 8, and protease 
cocktail inhibitor (Sigma-Aldrich)). Samples were separated on SDS PAGE gels and transferred 
to PVDF membranes (Millipore), incubated with primary antibodies followed by horseradish 
peroxidase-labeled secondary antibodies (Jackson ImmunoResearch Laboratories inc), and 
developed with enhanced chemiluminescence substrate mixture (ECL plus, Amersham, GE 
Healthcare). Blots were scanned on a Typhoon 9400 (GE Healthcare).
For flowcytometry, cells were detached either using trypsin/EDTA (in the case of GFP 
or integrin surface expression) or by 0.02% EDTA only (in the case of E-cadherin surface 
expression). Surface expression levels were determined using primary antibodies, followed 
by fluorescence-conjugated secondary antibodies, and analysis on a FACSCanto or sorting on 
a FACSCalibur (Becton Dickinson).
Statistical analysis.  Data are presented as mean ± SEM of at least 3 independent biological 
replicates unless otherwise stated. Student’s t test (two-tailed) was used to compare groups.
References to full methods.
23. Wright G.W. and Simon R. (2003) A random variance model for detection of differential 
gene expression in small microarray experiments. Bioinformatics 19:2448-2455.
24. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical 
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Summary and discussion
Embryo development, wound healing, angiogenesis, and cancer metastasis rely on 
cell motility and adhesion dynamics. This involves shifting integrin expression profiles, 
which may reflect the changing environment that the cells encounter and adapt to. 
For example, malignant cells migrating from primary to secondary sites will come 
across extracellular matrix (ECM) compositions that are different from their site of 
origin. In chapters 2 and 3 of this thesis, the roles of a5b1 and avb3 fibronectin 
(FN)-binding integrins in cell motility and adhesion dynamics are discussed. We find 
that when these integrins are ectopically expressed in the same cellular background 
(GE11), striking differences in cellular functions (cell morphology, cell-matrix adhesion 
dynamics and localization) are observed. Cells expressing a5b1 integrin exhibit a 
contractile fibroblastic morphology with highly dynamic centripetally orientated cell-
matrix adhesions and migrate in random fashion. In contrast, avb3 expressing cells, 
whose cell-matrix adhesions are more static and distributed across the basal surface, 
migrate in a highly persistent fashion.
What is the reason for these differences when both integrins interact with FN? One 
possible explanation could be the interaction of signaling and/or adaptor proteins 
with specific residues within the integrin cytoplasmic tail. However, a- and b- tail 
swapping experiments revealed that this is probably not the case. Rather, our evidently 
suggests that it is how the integrins interact with the FN that affects cell signaling. We 
demonstrate that both a5b1 and avb3 adhere to immobilized (stretched) FN, but 
only a5b1 binds to soluble folded (inactive) FN. RGD in immobilized (stretched) FN 
is reoriented in such a way that it is accessible to both integrins (Altroff et al., 2004). 
The ability of a5b1 to access the RGD site in soluble FN comes from the fact that 
this integrin has an additional FN binding region (Aota, Nomizu, and Yamada, 1994; 
Bowditch et al., 1994; Danen et al., 1995) and we show that placing the CTSEQNC 
hypervariable sequence in the I-like domain of b1 in the context of b3 allows avb3 
to also bind soluble FN. It has been suggested that the a5b1 hypervariable sequence 
binds to the PHSRN “synergy” region in IIIFN9 to stabilize interaction with the RGD 
region in IIIFN10 by changing the tilt angle between IIIFn10 and IIIFn9, subsequently 
exposing RGD loops. Our findings demonstrate that integrin avb3, even if locked in a 
high affinity state by different mutations, binds poorly to soluble FN because it lacks 
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this functionality (Danen et al., 1995; Sechler, Corbett, and schwarzbauer, 1997).
The association with the synergy region may explain the apparently specific ability of 
a5b1 to form a “catch-bond” with FN and mediate adhesion strengthening (Friedland, 
Lee, and Boettiger, 2009; Roca-Cusachs et al., 2009). Importantly, our findings indicate 
that switching between these two integrins with such distinct ligand-interaction 
modes strongly affects intracellular cellular with effects on RhoA activity, cytoskeletal 
contractility, and ECM assembly. 
In chapter 4, a novel avb3 binding partner is described that could also contribute 
to the specific avb3-mediated effects on cell morphology. MacMarcks (MRP) had 
been implicated in the activation of integrins and cell spreading by regulating the 
cortical actin network (Jin and Li, 2002). Interestingly, expression of b3 integrin 
transcriptionally down-regulates MRP. We demonstrate that the region in the vicinity 
of NITY domain of the b3 tail down-regulates MRP if associated with the av-subunit. 
Nonetheless, silencing MRP did not promote cell spreading in the parental line, and 
overexpression did not hamper cell spreading in cells using avb3 for adhesion. This 
suggests that b3 is required for MRP localization and expression but MRP is not 
essential for avb3-mediated cell spreading (in contrast to b2 integrins, which have 
been claimed to depend on MRP for spreading (Li et al., 1996).
As described in chapter 5, certain diseases display altered expression or functionality 
of integrins. For instance, high expression levels of various types of integrins have been 
correlated with tumor progression in a numbers of cancers (Mizejewski, 1999). For that 
reason, antagonists such as peptidomimetics and monoclonal antibodies have been 
developed targeting either a5b1 and avb3 integrins. Disintegrins are RGD-containing 
cysteine-rich peptides in snake venom that have been developed as therapeutic 
agents for angiogenesis-dependent tumor growth and metastasis (Huang, 1998). 
Unfortunately, these molecules are very large and have low metabolic stability limiting 
their use for clinical applications (McLane et al., 2004, Cai and Chen, 2006). Cyclic 
RGD-containing pentapeptides are the most commonly used RGD-based antagonist 
(Ruoslahti, 1996). c(RGDf(NMe)V) a.k.a Cilengitide (EMD 121974) (Goodman et 
al., 2002) has effectively induced apoptosis in glioblastoma and medullablastoma 
(Taga et al., 2002). Integrin antagonist can be applied in combination with cytotoxic 
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anticancer therapy, such as chemo- or radiotherapy to maximize therapeutic efficacy. 
For example, Cilengitide in combination with gemcitabine inhibits highly vascularized 
tumor growth (Colomer, 2004; Raguse et al., 2004). It has been reported that tumor-
associated endothelial cells can evade death by up-regulating avb3 integrin upon 
radiation exposure. Agents such as the avb3 inhibitor S247 have the potential to block 
growth of tumor cells and angiogenic vessels and cause inhibition of phosphorylation 
of PKB/Akt (Abdollahi et al., 2005).
Classic 2D culture conditions differ strongly from the in vivo situation and affect cell 
survival, proliferation, differentiation, cytoarchitecture, and migration (Kenny PA et 
al., 2007; Bjerkvig, 1990; Bissell, 1981; Wapita and Hay, 2002; Corcoran et al., 2003; 
Beliveau et al., 2010). For cancer metastasis-related studies, 3D invasion assays such 
as the Boyden chamber assay (trans-well migration assay) also may not properly 
resemble tumor cells disassociating from a solid tumor. For this purpose, cell spheroid 
(CS) cultures have been developed that mimic solid cancer microenvironments. 
This requires CS to be compact and contain an oxygen- and nutrient -depleted core, 
which are characteristics of solid tumors (Mueller-Klieser, 1987; Sutherlands, 1988). 
In addition, the ECM environment surrounding CS ideally mimics chemical (ECM 
protein type) and physical (rigidity, cross-linking) properties of tissue (Buxboim and 
Discher,2010; Friedl and Wolf, 2010, Leventhal et al., 2009).  In chapter 6, we describe 
the development a novel CS formation method in 3D collagen gels that fulfills these 
criteria and, for the first time, can be performed in high throughput with high accuracy 
and reproducibility.
There are several advantages of our approach based on microinjection over other 
methods. For one, we combined CS formation and gel embedding into a single step, 
thereby shortening preparation time from days to minutes. Secondly, CS formation 
from a broad spectrum of cell can be achieved without additive, e.g. matrigel such 
as used by others (Ivascu and Manfred, 2006, 2007). Thirdly, CS are produced with 
uniform size and shape with predefined spatial distribution, making this method ideal 
for HTS. Unlike other techniques, 2D tissue culturing steps are completely omitted, 
and freshly isolated tumor samples of mouse and human biopsies can be used directly 
for CS formation. Consequently, we have designed an automated 3D culture syste 
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that may be applied to drug screens for personalized treatment strategies.
According to several studies, b1 integrins support initiation and growth of breast 
cancer. By blocking b1 integrins with antibodies, breast tumors in mice have been 
sensitized to radiotherapy, indicating that b1 integrins may be suitable drug targets 
for breast cancer (White et al., 2004; Park et al., 2006). In chapter 7, we describe that 
silencing b1 in breast cancer cells indeed suppresses tumor growth but can also lead 
to enhanced intravasation and metastasis. Our data support a model where in the 
absence of b1 integrins, an epithelial-to-mesenchymal (EMT) transition is induced 
through transcriptional down regulating of E-cadherin by an altered balance between 
the ZEB and mir-200 families. Consequently, cells shift from cohesive multicellular 
strand invasion to individual cell migration in 3D matrices. This likely enables tumor 
cells to intravasate more efficiently through enhanced migration by eliminating the 
burden to travel as collective units (dragging force) or it may up-regulate survival 
mechanisms to resist the sheer stress within the blood vessel; or speed up.
Experiments using inhibitory peptides and a2 subunit silencing constructs, indicate 
that a2b1 is the b1 integrin that acts as a metastasis suppressor in this system. 
Interestingly, this integrin was very recently shown to be inversely correlated with 
breast cancer progression (Ramirez et al., 2010). Nevertheless, we do not detect 
a general loss of a2 or b1 integrins to correlate with E-cadherin loss. Histological 
samples provide a snapshot in the dynamic process of metastasis process and may 
not reveal key transient malignant modifications in the metastatic cascade; especially 
if these are rare and transient. Indeed, the down-regulation of E-cadherin in response 
to decreased b1-integrin-mediated adhesion may be such a transient process that 
occurs in a subpopulation of cancer cells within a tumor. Such events may be missed 
by the pathologist but play a role in metastasis of E-cadherin positive breast cancers.
From fundamental research to clinical application, integrins have presented 
themselves to be highly intriguing receptors. Besides mediating cell attachment to 
the microenvironment, integrins organize signal transduction cascades that regulate 
cell biology from proliferation and survival to migration. As such, they appear to be 




Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., . . . Huber, P. E. (2005). Inhibition of alpha(v)beta3 
integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clinical Cancer Research : An Official 
Journal of the American Association for Cancer Research, 11(17), 6270-6279. 
Altroff, H., Schlinkert, R., Van Der Walle, C. F., Bernini, A., Campbell, I. D., Werner, J. M., & Mardon, H. J. (2004). Interdomain tilt 
angle determines integrin-dependent function of the ninth and tenth FIII domains of human fibronectin. Journal of Biological 
Chemistry, 279(53), 55995-56003. 
Aota, S. -., Nomizu, M., & Yamada, K. M. (1994). The short amino acid sequence pro-his-ser-arg-asn in human fibronectin 
enhances cell-adhesive function. Journal of Biological Chemistry, 269(40), 24756-24761. 
Beliveau, A., Mott, J. D., Lo, A., Chen, E. I., Koller, A. A., Yaswen, P., . . . Bissell, M. J. (2010). Raf-induced MMP9 disrupts tissue 
architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes & Development, 
24(24), 2800-2811. 
Bissell, M. J. (1981). The differentiated state of normal and malignant cells or how to define a “normal” cell in culture. 
International Review of Cytology, 70, 27-100. 
Bjerkvig, R., Tonnesen, A., Laerum, O. D., & Backlund, E. O. (1990). Multicellular tumor spheroids from human gliomas maintained 
in organ culture. Journal of Neurosurgery, 72(3), 463-475. 
Bowditch, R. D., Hariharan, M., Tominna, E. F., Smith, J. W., Yamada, K. M., Getzoff, E. D., & Ginsberg, M. H. (1994). Identification 
of a novel integrin binding site in fibronectin. differential utilization by β3 integrins. Journal of Biological Chemistry, 269(14), 
10856-10863. 
Buxboim, A., & Discher, D. E. (2010). Stem cells feel the difference. Nature Methods, 7(9), 695-697. 
Cai, W., & Chen, X. (2006). Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anti-Cancer Agents in 
Medicinal Chemistry, 6(5), 407-428. 
Colomer, R. (2004). Gemcitabine and paclitaxel in metastatic breast cancer: A review. Oncology (Williston Park, N.Y.), 18(14 Suppl 
12), 8-12. 
Corcoran, A., De Ridder, L. I., Del Duca, D., Kalala, O. J., Lah, T., Pilkington, G. J., & Del Maestro, R. F. (2003). Evolution of the brain 
tumour spheroid model: Transcending current model limitations. Acta Neurochirurgica, 145(9), 819-824. 
Danen, E. H. J., Aota, S. -., Van Kraats, A. A., Yamada, K. M., Ruiter, D. J., & Van Muijen, G. N. P. (1995). Requirement for the 
___________________________________________________________________________________________________________Summary and discussion
117
synergy site for cell adhesion to fibronectin depends on the activation state of integrin α5β1. Journal of Biological Chemistry, 
270(37), 21612-21618. 
Friedl, P., & Wolf, K. (2010). Plasticity of cell migration: A multiscale tuning model. The Journal of Cell Biology, 188(1), 11-19. 
Friedland, J. C., Lee, M. H., & Boettiger, D. (2009). Mechanically activated integrin switch controls alpha5beta1 function. Science 
(New York, N.Y.), 323(5914), 642-644. 
Goodman, S. L., Holzemann, G., Sulyok, G. A., & Kessler, H. (2002). Nanomolar small molecule inhibitors for alphav(beta)6, 
alphav(beta)5, and alphav(beta)3 integrins. Journal of Medicinal Chemistry, 45(5), 1045-1051. 
Huang, T. F. (1998). What have snakes taught us about integrins? Cellular and Molecular Life Sciences : CMLS, 54(6), 527-540. 
Ivascu, A., & Kubbies, M. (2006). Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity 
analysis. Journal of Biomolecular Screening : The Official Journal of the Society for Biomolecular Screening, 11(8), 922-932. 
Ivascu, A., & Kubbies, M. (2007). Diversity of cell-mediated adhesions in breast cancer spheroids. International Journal of 
Oncology, 31(6), 1403-1413. 
Jin, T., & Li, J. (2002). Dynamitin controls beta 2 integrin avidity by modulating cytoskeletal constraint on integrin molecules. The 
Journal of Biological Chemistry, 277(36), 32963-32969. 
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., . . . Bissell, M. J. (2007). The morphologies of breast 
cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Molecular Oncology, 1(1), 84-96.  
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., . . . Weaver, V. M. (2009). Matrix crosslinking forces tumor 
progression by enhancing integrin signaling. Cell, 139(5), 891-906. 
Li, J., Zhu, Z., & Bao, Z. (1996). Role of MacMARCKS in integrin-dependent macrophage spreading and tyrosine phosphorylation 
of paxillin. The Journal of Biological Chemistry, 271(22), 12985-12990. 
McLane, M. A., Sanchez, E. E., Wong, A., Paquette-Straub, C., & Perez, J. C. (2004). Disintegrins. Current Drug Targets.
Cardiovascular & Haematological Disorders, 4(4), 327-355. 
Mizejewski, G. J. (1999). Role of integrins in cancer: Survey of expression patterns. Proceedings of the Society for Experimental 
Biology and Medicine.Society for Experimental Biology and Medicine (New York, N.Y.), 222(2), 124-138. 
Mueller-Klieser, W. (1987). Multicellular spheroids. A review on cellular aggregates in cancer research. Journal of Cancer 
Research and Clinical Oncology, 113(2), 101-122. 
___________________________________________________________________________________________________________
118
Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006). Beta1 integrin inhibitory antibody 
induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three 
dimensional cultures and in vivo. Cancer Research, 66(3), 1526-1535. 
Raguse, J. D., Gath, H. J., Bier, J., Riess, H., & Oettle, H. (2004). Cilengitide (EMD 121974) arrests the growth of a heavily pretreated 
highly vascularised head and neck tumour. Oral Oncology, 40(2), 228-230. 
Ramirez, N. E., Zhang, Z., Madamanchi, A., Boyd, K. L., O’Rear, L. D., Nashabi, A., . . . Zutter, M. M. (2011). The α2β1 integrin is a 
metastasis suppressor in mouse models and human cancer. Journal of Clinical Investigation, 121(1), 226-237. 
Roca-Cusachs, P., Gauthier, N. C., Del Rio, A., & Sheetz, M. P. (2009). Clustering of alpha(5)beta(1) integrins determines adhesion 
strength whereas alpha(v)beta(3) and talin enable mechanotransduction. Proceedings of the National Academy of Sciences of 
the United States of America, 106(38), 16245-16250. 
Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annual Review of Cell and Developmental Biology, 12, 
697-715. doi:10.1146/annurev.cellbio.12.1.697 
Schwarzbauer, J. E., & Sechler, J. L. (1999). Fibronectin fibrillogenesis: A paradigm for extracellular matrix assembly. Current 
Opinion in Cell Biology, 11(5), 622-627. 
Sechler, J. L., Corbett, S. A., & Schwarzbauer, J. E. (1997). Modulatory roles for integrin activation and the synergy site of 
fibronectin during matrix assembly. Molecular Biology of the Cell, 8(12), 2563-2573. 
Sutherland, R. M. (1988). Cell and environment interactions in tumor microregions: The multicell spheroid model. Science (New 
York, N.Y.), 240(4849), 177-184. 
Taga, T., Suzuki, A., Gonzalez-Gomez, I., Gilles, F. H., Stins, M., Shimada, H., . . . Laug, W. E. (2002). Alpha v-integrin antagonist 
EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. International Journal of Cancer.Journal 
International Du Cancer, 98(5), 690-697. 
Walpita, D., & Hay, E. (2002). Studying actin-dependent processes in tissue culture. Nature Reviews.Molecular Cell Biology, 3(2), 
137-141. 
White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004). Targeted disruption of beta1-
integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell, 
6(2), 159-170. doi:10.1016/j.ccr.2004.06.025 
Zutter, M. M., Mazoujian, G., & Santoro, S. A. (1990). Decreased expression of integrin adhesive protein receptors in 
adenocarcinoma of the breast. American Journal of Pathology, 137(4), 863-870. Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., 




Nederlandse samenvatting en discussie

Nederlandse samenvatting en discussie
Embryogenese, wondheling, angiogenese en kanker metastasering zijn afhankelijk van 
cel motiliteit en adhesie dynamiek. Dit behelst een verschuiving in integrine expressie 
profielen, wat mogelijk de veranderende omgeving waarin cellen zich bevinden en 
zich door aanpassen weergeeft. Bijvoorbeeld, kwaadaardige cellen die van primaire 
naar secundaire plaatsen in het lichaam migreren komen extracellulaire matrix (ECM) 
tegen dat verschilt van compositie in vergelijking met hun plaats van oorsprong. In 
hoofdstuk 2 en 3 van dit proefschrift wordt de rol van a5b1 en avb3 fibronectine (FN)-
bindende integrines in cel motiliteit en adhesie dynamiek bediscussieerd. Wij hebben 
aangetoond dat wanneer deze integrines ectopisch tot expressie worden gebracht in 
de zelfde cellulaire achtergrond (GE11), opmerkelijke verschillen in cellulaire functies 
(cel morfologie, cel-matrix adhesie dynamiek en lokalisatie) worden geobserveerd. 
Cellen die a5b1 integrine tot expressie brengen, hebben een contractiele fibroblast-
achtige morfologie met sterk dynamische centripetaal georiënteerde cel-matrix 
adhesies en migreren willekeurig. In tegenstelling tot cellen die avb3 integrines tot 
expressie brengen, wiens cel-matrix adhesies meer statisch en verdeeld over het 
basale oppervlak zijn en welke zeer persistent migreren. 
Wat is de reden voor deze verschillen wanneer beide integrines interacties aangaan 
met FN? Een mogelijke verklaring zou de interactie van signalerings en/of adapter 
eiwitten met specifieke residuen binnen het cytoplasmische gedeelte van integrine 
zijn. Echter, experimenten waarin het a- en b-gedeelte werden verwisseld hebben 
laten zien dat dit waarschijnlijk niet aan de orde is. Ons onderzoek suggereert dat het 
eerder de manier waarop integrines met FN interacties aangaan is. Wij demonstreren 
dat zowel a5b1 als avb3 aan geïmmobiliseerd (gestrekt) FN adheren, maar dat alleen 
a5b1 aan oplosbaar gevouwen (inactief) FN kan binden. RGD in geïmmobiliseerd 
(gestrekt) FN is op dusdaninge manier georiënteerd dat het toegankelijk is voor 
beide integrines (Altroff et al., 2004). Het vermogen van a5b1 om de RGD plaats te 
bereiken in oplosbaar FN wordt bewerkstelligt doordat dit integrine een additionele 
FN bindende regio heeft (Aota, Nomizu, and Yamada, 1994; Bowditch et al., 1994; 
Danen et al., 1995). Wij laten zien dat het plaatsen van de CTSEQNC hypervariabele 
sequentie uit het I-achtig domein van b1 in de context van b3 er voor zorgt dat avb3 
___________________________________________________________________________________________________________Nederlandse samenvatting en discussie
123
in die conditie ook aan oplosbaar FN kan binden. Er is gesuggereerd dat de a5b1 
hypervariabele sequentie bindt aan de PHSRN “synergie” regio in IIIFN9 om de interactie 
met de RGD regio in IIIFN10 te stabiliseren door de hellingshoek tussen IIIFN10en 
IIIFN9 te veranderen, en daardoor de RGD lussen vrij te leggen. Onze bevindingen 
demonstreren dat integrine avb3, zelfs als het door verschillende mutaties vast zit in 
een hoge affiniteit toestand, slecht bindt aan oplosbaar FN omdat deze functionaliteit 
ontbreekt (Danen et al., 1995; Sechler, Corbett, and Schwarzbauer, 1997).
De associatie met de synergie regio verklaart mogelijk het klaarblijkelijke specifieke 
vermogen van a5b1 voor het vormen van een “houtgreep” met FN en het 
bewerkstelligen van adhesie versterking (Friedland, Lee, and Boettiger, 2009; Roca-
Cusachs et al., 2009). Belangrijker nog, onze bevindingen wijzen er op dat het wisselen 
tussen deze twee integrines die dusdanig verschillende ligand-interacties vormen, 
een sterke invloed heeft op intracellulaire processen, met effecten op RhoA activiteit, 
contractiliteit van het cytoskelet en ECM opbouw. 
In hoofdstuk 4 wordt een nieuwe avb3 bindingspartner beschreven die mogelijk ook 
bijdraagt aan de specifieke avb3-gemedieerde effecten op cel morfologie. MacMarcks 
(MRP) is betrokken bij de activatie van integrines en cel spreiding door het reguleren 
van het corticale actine netwerk (Jin and Li, 2002). Interessant is dat de expressie 
van b3 integrine leidt tot verminderde expressie van MRP op transcript niveau. Wij 
hebben gedemonstreerd dat de regio in de nabijheid van het NITY domein van het b3 
gedeelte, wanneer geassocieerd met de av subunit, zorgt voor verminderde expressie 
van MRP. Niettemin leidt suppressie van MRP expressie niet tot de bevordering 
van cel spreiding in de oorspronkelijke cellijn, en overexpressie heeft geen effect 
op cel spreiding in cellen die avb3 gebruiken voor adhesie. Dit suggereert dat b3 
noodzakelijk is voor MRP lokalisatie en expressie maar dat MRP niet essentieel is 
voor avb3-gemedieerde cel spreiding (in tegenstelling tot b2 integrines, waarvan is 
aangetoond dat ze MRP-afhankelijk zijn voor cel spreiding (Li et al., 1996)).
Zoals beschreven in hoofdstuk 5, gaan bepaalde ziektes gepaard met veranderende 
expressie of functionaliteit van integrines. Bijvoorbeeld, hoge expressie niveaus 
van verscheidende types integrines zijn in een aantal soorten kanker gecorreleerd 
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aan tumor progressie (Mizejewski, 1999). Om die redenen zijn antagonisten zoals 
peptidomimetics en monoklonale antilichamen tegen a5b1 of avb3 ontwikkeld. 
Disintegrines zijn RGD-bevattende cysteine-rijke peptides in slangengif die verder 
ontwikkeld zijn als therapeutische middelen voor angiogenese-afhankelijke tumor 
groei en metastasering (Huang, 1998). Deze moleculen zijn echter erg groot en 
hebben een lage metabolische stabiliteit waardoor hun therapeutische toepassing 
beperkt is (McLane et al., 2004; Cai and Chen, 2006). Cyclisch RGD-bevattende 
pentapeptides zijn de meest gebruikte RSD-gebaseerde antagonisten (Ruoslathi, 
1996). c(RGDf(NMe)V), ook wel Cilengitide genoemd (EMD 121974) (Goodman et 
al., 2002) induceert efficiënt apoptose in glioblastoma en medullablastoma (Taga 
et al., 2002). Integrine antagonisten kunnen worden toegepast in combinatie met 
cytotoxische antikanker therapie, zoals chemo- of radiotherapie om de therapeutische 
efficiënte te maximaliseren. Bijvoorbeeld, Cilengitide in combinatie met gemcitabine 
inhibeert tumoren met geavanceerd vasculatuur (Colomer, 2004; Raguse et al., 2004). 
Het is beschreven dat tumor-geassocieerde endotheel cellen kunnen ontsnappen aan 
cel dood door na blootstelling aan radiatie avb3 verhoogd tot expressie te brengen. 
Moleculen zoals de avb3 inhibitor S247 kunnen potentieel de groei van tumor cellen 
en angiogenese blokkeren en de fosforylering van PKB/Akt inhiberen (Abdollahi et 
al.m 2005).         
Klassieke 2D kweek condities verschillen sterk van de in vivo situatie en beїnvloeden 
cel overleving, proliferatie, differentiatie, cytoarchitectuur, en migratie (Kenny PA et 
al., 2007; Bjerkvig, 1990; Bissell, 1981; Wapita and Hay, 2002; Corcoran et al., 2003; 
Beliveau et al., 2010). Voor metastase gerelateerde studies geven 3D invasie studies 
zoals de Boyden kamer analyse (trans-wel migratie analyse) waarschijnlijk ook niet 
de juiste representatie van tumor cellen die zich afscheiden van een solide tumor. 
Om deze reden zijn cel sferoїde (CS) culturen ontwikkeld die het micromilieu van 
solide tumoren nabootst. Deze CS behoren compact te zijn met een zuurstof- en 
voedingstoffen-loze kern. Dit is karakteristiek voor solide tumoren (Mueller-Klieser, 
1987; Sutherlands, 1988). Daarbij behoort het ECM milieu dat de CS omringt dezelfde 
chemische (ECM eiwit type) en fysische (stijfheid, kruis-koppelingen) eigenschappen 
te hebben als dat van weefsel (Buxboim and Discher,2010; Friedl and Wolf, 2010, 
Leventhal et al., 2009). In hoofdstuk 6 beschrijven we de ontwikkeling van een 
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nieuwe CS formatie methode in 3D collageen gelen die voldoet aan deze kriteria en 
die ook, voor het eerst, op een “high throughput” manier met hoge accuratie en 
reproduceerbaarheid uitgevoerd kan worden.
Onze methode, die gebaseerd is op microinjecties, levert een aantal voordelen op 
in vergelijking met andere methodes. Ten eerste, combineren wij CS formatie en gel 
inbedding in één stap. Op deze manier wordt de preparatie tijd verkort van dagen 
tot minuten. Ten tweede, formatie van CS uit een breed spectrum van cellen kan 
worden bereikt zonder additieven, zoals matrigel dat door andere groepen wordt 
gebruikt (Ivascu and Manfred, 2006, 2007). Ten derde, CS worden in gelijke groottes 
en vormen geproduceerd met een vooraf gedefinieerde ruimtelijke distributie, wat 
deze methode geschikt maakt voor microscopische screening. In tegenstelling tot 
andere technieken wordt de 2D weefselkweek stap overgeslagen en kunnen vers 
geïsoleerde tumor monsters uit muis en humane biopten direct gebruikt worden voor 
CS vorming. Met deze nieuwe methode hebben wij een geautomatiseerd 3D kweek 
systeem ontwikkeld dat gebruikt kan worden voor het testen van medicijnen voor 
gepersonaliseerde behandelings strategieën. 
Volgens verschillende studies beїnvloedt b1 integrine de initiatie en groei van 
borstkanker. Blokkeren van b1 integrine met antilichamen maakt borstkanker tumoren 
in muizen gevoelig voor radiotherapie, wat aangeeft dat b1 integrine waarschijnlijk 
een geschikt doel is voor de ontwikkeling van medicijnen tegen borstkanker (White et 
al., 2004; Park et al., 2006). In hoofdstuk 7 beschrijven we hoe het uitschakelen van b1 
in borstkanker cellen inderdaad de groei van tumoren onderdrukt. Dit kan echter ook 
leiden tot verhoogde intravasatie en metastasering. Onze data ondersteunt een model 
waarin, bij de afwezigheid van b1 integrine, een epitheliale-tot-mesenchymale (EMT) 
transitie geїnduceerd wordt door E-cadherine op transcriptie niveau naar beneden 
te reguleren ten gevolge van een wisseling in de balans tussen de ZEB en mir-200 
famillies. Vervolgens verschuiven de cellen van een samenhangende multicellulaire 
streng invasie naar migratie van individuele cellen in 3D matrices. Waarschijnlijk stelt 
deze verschuiving tumor cellen in staat tot een efficiëntere manier van intravasatie 
met een verhoogde migratie doordat de ballast van het migreren als een collectieve 
eenheid afvalt of doordat overlevings mechanismen om de stroming in het bloedvat 
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te weerstaan worden geactiveerd. 
Experimenten die gebruik maken van inhiberende peptides en a2 subeenheid 
silencing constructen duiden aan dat van de b1 integrines de a2b1 metastasering 
onderdrukt in dit systeem. Van dit integrine is reeds aangetoond dat het omgekeerd 
gecorreleerd is met borstkanker progressie (Ramirez et al., 2010). Desondanks 
detecteren wij in patient materiaal geen algemeen verlies van a2 of b1 integrines 
dat gecorreleerd is aan E-cadherine verlies. Histologische secties geven alleen een 
momentopname uit het dynamische process van metastasering en missen mogelijk 
een belangrijke kwaadaardige modificatie in de metastase cascade. De verminderde 
expressie van E-cadherine naar aanleiding van de vermindering van b1-integrine-
gemedieerde adhesie is mogelijk een tijdelijk proces dat in een subpopulatie van 
kanker cellen in een tumor voorkomt. Dit soort evenementen kunnen makkelijk over 
het hoofd worden gezien door de patholoog terwijl ze een belangrijke rol spelen in de 
metastasering van E-cadherine positieve borstkanker. 
Van fundamenteel onderzoek tot klinische toepassingen blijken integrines hoogst 
interessante receptoren. Naast het mediëren van cel adhesie aan de micro-omgeving 
induceren integrines ook signaal transductie cascades die proliferatie, overleving en 
migratie reguleren. Zodoende blijken integrines bruikbare biomarkers en kunnen ze 
worden gebruikt als doel om medicijnen tegen te ontwikkelen in verschillende ziektes, 
waaronder kanker.
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